Patent Grant
10201502
The invention relates to tamper-resistant tablets comprising a matrix material and a plurality of coated particulates which comprise a pharmacologically active compound and form a discontinuous phase within the matrix material, preferably providing under in vitro conditions immediate release of the pharmacologically active compound.
A large number of pharmacologically active substances have a potential for being abused or misused, i.e. they can be used to produce effects which are not consistent with their intended use. Thus, e.g. opioids which exhibit an excellent efficacy in controlling severe to extremely severe pain, are frequently abused to induce euphoric states similar to being intoxicated. In particular, active substances which have a psychotropic effect are abused accordingly.
To enable abuse, the corresponding dosage forms, such as tablets or capsules are crushed, for example ground by the abuser, the active substance is extracted from the thus obtained powder using a preferably aqueous liquid and after being optionally filtered through cotton wool or cellulose wadding, the resultant solution is administered parenterally, in particular intravenously. This type of dosage results in an even faster diffusion of the active substance compared to the oral abuse, with the result desired by the abuser, namely the kick. This kick or these intoxication-like, euphoric states are also reached if the powdered dosage form is administered nasally, i.e. is sniffed.
Various concepts for the avoidance of drug abuse have been developed.
It has been proposed to incorporate in dosage forms aversive agents and/or antagonists in a manner so that they only produce their aversive and/or antagonizing effects when the dosage forms are tampered with. However, the presence of such aversive agents is principally not desirable and there is a need to provide sufficient tamper-resistance without relying on aversive agents and/or antagonists.
Another concept to prevent abuse relies on the mechanical properties of the pharmaceutical dosage forms, particularly an increased breaking strength (resistance to crushing). The major advantage of such pharmaceutical dosage forms is that comminuting, particularly pulverization, by conventional means, such as grinding in a mortar or fracturing by means of a hammer, is impossible or at least substantially impeded. Thus, the pulverization, necessary for abuse, of the dosage forms by the means usually available to a potential abuser is prevented or at least complicated.
Such pharmaceutical dosage forms are useful for avoiding drug abuse of the pharmacologically active compound contained therein, as they may not be powdered by conventional means and thus, cannot be administered in powdered form, e.g. nasally. The mechanical properties, particularly the high breaking strength of these pharmaceutical dosage forms renders them tamper-resistant. In the context of such tamper-resistant pharmaceutical dosage forms it can be referred to, e.g., WO 2005/016313, WO 2005/016314, WO 2005/063214, WO 2005/102286, WO 2006/002883, WO 2006/002884, WO 2006/002886, WO 2006/082097, WO 2006/082099, and WO2009/092601.
These dosage forms secured against abuse are distinguished by a controlled, preferably retarded release of the active substance which has abuse potential. However, a rapid release of the active substance is necessary for numerous therapeutic applications, for example pain relief using active substances with abuse potential.
WO 2010/140007 discloses dosage forms comprising melt-extruded uncoated particulates comprising a drug, wherein said melt-extruded particulates are present as a discontinuous phase in a matrix. The dosage forms provide prolonged release of the drug.
WO 2008/107149 discloses multiparticulate dosage forms with impeded abuse containing, one or more active substances having abuse potential, at least one synthetic or natural polymer, and at least one disintegrant, with the individual particles of the tablet having a breaking strength of at least 500 N and a release of the active substance of at least 75% after 45 minutes. The exemplified capsules provide rapid release of the pharmacologically active compound.
US 2010/0092553 and US 2007/224129 A1 disclose solid multiparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse. The microparticles have an extremely thick coating layer which assures the modified release of the drug and simultaneously imparts crushing resistance to the coated microparticles so as to avoid misuse.
WO 2008/033523 discloses a pharmaceutical composition that may include a granulate which may at least include one active pharmaceutical ingredient susceptible to abuse. The particle contains both an alcohol soluble and alcohol insoluble and at leasts partially water soluble material. Both materials are granulated in the presence of alcohol and water. The granulate may also include a coating on the granulate exhibiting crush resistance. Material deposition on the granule is performed using an alcohol based solvent.
The properties of capsules, however, are not satisfactory in every respect, e.g. with respect to disintegration time, patient compliance (e.g. swallowability) and ease of manufacture. Further, capsules frequently contain gelatine thus causing the risk of bovine spongiform encephalopathy (BSE, or TSE). As far as tamper-resistant dosage forms are concerned, capsules are disadvantageous as they can typically be opened easily thereby releasing the ingredients in powdery or particulate form without requiring any mechanical impact. If components of different type are contained in a capsule, e.g. drug-containing particles besides drug-free particles, a potential abuser might be able to visually distinguish the intact, undisrupted components of different type (e.g. according to their color, size or other macroscopic properties) allowing for manual separation.
The properties of these tamper-resistant dosage forms, however, are not satisfactory in every respect. There is a need for tamper-resistant dosage forms that possess crush resistance and release the pharmacologically active compound as quick as possible (immediate release), i.e. should show a gradual increase reaching 85% to 100% at about 30 to 45 minutes or earlier. The dosage form should advantageously be of a shape, size and weight that can be taken orally with ease. Of course, the dosage form should also be easy to make in a cost effective manner. When trying to tamper the dosage form in order to prepare a formulation suitable for abuse by intravenous administration, the liquid part of the formulation that can be separated from the remainder by means of a syringe should be as less as possible, e.g. should contain not more than 20 wt.-% of the pharmacologically active compound originally contained in the dosage form.
The manufacturing of functionally coated microparticles or granules, however, is not satisfactory with respect to the excessive manufacturing effort by applying the film-coating in an organic spraying procedure, which needs extensive measure to prevent vapor explosions. From an environmental and toxicological perspective the use of organic solvents is further undesirable. Furthermore, applying a functional film coat in general requires high efforts to assure the integrity of the functional barrier and is therefore a production step generating high manufacturing cost.
It is an object according to the invention to provide tamper-resistant pharmaceutical dosage forms that provide rapid release of the pharmacologically active compound and that have advantages compared to the tamper-resistant pharmaceutical dosage forms of the prior art.
This object has been achieved by the patent claims.
The invention relates to a tamper-resistant tablet, preferably for oral administration, comprising
It has been surprisingly found that the in vitro release profile of tamper-resistant dosage forms can be accelerated by embedding particulates containing the pharmacologically active compound in a matrix material and increasing the relative weight ratio of the matrix material to the coated particulates.
Further, it has been surprisingly found that mixtures of matrix material, optionally in pre-compacted or pre-granulated form, can be mixed with the coated particulates and subsequently be compacted to tablets which in turn exhibit excellent, i.e. accelerated disintegration times and in vitro release characteristics.
Still further, it has been surprisingly found that oral dosage forms can be designed that provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
In particular, it has been surprisingly found that disintegration and drug release can be accelerated when providing the particulates with a coating, preferably with a coating material comprising a water-soluble polymer. It has been unexpectedly found that the dissolution of said coating does not additionally impede disintegration and drug release, respectively, but causes a significant acceleration thereof.
The invention will now be described in greater detail with reference to the drawings, wherein:
As used herein, the term “tablet” refers to a pharmaceutical entity that is comprised of a pharmacologically active compound and which is actually administered to, or taken by, a patient. It may be compressed or molded in its manufacture, and it may be of almost any size, shape, weight, and color. Most tablets are intended to be swallowed whole and accordingly, preferred tablets according to the invention are designed for oral administration. However, alternatively tablets may be dissolved in the mouth, chewed, or dissolved in liquid before swallowing, and some may be placed in a body cavity. Thus, the tablet according to the invention may alternatively be adapted for buccal, lingual, rectal or vaginal administration. Implants are also possible.
The tablet according to the invention preferably can be regarded as a MUPS formulation (multiple unit pellet system). In a preferred embodiment, the tablet according to the invention is monolithic. In another preferred embodiment, the tablet according to the invention is not monolithic. In this regard, monolithic preferably means that the tablet is formed or composed of material without joints or seams or consists of or constitutes a single unit.
Preferably, the tablet according to the invention contains all ingredients in a dense compact unit which in comparison to capsules has a comparatively high density.
The tablets according to the invention comprise subunits having different morphology and properties, namely drug-containing particulates and matrix material, wherein the coated particulates form a discontinuous phase within the matrix material. The coated particulates typically have mechanical properties that differ from the mechanical properties of the matrix material. Preferably, the coated particulates have a higher mechanical strength than the matrix material. The coated particulates within the tablets according to the invention can be visualized by conventional means such as solid state nuclear magnetic resonance spectroscopy, raster electron microscopy, terahertz spectroscopy and the like.
An advantage of the tablets according to the invention is that the same particulates may be mixed with matrix material in different amounts to thereby produce tablets of different strengths.
The tablet according to the invention has preferably a total weight in the range of 0.01 to 1.5 g, more preferably in the range of 0.05 to 1.2 g, still more preferably in the range of 0.1 g to 1.0 g, yet more preferably in the range of 0.2 g to 0.9 g, and most preferably in the range of 0.3 g to 0.8 g. In a preferred embodiment, the total tablet weight is within the range of 500±450 mg, more preferably 500±300 mg, still more preferably 500±200 mg, yet more preferably 500±150 mg, most preferably 500±100 mg, and in particular 500±50 mg.
It has been surprisingly found that the total tablet weight, which is a function of the total size of the tablet, can be optimized in order to provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
In a preferred embodiment, the tablet according to the invention is a round tablet. Tablets of this embodiment preferably have a diameter in the range of about 1 mm to about 30 mm, in particular in the range of about 2 mm to about 25 mm, more in particular about 5 mm to about 23 mm, even more in particular about 7 mm to about 13 mm; and a thickness in the range of about 1.0 mm to about 12 mm, in particular in the range of about 2.0 mm to about 10 mm, even more in particular from 3.0 mm to about 9.0 mm, even further in particular from about 4.0 mm to about 8.0 mm.
In another preferred embodiment, the tablet according to the invention is an oblong tablet. Tablets of this embodiment preferably have a lengthwise extension (longitudinal extension) of about 1 mm to about 30 mm, in particular in the range of about 2 mm to about 25 mm, more in particular about 5 mm to about 23 mm, even more in particular about 7 mm to about 20 mm; a width in the range of about 1 mm to about 30 mm, in particular in the range of about 2 mm to about 25 mm, more in particular about 5 mm to about 23 mm, even more in particular about 7 mm to about 13 mm; and a thickness in the range of about 1.0 mm to about 12 mm, in particular in the range of about 2.0 mm to about 10 mm, even more in particular from 3.0 mm to about 9.0 mm, even further in particular from about 4.0 mm to about 8.0 mm.
The tablets according to the invention can optionally be provided, partially or completely, with a conventional coating. The tablets according to the invention are preferably film coated with conventional film coating compositions. Suitable coating materials are commercially available, e.g. under the trademarks Opadry® and Eudragit®.
Examples of suitable materials include cellulose esters and cellulose ethers, such as methylcellulose (MC), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), sodium carboxymethylcellulose (Na—CMC), poly(meth)acrylates, such as aminoalkylmethacrylate copolymers, methacrylic acid methylmethacrylate copolymers, methacrylic acid methylmethacrylate copolymers; vinyl polymers, such as polyvinylpyrrolidone, polyvinyl alcohol, polyvinylacetate; and natural film formers.
In a particularly preferred embodiment, the coating is water-soluble. In a preferred embodiment, the coating is based on polyvinyl alcohol, such as polyvinyl alcohol-part. hydrolyzed, and may additionally contain polyethylene glycol, such as macrogol 3350, and/or pigments. In another preferred embodiment, the coating is based on hydroxypropylmethyl-cellulose, preferably hypromellose type 2910 having a viscosity of 3 to 15 mPas.
The coating can be resistant to gastric juices and dissolve as a function of the pH value of the release environment. By means of this coating, it is possible to ensure that the tablet according to the invention passes through the stomach undissolved and the active compound is only released in the intestines. The coating which is resistant to gastric juices preferably dissolves at a pH value of between 5 and 7.5.
The coating can also be applied e.g. to improve the aesthetic impression and/or the taste of the tablets and the ease with which they can be swallowed. Coating the tablets according to the invention can also serve other purposes, e.g. improving stability and shelf-life. Suitable coating formulations comprise a film forming polymer such as, for example, polyvinyl alcohol or hydroxypropyl methylcellulose, e.g. hypromellose, a plasticizer such as, for example, a glycol, e.g. propylene glycol or polyethylene glycol, an opacifier, such as, for example, titanium dioxide, and a film smoothener, such as, for example, talc. Suitable coating solvents are water as well as organic solvents. Examples of organic solvents are alcohols, e.g. ethanol or isopropanol, ketones, e.g. acetone, or halogenated hydrocarbons, e.g. methylene chloride. Coated tablets according to the invention are preferably prepared by first making the cores and subsequently coating said cores using conventional techniques, such as coating in a coating pan.
As used herein, the term “tamper-resistant” refers to tablets that are resistant to conversion into a form suitable for misuse or abuse, particular for nasal and/or intravenous administration, by conventional means such as grinding in a mortar or crushing by means of a hammer. In this regard, the tablets as such may be crushable by conventional means. However, the coated particulates contained in the tablets according to the invention exhibit mechanical properties such that they cannot be pulverized by conventional means any further. As the coated particulates are of macroscopic size and contain the pharmacologically active compound, they cannot be administered nasally thereby rendering the tablets tamper-resistant. Preferably, when trying to tamper the dosage form in order to prepare a formulation suitable for abuse by intravenous administration, the liquid part of the formulation that can be separated from the remainder by means of a syringe is as less as possible, preferably it contains not more than 20 wt.-%, more preferably not more than 15 wt.-%, still more preferably not more than 10 wt.-%, and most preferably not more than 5 wt.-% of the originally contained pharmacologically active compound. Preferably, this property is tested by (i) dispensing a tablet that is either intact or has been manually comminuted by means of two spoons in 5 ml of purified water, (ii) heating the liquid up to its boiling point, (iii) boiling the liquid in a covered vessel for 5 min without the addition of further purified water, (iv) drawing up the hot liquid into a syringe (needle 21G equipped with a cigarette filter), (v) determining the amount of the pharmacologically active compound contained in the liquid within the syringe.
Further, when trying to disrupt the tablets by means of a hammer or mortar, the coated particulates may also, depending on the circumstances, tend to adhere to one another thereby forming aggregates and agglomerates, respectively, which are larger in size than the untreated coated particulates.
The subjects to which the tablets according to the invention can be administered are not particularly limited. Preferably, the subjects are animals, more preferably human beings.
In the tablets according to the invention, the coated particulates are incorporated into a matrix material. From a macroscopic perspective, the matrix material preferably forms a continuous phase in which the coated particulates are embedded as discontinuous phase.
Preferably, the matrix material is a homogenous coherent mass, preferably a homogeneous mixture of solid constituents, in which the coated particulates are embedded thereby spatially separating the coated particulates from one another. While it is possible that the surfaces of coated particulates are in contact or at least in very close proximity with one another, the plurality of coated particulates preferably cannot be regarded as a single continuous coherent mass within the tablet.
In other words, the tablet according to the invention comprises the coated particulates as volume element(s) of a first type in which the pharmacologically active compound and the physiologically acceptable polymer, preferably the polyalkylene oxide are contained, preferably homogeneously, and the matrix material as volume element of a second type differing from the material that forms the coated particulates, preferably containing neither pharmacologically active compound nor physiologically acceptable polymer, preferably no polyalkylene oxide, but optionally polyethylene glycol which differs from polyethylene oxide in its molecular weight.
A purpose of the matrix material in the tablet according to the invention is to ensure rapid disintegration and subsequent release of the pharmacologically active compound from the disintegrated tablets, i.e. from the coated particulates. Thus, the matrix material preferably does not contain any excipient that might have a retardant effect on disintegration and drug release, respectively. Thus, the matrix material preferably does not contain any polymer that is typically employed as matrix material in prolonged release formulations.
The tamper-resistant tablet according to the invention comprises the matrix material in an amount of more than one third of the total weight of the tablet.
It has been surprisingly found that the content of the matrix material in the tablet can be optimized in order to provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
Preferably, the content of the matrix material is at least 35 wt.-%, at least 37.5 wt.-% or at least 40 wt.-%; more preferably at least 42.5 wt.-%, at least 45 wt.-%, at least 47.5 wt.-% or at least 50 wt.-%; still more preferably at least 52.5 wt.-%, at least 55 wt.-%, at least 57.5 wt.-% or at least 60 wt.-%; yet more preferably at least 62.5 wt.-%, at least 65 wt.-%, at least 67.5 wt.-% or at least 60 wt.-%; most preferably at least 72.5 wt.-%, at least 75 wt.-%, at least 77.5 wt.-% or at least 70 wt.-%; and in particular at least 82.5 wt.-%, at least 85 wt.-%, at least 87.5 wt.-% or at least 90 wt.-%; based on the total weight of the tablet.
Preferably, the content of the matrix material is at most 90 wt.-%, at most 87.5 wt.-%, at most 85 wt.-%, or at most 82.5 wt.-%; more preferably at most 80 wt.-%, at most 77.5 wt.-%, at most 75 wt.-% or at most 72.5 wt.-%; still more preferably at most 70 wt.-%, at most 67.5 wt.-%, at most 65 wt.-% or at most 62.5 wt.-%; yet more preferably at most 60 wt.-%, at most 57.5 wt.-%, at most 55 wt.-% or at most 52.5 wt.-%; most preferably at most 50 wt.-%, at most 47.5 wt.-%, at most 45 wt.-% or at most 42.5 wt.-%; and in particular at most 40 wt.-%, at most 37.5 wt.-%, or at most 35 wt.-%; based on the total weight of the tablet.
In a preferred embodiment, the content of the matrix material is within the range of 40±5 wt.-%, more preferably 40±2.5 wt.-%, based on the total weight of the tablet. In another preferred embodiment, the content of the matrix material is within the range of 45±10 wt.-%, more preferably 45±7.5 wt.-%, still more preferably 45±5 wt.-%, and most preferably 45±2.5 wt.-%, based on the total weight of the tablet. In still another preferred embodiment, the content of the matrix material is within the range of 50±10 wt.-%, more preferably 50±7.5 wt.-%, still more preferably 50±5 wt.-%, and most preferably 50±2.5 wt.-%, based on the total weight of the tablet. In yet another preferred embodiment, the content of the matrix material is within the range of 55±10 wt.-%, more preferably 55±7.5 wt.-%, still more preferably 55±5 wt.-%, and most preferably 55±2.5 wt.-%, based on the total weight of the tablet.
Preferably, the matrix material is a mixture, preferably a homogeneous mixture of at least two different constituents, more preferably of at least three different constituents. In a preferred embodiment, all constituents of the matrix material are homogeneously distributed in the continuous phase that is formed by the matrix material.
In a preferred embodiment, the mixture of all constituents of the matrix material is blended and employed as a powder, i.e. in non-pre-compacted form, subsequently mixed with the particulates that contain the pharmacologically active compound and the polyalkylene oxide, and then compressed into tablets. Tablets having acceptance values between about 5 and 6 according to Ph. Eur. 2.9.40 “Uniformity of Dosage Units” (UDU) can be obtained when properly adjusting the tablet press. Vibrations should be avoided to a maximal extent (e.g. by decoupling of hopper and tablet press) and clearance of equipment parts should be as small as possible. For example, on a rotary tablet press IMA S250 plus with 26 stations, the following parameters are suitable: round punches 10 mm diameter, radius of curvature 8 mm without debossing; fill curve 13 mm; tablet weight 500 mg; speed: 13700-13800 tablets per hour; pre compression force 4.7 kN; main compression force 6.7 kN and 8.7 kN; fill depth 14.5 mm and 15 mm; height of tablet bar (pre compression): 3.5 mm; height of tablet bar (main compression): 3.3 mm and 3.1 mm; revolution speed of feeder (Filomat): 40 rmp.
In another preferred embodiment, the matrix material is also provided in particulate form, i.e. in the course of the manufacture of the tablets according to the invention, the constituents of the matrix material are preferably processed into particulates, subsequently mixed with the coated particulates that contain the pharmacologically active compound and the physiologically acceptable polymer, preferably the polyalkylene oxide, and then compressed into the tablets.
Preferably, the average size of the particulates of the matrix material is within the range of ±60%, more preferably ±50%, still more preferably ±40%, yet more preferably ±30%, most preferably ±20%, and in particular ±10% of the average size of the coated particulates that contain the pharmacologically active compound and the physiologically acceptable polymer, preferably the polyalkylene oxide.
It has been surprisingly found that when proceeding this way, segregation phenomena upon blending the coated particulates with the matrix material in particulate form can be reduced or even completely suppressed, thereby substantially improving the content uniformity of the tablets according to the invention.
This is particularly surprising, as the larger the particulates are which are to be mixed and compressed to tablets, the more difficult it typically is to satisfy content uniformity requirements. Compared to conventional tablets, the tablets according to the invention are manufactured from comparatively large coated particulates and optionally, also from comparatively large pre-compacted particulates of matrix material. Preferably, the AV (acceptance value) concerning the content uniformity of the tablets according to the invention is at most 15, more preferably at most 14, still more preferably at most 13, yet more preferably at most 12, even more preferably at most 11, most preferably at most 10 and in particular at most 9. Methods to determine the AV are known to the skilled artisan. Preferably, the AV is determined in accordance with Eur. Ph.
This preferred embodiment of the tablets according to the invention is schematically illustrated in
The particulates of the matrix material can principally also be coated, optionally with the same coating material of the coated particulates according to the invention or with another coating material. Preferably, however, the particulates of the matrix material are uncoated.
The particulates of the matrix material can be manufactured by conventional methods for the preparation of aggregates and agglomerates from powder mixtures such as granulating and compacting.
In a preferred embodiment, the mixture of all constituents of the matrix material is blended and pre-compacted thereby yielding a pre-compacted matrix material.
Suitable methods for the manufacture of such a pre-compacted matrix material are known to the skilled person. Preferably, pre-compaction proceeds by dry granulation, preferably slugging or roller compaction. When proceeding this way, the process parameters are typically to be adjusted in order to achieve the desired properties (see below). Typical process parameters are compaction force (preferably adjusted within the range of 2 to 12 kN), roller displacement (preferably adjusted within the range of 2 to 5 mm) and granule sieve (preferably adjusted within the range of 1.0 to 2.0 mm). The desired properties of the pre-compacted material include primarily the particle size and the content of fine particles. The density may also play a role. The particle size is preferably within the range for the size of the particulates (preferably at least 60%>700 μm for particulates having dimensions of 0.8×0.8 mm). The content of fine particles (i.e. particles having a size of less than 600 μm) is preferably at most 40%, more preferably at most 30%, most preferably at most 20%. The effect of said process parameters on said desired properties can be easily determined by a skilled person by routine experimentation.
In another preferred embodiment, the mixture of all constituents of the matrix material is dry granulated thereby yielding a granulated matrix material. In still another preferred embodiment, the mixture of all constituents of the matrix material is wet granulated by means of a non-aqueous solvent e.g. ethanol thereby yielding another granulated matrix material. Aqueous granulation, however, is preferably avoided, as this typically has a detrimental influence on disintegration of the tablet. In yet another preferred embodiment, the mixture of all constituents of the matrix material is melt granulated, e.g. by means of an extruder, a heatable high-shear mixer or a granulator.
As already mentioned above, the matrix material in the tablet according to the invention should ensure rapid disintegration and subsequent release of the pharmacologically active compound from the disintegrated tablets, i.e. from the coated particulates. Thus, the matrix material preferably does not contain any excipient that might have a retardant effect on disintegration and drug release, respectively. Further, the matrix material preferably does not contain any pharmacologically active compound.
Preferably, the matrix material comprises a disintegrant. Suitable disintegrants are known to the skilled person and are preferably selected from the group consisting of crosslinked sodium carboxymethylcellulose (Na-CMC) (e.g. Crosscarmellose, Ac-Di-Sol®); crosslinked casein (e.g. Esma-Spreng®); polysaccharide mixtures obtained from soybeans (e.g. Emcosoy®); pretreated maize starch (e.g. Amijel®); sodium alginate; polyvinylpyrrolidone (PVP) (e.g. Kollidone®, Polyplasdone®, Polydone®); crosslinked polyvinylpyrrolidone (PVP CI) (e.g. Polyplasdone® XL); starch and pretreated starch such as sodium carboxymethyl starch (e.g. Explotab®, Prejel®, Primotab® ET, Starch® 1500, Ulmatryn. Crosslinked polymers are particularly preferred disintegrants, especially crosslinked sodium carboxymethylcellulose (Na—CMC) or crosslinked polyvinylpyrrolidone (PVP CI).
Preferably, the disintegrant is contained in the matrix material but not in the coated particulates of the tablet according to the invention.
In a preferred embodiment, the content of the disintegrant in the matrix material is within the range of 5±4 wt.-%, more preferably 5±3 wt.-%, still more preferably 5±2.5 wt.-%, yet more preferably 5±2 wt.-%, most preferably 5±1.5 wt.-%, and in particular 5±1 wt.-%, based on the total weight of matrix material. In another preferred embodiment, the content of the disintegrant in the matrix material is within the range of 7.5±4 wt.-%, more preferably 7.5±3 wt.-%, still more preferably 7.5±2.5 wt.-%, yet more preferably 7.5±2 wt.-%, most preferably 7.5±1.5 wt.-%, and in particular 7.5±1 wt.-%, based on the total weight of matrix material. In still another preferred embodiment, the content of the disintegrant in the matrix material is within the range of 10±4 wt.-%, more preferably 10±3 wt.-%, still more preferably 10±2.5 wt.-%, yet more preferably 10±2 wt.-%, most preferably 10±1.5 wt.-%, and in particular 10±1 wt.-%, based on the total weight of matrix material. In another preferred embodiment, the content of the disintegrant in the matrix material is within the range of 12.5±4 wt.-%, more preferably 12.5±3 wt.-%, still more preferably 12.5±2.5 wt.-%, yet more preferably 12.5±2 wt.-%, most preferably 12.5±1.5 wt.-%, and in particular 12.5±1 wt.-%, based on the total weight of matrix material.
In a preferred embodiment, the content of the disintegrant in the tablet is within the range of 2±1.8 wt.-%, more preferably 2±1.5 wt.-%, still more preferably 2±1.3 wt.-%, yet more preferably 2±1.0 wt.-%, most preferably 2±0.8 wt.-%, and in particular 2±0.5 wt.-%, based on the total weight of tablet. In another preferred embodiment, the content of the disintegrant in the tablet is within the range of 4±1.8 wt.-%, more preferably 4±1.5 wt.-%, still more preferably 4±1.3 wt.-%, yet more preferably 4±1.0 wt.-%, most preferably 4±0.8 wt.-%, and in particular 4±0.5 wt.-%, based on the total weight of tablet. In still another preferred embodiment, the content of the disintegrant in the tablet is within the range of 6±1.8 wt.-%, more preferably 6±1.5 wt.-%, still more preferably 6±1.3 wt.-%, yet more preferably 6±1.0 wt.-%, most preferably 6±0.8 wt.-%, and in particular 6±0.5 wt.-%, based on the total weight of tablet. In another preferred embodiment, the content of the disintegrant in the tablet is within the range of 8±1.8 wt.-%, more preferably 8±1.5 wt.-%, still more preferably 8±1.3 wt.-%, yet more preferably 8±1.0 wt.-%, most preferably 8±0.8 wt.-%, and in particular 8±0.5 wt.-%, based on the total weight of tablet.
Preferably, the matrix material comprises a disintegrant in combination with one or more water insoluble pharmaceutical excipients, preferably fillers/binders and/or lubricants.
Preferably, the matrix material comprises a filler or a binder. As many fillers can be regarded as binders and vice versa, for the purpose of specification “filler/binder” refers to any excipient that is suitable as filler, binder or both. Thus, the matrix material preferably comprises a filler/binder.
Preferred fillers (=filler/binders) are selected from the group consisting of silicium dioxide (e.g. Aerosil®), microcrystalline cellulose (e.g. Avicel®, Elcema®, Emocel®, ExCel®, Vitacell®); cellulose ether (e.g. Natrosol®, Klucel®, Methocel®, Blanose®, Pharmacoat®, Viscontran®); mannitol; dextrines; dextrose; calciumhydrogen phosphate (e.g. Emcompress®); maltodextrine (e.g. Emdex®); lactose (e.g. Fast-Flow Lactose®; Ludipress®, Tablettose®, Zeparox®); polyvinylpyrrolidone (PVP) (e.g. Kollidone®, Polyplasdone®, Polydone®); saccharose (e.g. Nu-Tab®, Sugar Tab®); magnesium salts (e.g. MgCO3, MgO, MgSiO3); starches and pretreated starches (e.g. Prejel®, Primotab® ET, Starch® 1500). Preferred binders are selected from the group consisting of alginates; chitosanes; and any of the fillers mentioned above (=fillers/binders).
Some fillers/binders may also serve other purposes. It is known, for example, that silicium dioxide exhibits excellent function as a glidant. Thus, preferably, the matrix material comprises a glidant such as silicium dioxide.
In a preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the matrix material is within the range of 50±25 wt.-%, more preferably 50±20 wt.-%, still more preferably 50±15 wt.-%, yet more preferably 50±10 wt.-%, most preferably 50±7.5 wt.-%, and in particular 50±5 wt.-%, based on the total weight of matrix material. In another preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the matrix material is within the range of 65±25 wt.-%, more preferably 65±20 wt.-%, still more preferably 65±15 wt.-%, yet more preferably 65±10 wt.-%, most preferably 65±7.5 wt.-%, and in particular 65±5 wt.-%, based on the total weight of matrix material. In still another preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the matrix material is within the range of 80±19 wt.-%, more preferably 80±17.5 wt.-%, still more preferably 80±15 wt.-%, yet more preferably 80±10 wt.-%, most preferably 80±7.5 wt.-%, and in particular 80±5 wt.-%, based on the total weight of matrix material. In another preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the matrix material is within the range of 90±9 wt.-%, more preferably 90±8 wt.-%, still more preferably 90±7 wt.-%, yet more preferably 90±6 wt.-%, most preferably 90±5 wt.-%, and in particular 90±4 wt.-%, based on the total weight of matrix material.
In a preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the tablet is within the range of 25±24 wt.-%, more preferably 25±20 wt.-%, still more preferably 25±16 wt.-%, yet more preferably 25±12 wt.-%, most preferably 25±8 wt.-%, and in particular 25±4 wt.-%, based on the total weight of tablet. In another preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the tablet is within the range of 30±29 wt.-%, more preferably 30±25 wt.-%, still more preferably 30±20 wt.-%, yet more preferably 30±15 wt.-%, most preferably 30±10 wt.-%, and in particular 30±5 wt.-%, based on the total weight of tablet. In still another preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the tablet is within the range of 35±34 wt.-%, more preferably 35±28 wt.-%, still more preferably 35±22 wt.-%, yet more preferably 35±16 wt.-%, most preferably 35±10 wt.-%, and in particular 35±4 wt.-%, based on the total weight of tablet. In another preferred embodiment, the content of the filler/binder or mixture of fillers/binders in the tablet is within the range of 40±39 wt.-%, more preferably 40±32 wt.-%, still more preferably 40±25 wt.-%, yet more preferably 40±18 wt.-%, most preferably 40±11 wt.-%, and in particular 40±4 wt.-%, based on the total weight of tablet.
Preferably, the filler/binder is contained in the matrix material but not in the coated particulates of the tablet according to the invention.
In a preferred embodiment, a portion (e.g. 10% of the total tablet mass) of the matrix is granulated on the coated particulates (preferably by non-aqueous wet granulation, e.g. with isopropylic alcohol) and the remaining matrix material is added to the thus granulated coated particulates and blended prior to compression/processing to tablets. Thus, according to this embodiment, the particulates are coated by a coating that in turn is overcoated a portion of the matrix material, whereas the remainder of the matrix material is preferably employed in non-granulated form.
Preferably, the matrix material comprises a diluent or lubricant, preferably selected from the group consisting of calcium stearate; magnesium stearate; glycerol monobehenate (e.g. Compritol®); Myvatex®; Precirol®; Precirol® Ato5; sodium stearylfumarate (e.g. Pruv®); and talcum. Magnesium stearate is particularly preferred. Preferably, the content of the lubricant in the matrix material is at most 10.0 wt.-%, more preferably at most 7.5 wt.-%, still more preferably at most 5.0 wt.-%, yet more preferably at most 2.0 wt.-%, even more preferably at most 1.0 wt.-%, and most preferably at most 0.5 wt.-%, based on the total weight of the matrix material and based on the total weight of tablet.
In particularly preferred embodiment, the matrix material comprises a combination of disintegrant, filler/binder and lubricant.
Particularly preferred contents of disintegrant, filler/binder and lubricant of the matrix material, relative to the total weight of the matrix material, are summarized as embodiments A1 to A6 in the table here below:
wherein the disintegrant is preferably crosslinked sodium carboxymethyl cellulose (Na-CMC) or crosslinked polyvinylpyrrolidone (PVP CI); the filler binder is preferably microcrystalline cellulose or a combination of microcrystalline cellulose with colloidal silicon dioxide; and the lubricant is preferably magnesium stearate.
The matrix material of the tablets according to the invention may additionally contain other excipients that are conventional in the art, e.g. diluents, binders, granulating aids, colourants, flavourants, pore formers, surfactants, glidants, wet-regulating agents and disintegrants. The skilled person will readily be able to determine appropriate quantities of each of these excipients.
Preferred pore formers include, but are not limited to glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, water-soluble hydrophilic polymers, hydroxyalkyl-celluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbowaxes, carbopol, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α-ω)alkylenediols; inorganic compounds; alkali metal salts; alkaline earth metal salts, or combinations thereof.
Preferred surfactants are nonionic, anionic, cationic or amphoteric surfactants.
In a preferred embodiment, the matrix material contains an ionic surfactant, in particular an anionic surfactant.
Suitable anionic surfactants include but are not limited to sulfuric acid esters such as sodium lauryl sulfate (sodium dodecyl sulfate, e.g. Texapon® K12), sodium cetyl sulfate (e.g. Lanette E®), sodium cetylstearyl sulfate, sodium stearyl sulfate, sodium dioctylsulfosuccinate (docusate sodium); and the corresponding potassium or calcium salts thereof.
Preferably, the anionic surfactant has the general formula (II-a)
CnH2n+1O—SO3−M+ (II-a),
Further suitable anionic surfactants include salts of cholic acid including sodium glycocholate (e.g. Konakion® MM, Cernevit®), sodium taurocholate and the corresponding potassium or ammonium salts.
In another preferred embodiment, the matrix material contains a non-ionic surfactant. Suitable non-ionic surfactants include but are not limited to
In a preferred embodiment, the matrix material according to the invention comprises a surfactant or mixture of different surfactants obtainable by
In a preferred embodiment, the content of the surfactant is at least 0.001 wt.-% or at least 0.005 wt.-%, more preferably at least 0.01 wt.-% or at least 0.05 wt.-%, still more preferably at least 0.1 wt.-%, at least 0.2 wt.-%, or at least 0.3 wt.-%, yet more preferably at least 0.4 wt.-%, at least 0.5 wt.-%, or at least 0.6 wt.-%, and in particular at least 0.7 wt.-%, at least 0.8 wt.-%, at least 0.9 wt.-%, or at least 1.0 wt.-%, based on the total weight of the tablet.
In a preferred embodiment, however, the matrix material of the tablet according to the invention consists of one or more disintegrants, one or more filler/binder's and one or more lubricants, but does not contain any other constituents.
In a particularly preferred embodiment, the matrix material of the tablet according to the invention does not contain one or more gel-forming agents and/or a silicone.
As used herein the term “gel-forming agent” is used to refer to a compound that, upon contact with a solvent (e.g. water), absorbs the solvent and swells, thereby forming a viscous or semi-viscous substance. Preferred gel-forming agents are not cross-linked. This substance may moderate pharmacologically active compound release from the embedded particulates in both aqueous and aqueous alcoholic media. Upon full hydration, a thick viscous solution or dispersion is typically produced that significantly reduces and/or minimizes the amount of free solvent which can contain an amount of solubilized pharmacologically active compound, and which can be drawn into a syringe. The gel that is formed may also reduce the overall amount of pharmacologically active compound extractable with the solvent by entrapping the pharmacologically active compound within a gel structure. Thus the gel-forming agent may play an important role in conferring tamper-resistance to the tablets according to the invention.
Gel-forming agents that preferably are not contained in the matrix material include pharmaceutically acceptable polymers, typically hydrophilic polymers, such as hydrogels. Representative examples of gel-forming agent include polyethylene oxide, polyvinyl alcohol, hydroxypropylmethyl cellulose, carbomers, poly(uronic) acids and mixtures thereof.
Thus, the physiologically acceptable polymer, preferably the polyalkylene oxide that is contained in the coated particulates of the tablets according to the invention is preferably not also contained in the matrix material.
Preferably, the pharmacologically active compound which is contained in the coated particulates of the tablet according to the invention is preferably not also contained in the matrix material.
Thus, in a preferred embodiment, the total amount of pharmacologically active compound contained in the tablet according to the invention is present in the coated particulates which form a discontinuous phase within the matrix material; and the matrix material forming a continuous phase does not contain any pharmacologically active compound.
The tablet according to the invention contains a plurality of coated particulates. The coated particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide. Preferably, the pharmacologically active compound is dispersed in the physiologically acceptable polymer, preferably the polyalkylene oxide.
For the purpose of specification, the term “particulate” refers to a discrete mass of material that is solid, e.g. at 20° C. or at room temperature or ambient temperature. Preferably a particulate is solid at 20° C. Preferably, the coated particulates are monoliths. Preferably, the pharmacologically active compound and the physiologically acceptable polymer, preferably the polyalkylene oxide are intimately homogeneously distributed in the coated particulates so that the coated particulates do not contain any segments where either pharmacologically active compound is present in the absence of physiologically acceptable polymer, preferably polyalkylene oxide or where physiologically acceptable polymer, preferably polyalkylene oxide is present in the absence of pharmacologically active compound.
The particulates are film coated and the physiologically acceptable polymer, preferably the polyalkylene oxide is preferably homogeneously distributed in the core of the pharmaceutical dosage form (tablet), i.e. the film coating preferably does not contain physiologically acceptable polymer, preferably polyalkylene oxide, but optionally polyalkylene glycol that differs from polyalkylene oxide in its lower molecular weight. Nonetheless, the film coating as such may of course contain one or more polymers, which however, preferably differ from the polyalkylene oxide contained in the core.
The coated particulates are of macroscopic size, typically the average diameter is within the range of from 100 μm to 1500 μm, preferably 200 μm to 1500 μm, more preferably 300 μm to 1500 μm, still more preferably 400 μm to 1500 μm, most preferably 500 μm to 1500 μm, and in particular 600 μm to 1500 μm. The tablets according to the invention comprise particulates as a discontinuous phase, i.e. the coated particulates form a discontinuous phase in the matrix material which in turn preferably forms a continuous phase. In this regard, discontinuous means that not each and every particulate is in intimate contact with another particulate but that the coated particulates are at least partially separated from one another by the matrix material in which the coated particulates are embedded. In other words, the coated particulates preferably do not form a single coherent mass within the tablets according to the invention.
The tablet according to the invention comprises particulates in an amount of less than two thirds of the total weight of the tablet.
It has been surprisingly found that the content of particulates in the tablet can be optimized in order to provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
Preferably, the content of the coated particulates in the tablets according to the invention is at most 65 wt.-%, more preferably at most 62.5 wt.-%, still more preferably at most 60 wt.-%, yet more preferably at most 57.5 wt.-%, most preferably at most 55 wt.-% and in particular at most 52.5 wt.-%, based on the total weight of the tablets.
Preferably, the content of the coated particulates in the tablets according to the invention is at least 10 wt.-%, at least 12.5 wt.-%, at least 15 wt.-% or at least 17.5 wt.-%; more preferably at least 20 wt.-%, at least 22.5 wt.-%, at least 25 wt.-% or at least 27.5 wt.-%; most preferably at least 30 wt.-%, at least 32.5 wt.-%, at least 35 wt.-% or at least 37.5 wt.-%; and in particular at least 40 wt.-%, at least 42.5 wt.-%, at least 45 wt.-% or at least 47.5 wt.-%; based on the total weight of the tablet.
In a preferred embodiment, the content of the coated particulates in the tablets according to the invention is within the range of 35±30 wt.-%, more preferably 35±25 wt.-%, still more preferably 35±20 wt.-%, yet more preferably 35±15 wt.-%, most preferably 35±10 wt.-%, and in particular 35±5 wt.-%, based on the total weight of the tablet. In another preferred embodiment, the content of the coated particulates in the tablets according to the invention is within the range of 40±30 wt.-%, more preferably 40±25 wt.-%, still more preferably 40±20 wt.-%, yet more preferably 40±15 wt.-%, most preferably 40±10 wt.-%, and in particular 40±5 wt.-%, based on the total weight of the tablet. In still another preferred embodiment, the content of the coated particulates in the tablets according to the invention is within the range of 45±30 wt.-%, more preferably 45±25 wt.-%, still more preferably 45±20 wt.-%, yet more preferably 45±15 wt.-%, most preferably 45±10 wt.-%, and in particular 45±5 wt.-%, based on the total weight of the tablet. In yet another preferred embodiment, the content of the coated particulates in the tablets according to the invention is within the range of 50±30 wt.-%, more preferably 50±25 wt.-%, still more preferably 50±20 wt.-%, yet more preferably 50±15 wt.-%, most preferably 50±10 wt.-%, and in particular 50±5 wt.-%, based on the total weight of the tablet. In another preferred embodiment, the content of the coated particulates in the tablets according to the invention is within the range of 55±30 wt.-%, more preferably 55±25 wt.-%, still more preferably 55±20 wt.-%, yet more preferably 55±15 wt.-%, most preferably 55±10 wt.-%, and in particular 55±5 wt.-%, based on the total weight of the tablet. In still another preferred embodiment, the content of the coated particulates in the tablets according to the invention is within the range of 60±30 wt.-%, more preferably 60±25 wt.-%, still more preferably 60±20 wt.-%, yet more preferably 60±15 wt.-%, most preferably 60±10 wt.-%, and in particular 60±5 wt.-%, based on the total weight of the tablet.
The shape of the coated particulates is not particularly limited. As the coated particulates are preferably manufactured by hot-melt extrusion, preferred coated particulates present in the tablets according to the invention are generally cylindrical in shape. The diameter of such coated particulates is therefore the diameter of their circular cross section. The cylindrical shape is caused by the extrusion process according to which the diameter of the circular cross section is a function of the extrusion die and the length of the cylinders is a function of the cutting length according to which the extruded strand of material is cut into pieces of preferably more or less predetermined length.
The suitability of cylindrical, i.e. a spherical particulates for the manufacture of the tablets according to the invention is unexpected. Typically, the aspect ratio is regarded as an important measure of the spherical shape. The aspect ratio is defined as the ratio of the maximal diameter (dmax) and its orthogonal Feret-diameter. For aspherical particulates, the aspect ratio has values above 1. The smaller the value the more spherical is the particulate. Aspect ratios below 1.1 are typically considered satisfactory, aspect ratios above 1.2, however, are typically considered not suitable for the manufacture of conventional tablets. The inventors have surprisingly found that when manufacturing the tablets according to the invention, even particulates having aspect ratios above 1.2 can be processed without difficulties and that it is not necessary to provide spherical particulates. In a preferred embodiment, the aspect ratio of the coated particulates is at most 1.40, more preferably at most 1.35, still more preferably at most 1.30, yet more preferably at most 1.25, even more preferably at most 1.20, most preferably at most 1.15 and in particular at most 1.10. In another preferred embodiment, the aspect ratio of the coated particulates is at least 1.10, more preferably at least 1.15, still more preferably at least 1.20, yet more preferably at least 1.25, even more preferably at least 1.30, most preferably at least 1.35 and in particular at least 1.40.
The coated particulates in the tablets according to the invention are of macroscopic size, i.e. typically have an average particle size of at least 50 μm, more preferably at least 100 μm, still more preferably at least 150 μm or at least 200 μm, yet more preferably at least 250 μm or at least 300 μm, most preferably at least 400 μm or at least 500 μm, and in particular at least 550 μm or at least 600 μm.
Preferred coated particulates have an average length and average diameter of about 1000 μm or less. When the coated particulates are manufactured by extrusion technology, the “length” of coated particulates is the dimension of the coated particulates that is parallel to the direction of extrusion. The “diameter” of coated particulates is the largest dimension that is perpendicular to the direction of extrusion.
Particularly preferred coated particulates have an average diameter of less than about 1000 μm, more preferably less than about 800 μm, still more preferably of less than about 650 μm. Especially preferred coated particulates have an average diameter of less than 700 μm, particularly less than 600 μm, still more particularly less than 500 μm, e.g. less than 400 μm. Particularly preferred particulates have an average diameter in the range 200-1000 μm, more preferably 400-800 μm, still more preferably 450-700 μm, yet more preferably 500-650 μm, e.g. about 500-600 μm. Further preferred particulates have an average diameter of between about 300 μm and about 400 μm, of between about 400 μm and 500 μm, or of between about 500 μm and 600 μm, or of between 600 μm and 700 μm or of between 700 μm and 800 μm.
Preferred particulates that are present in the tablets according to the invention have an average length of less than about 1000 μm, preferably an average length of less than about 800 μm, still more preferably an average length of less than about 650 μm, e.g. a length of about 800 μm, about 700 μm about 600 μm, about 500 μm, about 400 μm or about 300 μm. Especially preferred particulates have an average length of less than 700 μm, particularly less than 650 μm, still more particularly less than 550 μm, e.g. less than 450 μm. Particularly preferred particulates therefore have an average length in the range 200-1000 μm, more preferably 400-800 μm, still more preferably 450-700 μm, yet more preferably 500-650 μm, e.g. about 500-600 μm. The minimum average length of the microparticulates is determined by the cutting step and may be, e.g. 500 μm, 400 μm, 300 μm or 200 μm.
In a preferred embodiment, the coated particulates have (i) an average diameter of about 1000±300 μm, more preferably 1000±250 μm, still more preferably 1000±200 μm, yet more preferably 100±150 μm, most preferably 1000±100 μm, and in particular 1000±50 μm; and/or (ii) an average length of about 750±300 μm, more preferably 750±250 μm, still more preferably 750±200 μm, yet more preferably 750±150 μm, most preferably 750±100 μm, and in particular 750±50 μm.
In another preferred embodiment, the coated particulates have (i) an average diameter of about 750±300 μm, more preferably 750±250 μm, still more preferably 750±200 μm, yet more preferably 750±150 μm, most preferably 750±100 μm, and in particular 750±50 μm; and/or (ii) an average length of about 750±300 μm, more preferably 750±250 μm, still more preferably 750±200 μm, yet more preferably 750±150 μm, most preferably 750±100 μm, and in particular 750±50 μm.
It has been surprisingly found that the size of the coated particulates in the tablet can be optimized in order to provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
The size of particulates may be determined by any conventional procedure known in the art, e.g. laser light scattering, sieve analysis, light microscopy or image analysis.
Preferably, the plurality of coated particulates that is contained in the tablet according to the invention has an arithmetic average weight, in the following referred to as “aaw”, wherein at least 70%, more preferably at least 75%, still more preferably at least 80%, yet more preferably at least 85%, most preferably at least 90% and in particular at least 95% of the individual particles contained in said plurality of coated particulates has an individual weight within the range of aaw±30%, more preferably aaw±25%, still more preferably aaw±20%, yet more preferably aaw±15%, most preferably aaw±10%, and in particular aaw±5%. For example, if the tablet according to the invention contains a plurality of 100 particulates and aaw of said plurality of coated particulates is 1.00 mg, at least 75 individual particles (i.e. 75%) have an individual weight within the range of from 0.70 to 1.30 mg (1.00 mg±30%).
The particulates are coated, preferably film coated. It has been surprisingly found that when the particulates are film coated, the disintegration time and/or the drug release from the tablets can be further accelerated, which is particularly significant for tablets with immediate drug release.
Preferably, the plurality of coated particulates contained in the dosage form according to the invention encompasses the total quantity of particulates which contain the pharmacologically active compound, i.e. preferably all active compound containing particulates are coated.
Preferably, the coating material does not contain a disintegrant.
The particulates according to the invention are provided, partially or preferably completely, with a coating. The particulates according to the invention are preferably film coated with film coating compositions. Suitable coating materials are commercially available, e.g. under the trademarks Opadry® and Eudragit®.
Preferably, the coating material comprises a water-soluble polymer. For the purpose of specification, a water-soluble polymer is preferably a non-enteric polymer that rapidly dissolves when being exposed to an acidic medium such as gastric juice. Preferably, the water-solubility of the polymer in 100 g artificial gastric juice (HCl aq.) at pH 1.2 and 21° C. is at least 1.0 g, more preferably at least 2.0 g, still more preferably at least 3.0 g, yet more preferably at least 4.0 g, most preferably at least 5.0 g, and in particular at least 6.0 g.
Examples of suitable coating materials include cellulose esters and cellulose ethers, such as methylcellulose (MC), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), sodium carboxymethylcellulose (Na—CMC), ethylcellulose (EC), cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose phthalate (HPMCP); poly(meth)acrylates, such as aminoalkylmethacrylate copolymers, ethylacrylate methyl-methacrylate copolymers, methacrylic acid methylmethacrylate copolymers, methacrylic acid methylmethacrylate copolymers; vinyl polymers, such as polyvinylpyrrolidone, polyvinyl-acetatephthalate, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft copolymers, polyvinylacetate; and natural film formers.
The coating material may contain excipients such as stabilizers (e.g. surfactants such as macrogol cetostearylether, sodium dodecylsulfate, and the like). Suitable excipients of film coating materials are known to the skilled person.
In a particularly preferred embodiment, the coating is water-soluble. In a preferred embodiment, the coating is based on polyvinyl alcohol, such as polyvinyl alcohol-part. hydrolyzed, and may additionally contain polyethylene glycol, such as macrogol 3350, and/or pigments. In another preferred embodiment, the coating is based on hydroxypropylmethyl-cellulose, preferably hypromellose type 2910 having a viscosity of 3 to 15 mPas.
A particularly preferred coating contains polyvinyl alcohol and optionally, further excipients such as xanthan gum and/or talcum.
The particulates are film coated and the content of the dried film coating is preferably at most 5 wt.-%, more preferably at most 4 wt.-%, still more preferably at most 3.5 wt.-%, yet more preferably at most 3 wt.-%, most preferably at most 2.5 wt.-%, and in particular at most 2 wt.-%, based on the total weight of the coated particulates. In a particularly preferred embodiment, the weight increase relative to the total weight of the particulates (uncoated starting material) is within the range of from 3.0 to 4.7 wt.-%, more preferably 3.1 to 4.6 wt.-%, still more preferably 3.2 to 4.5 wt.-%, yet more preferably 3.3 to 4.4 wt.-%, most preferably 3.4 to 4.3 wt.-%, and in particular 3.5 to 4.2 wt.-%.
It has been surprisingly found that the relative weight ratio of matrix material:particulates in the tablet can be optimized in order to provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
Preferably, said relative weight ratio is within the range of 1:1.00±0.75, more preferably 1:1.00±0.50, still more preferably 1:1.00±0.40, yet more preferably 1:1.00±0.30, most preferably 1:1.00±0.20, and in particular 1:1.00±0.10.
The coated particulates contain at least a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide. Preferably, however, the coated particulates contain additional pharmaceutical excipients such as antioxidants and plasticizers.
The pharmacologically active compound is not particularly limited. Preferably, the pharmacologically active compound is an opioid.
In a preferred embodiment, the coated particulates and the tablet, respectively, contain only a single pharmacologically active compound. In another preferred embodiment, the coated particulates and the tablet, respectively, contain a combination of two or more pharmacologically active compounds.
Preferably, pharmacologically active compound is an active ingredient with potential for being abused. Active ingredients with potential for being abused are known to the person skilled in the art and comprise e.g. tranquillizers, stimulants, barbiturates, narcotics, opioids or opioid derivatives.
Preferably, the pharmacologically active compound exhibits psychotropic action.
Preferably, the pharmacologically active compound is selected from the group consisting of opiates, opioids, stimulants, tranquilizers, and other narcotics.
Particularly preferably, the pharmacologically active compound is an opioid. According to the ATC index, opioids are divided into natural opium alkaloids, phenylpiperidine derivatives, diphenylpropylamine derivatives, benzomorphan derivatives, oripavine derivatives, morphinan derivatives and others.
The following opiates, opioids, tranquillizers or other narcotics are substances with a psychotropic action, i.e. have a potential of abuse, and hence are preferably contained in the tablet and the coated particulates, respectively: alfentanil, allobarbital, allylprodine, alphaprodine, alprazolam, amfepramone, amphetamine, amphetaminil, amobarbital, anileridine, apocodeine, axomadol, barbital, bemidone, benzylmorphine, bezitramide, bromazepam, brotizolam, buprenorphine, butobarbital, butorphanol, camazepam, carfentanil, cathine/D-norpseudoephedrine, chlordiazepoxide, clobazam clofedanol, clonazepam, clonitazene, clorazepate, clotiazepam, cloxazolam, cocaine, codeine, cyclobarbital, cyclorphan, cyprenorphine, delorazepam, desomorphine, dextromoramide, dextropropoxyphene, dezocine, diampromide, diamorphone, diazepam, dihydrocodeine, dihydromorphine, dihydromorphone, dimenoxadol, dimephetamol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, dronabinol, eptazocine, estazolam, ethoheptazine, ethylmethylthiambutene, ethyl loflazepate, ethylmorphine, etonitazene, etorphine, faxeladol, fencamfamine, fenethylline, fenpipramide, fenproporex, fentanyl, fludiazepam, flunitrazepam, flurazepam, halazepam, haloxazolam, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, hydroxymethylmorphinan, ketazolam, ketobemidone, levacetylmethadol (LAAM), levomethadone, levorphanol, levophenacylmorphane, levoxemacin, lisdexamfetamine dimesylate, lofentanil, loprazolam, lorazepam, lormetazepam, mazindol, medazepam, mefenorex, meperidine, meprobamate, metapon, meptazinol, metazocine, methylmorphine, metamphetamine, methadone, methaqualone, 3-methylfentanyl, 4-methylfentanyl, methylphenidate, methylphenobarbital, methyprylon, metopon, midazolam, modafinil, morphine, myrophine, nabilone, nalbuphene, nalorphine, narceine, nicomorphine, nimetazepam, nitrazepam, nordazepam, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxazepam, oxazolam, oxycodone, oxymorphone, Papaver somniferum, papavereturn, pernoline, pentazocine, pentobarbital, pethidine, phenadoxone, phenomorphane, phenazocine, phenoperidine, piminodine, pholcodeine, phenmetrazine, phenobarbital, phentermine, pinazepam, pipradrol, piritramide, prazepam, profadol, proheptazine, promedol, properidine, propoxyphene, remifentanil, secbutabarbital, secobarbital, sufentanil, tapentadol, temazepam, tetrazepam, tilidine (cis and trans), tramadol, triazolam, vinylbital, N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)propionamide, (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, (1R,2R,4S)-2-(dimethylamino)-methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl)cyclohexanol, (1R,2R)-3-(2-dimethyl-aminomethyl-cyclohexyl)phenol, (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, (2R,3R)-1-dimethylamino-3(3-methoxyphenyl)-2-methyl-pentan-3-ol, (1RS,3RS,6RS)-6-di-methylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, preferably as racemate, 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl 2-(4-isobutyl-phenyl)propionate, 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl 2-(6-methoxy-naphthalen-2-yl)propionate, 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(4-isobutyl-phenyl)propionate, 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)propionate, (RR—SS)-2-acetoxy-4-trifluoromethyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-trifluoromethyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-4-chloro-2-hydroxy-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-methyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-methoxy-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-5-nitro-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2′,4′-difluoro-3-hydroxy-biphenyl-4-carboxylic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, and corresponding stereoisomeric compounds, in each case the corresponding derivatives thereof, physiologically acceptable enantiomers, stereoisomers, diastereomers and racemates and the physiologically acceptable derivatives thereof, e.g. ethers, esters or amides, and in each case the physiologically acceptable compounds thereof, in particular the acid or base addition salts thereof and solvates, e.g. hydrochlorides.
In a preferred embodiment, the pharmacologically active compound is selected from the group consisting of DPI-125, M6G (CE-04-410), ADL-5859, CR-665, NRP290 and sebacoyl dinalbuphine ester.
In a preferred embodiment, the pharmacologically active compound is selected from the group consisting of oxymorphone, hydromorphone and morphine.
In another preferred embodiment, the pharmacologically active compound is selected from the group consisting of tapentadol, faxeladol and axomadol.
In still another preferred embodiment, the pharmacologically active compound is selected from the group consisting of 1,1-(3-dimethylamino-3-phenylpentamethylene)-6-fluoro-1,3,4,9-tetrahydropyrano[3,4-b]indole, particularly its hemicitrate; 1,1-[3-dimethylamino-3-(2-thienyl)-pentamethylene]-1,3,4,9-tetrahydropyrano[3,4-b]indole, particularly its citrate; and 1,1-[3-dimethylamino-3-(2-thienyl)pentamethylene]-1,3,4,9-tetrahydropyrano[3,4-b]-6-fluoroindole, particularly its hemicitrate. These compounds are known from, e.g., WO 2004/043967, WO 2005/066183.
The pharmacologically active compound may be present in form of a physiologically acceptable salt, e.g. physiologically acceptable acid addition salt.
Physiologically acceptable acid addition salts comprise the acid addition salt forms which can conveniently be obtained by treating the base form of the active ingredient with appropriate organic and inorganic acids. Active ingredients containing an acidic proton may be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases. The term addition salt also comprises the hydrates and solvent addition forms which the active ingredients are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
It has been surprisingly found that the content of the pharmacologically active compound in the tablet and in the coated particulates, respectively, can be optimized in order to provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
The pharmacologically active compound is present in the tablet in a therapeutically effective amount. The amount that constitutes a therapeutically effective amount varies according to the active ingredients being used, the condition being treated, the severity of said condition, the patient being treated, and the frequency of administration.
The content of the pharmacologically active compound in the tablet is not limited. The dose of the pharmacologically active compound which is adapted for administration preferably is in the range of 0.1 mg to 500 mg, more preferably in the range of 1.0 mg to 400 mg, even more preferably in the range of 5.0 mg to 300 mg, and most preferably in the range of 10 mg to 250 mg. In a preferred embodiment, the total amount of the pharmacologically active compound that is contained in the tablet is within the range of from 0.01 to 200 mg, more preferably 0.1 to 190 mg, still more preferably 1.0 to 180 mg, yet more preferably 1.5 to 160 mg, most preferably 2.0 to 100 mg and in particular 2.5 to 80 mg.
Preferably, the content of the pharmacologically active compound is within the range of from 0.01 to 80 wt.-%, more preferably 0.1 to 50 wt.-%, still more preferably 1 to 25 wt.-%, based on the total weight of the tablet.
In a preferred embodiment, the content of pharmacologically active compound is within the range of from 5.0±4.5 wt.-%, or 7.5±7.0 wt.-%, or 10±9.0 wt.-%, or 12.5±12.0 wt.-%, or 15±14 wt.-%, or 17.5±17.0 wt.-%, or 20±19 wt.-%, or 22.5±22.0 wt.-%, or 25±24 wt.-%; more preferably 5.0±4.0 wt.-%, or 7.5±6.0 wt.-%, or 10±8.0 wt.-%, or 12.5±12.0 wt.-%, or 15±12 wt.-%, or 17.5±15.0 wt.-%, or 20±19 wt.-%, or 22.5±22.0 wt.-%, or 25±24 wt.-%; still more preferably 5.0±3.5 wt.-%, or 7.5±5.0 wt.-%, or 10±7.0 wt.-%, or 12.5±10.0 wt.-%, or 15±10 wt.-%, or 17.5±13.0 wt.-%, or 20±17 wt.-%, or 22.5±19.0 wt.-%, or 25±21 wt.-%; yet more preferably 5.0±3.0 wt.-%, or 7.5±4.0 wt.-%, or 10±6.0 wt.-%, or 12.5±8.0 wt.-%, or 15±8.0 wt.-%, or 17.5±11.0 wt.-%, or 20±15 wt.-%, or 22.5±16.0 wt.-%, or 25±18 wt.-%; even more preferably 5.0±2.5 wt.-%, or 7.5±3.0 wt.-%, or 10±5.0 wt.-%, or 12.5±6.0 wt.-%, or 15±6.0 wt.-%, or 17.5±9.0 wt.-%, or 20±13 wt.-%, or 22.5±13.0 wt.-%, or 25±15 wt.-%; most preferably 5.0±2.0 wt.-%, or 7.5±2.0 wt.-%, or 10±4.0 wt.-%, or 12.5±4.0 wt.-%, or 15±4.0 wt.-%, or 17.5±7.0 wt.-%, or 20±11 wt.-%, or 22.5±10.0 wt.-%, or 25±12 wt.-%; and in particular 5.0±1.5 wt.-%, or 7.5±1.0 wt.-%, or 10±3.0 wt.-%, or 12.5±2.0 wt.-%, or 15±2.0 wt.-%, or 17.5±5.0 wt.-%, or 20±9 wt.-%, or 22.5±7.0 wt.-%, or 25±9 wt.-%; in each case based on the total weight of the tablet.
In a further preferred embodiment, the content of pharmacologically active compound is within the range of from 20±6 wt.-%, more preferably 20±5 wt.-%, still more preferably 20±4 wt.-%, most preferably 20±3 wt.-%, and in particular 20±2 wt.-%, based on the total weight of the tablet. In another preferred embodiment, the content of pharmacologically active compound is within the range of from 25±6 wt.-%, more preferably 25±5 wt.-%, still more preferably 25±4 wt.-%, most preferably 25±3 wt.-%, and in particular 25±2 wt.-%, based on the total weight of the tablet.
The skilled person may readily determine an appropriate amount of pharmacologically active compound to include in a tablet. For instance, in the case of analgesics, the total amount of pharmacologically active compound present in the tablet is that sufficient to provide analgesia. The total amount of pharmacologically active compound administered to a patient in a dose will vary depending on numerous factors including the nature of the pharmacologically active compound, the weight of the patient, the severity of the pain, the nature of other therapeutic agents being administered etc.
In a preferred embodiment, the pharmacologically active compound is contained in the tablet in an amount of 7.5±5 mg, 10±5 mg, 20±5 mg, 30±5 mg, 40±5 mg, 50±5 mg, 60±5 mg, 70±5 mg, 80±5 mg, 90±5 mg, 100±5 mg, 110±5 mg, 120±5 mg, 130±5, 140±5 mg, 150±5 mg, 160±5 mg, 170±5 mg, 180±5 mg, 190±5 mg, 200±5 mg, 210±5 mg, 220±5 mg, 230±5 mg, 240±5 mg, 250±5 mg, 260±5 mg, 270±5 mg, 280±5 mg, 290±5 mg, or 300±5 mg. In another preferred embodiment, the pharmacologically active compound is contained in the tablet in an amount of 5±2.5 mg, 7.5±2.5 mg, 10±2.5 mg, 15±2.5 mg, 20±2.5 mg, 25±2.5 mg, 30±2.5 mg, 35±2.5 mg, 40±2.5 mg, 45±2.5 mg, 50±2.5 mg, 55±2.5 mg, 60±2.5 mg, 65±2.5 mg, 70±2.5 mg, 75±2.5 mg, 80±2.5 mg, 85±2.5 mg, 90±2.5 mg, 95±2.5 mg, 100±2.5 mg, 105±2.5 mg, 110±2.5 mg, 115±2.5 mg, 120±2.5 mg, 125±2.5 mg, 130±2.5 mg, 135±2.5 mg, 140±2.5 mg, 145±2.5 mg, 150±2.5 mg, 155±2.5 mg, 160±2.5 mg, 165±2.5 mg, 170±2.5 mg, 175±2.5 mg, 180±2.5 mg, 185±2.5 mg, 190±2.5 mg, 195±2.5 mg, 200±2.5 mg, 205±2.5 mg, 210±2.5 mg, 215±2.5 mg, 220±2.5 mg, 225±2.5 mg, 230±2.5 mg, 235±2.5 mg, 240±2.5 mg, 245±2.5 mg, 250±2.5 mg, 255±2.5 mg, 260±2.5 mg, or 265±2.5 mg.
In a particularly preferred embodiment, the pharmacologically active compound is tapentadol, preferably its HCl salt, and the tablet is adapted for administration once daily, twice daily, thrice daily or more frequently. In this embodiment, pharmacologically active compound is preferably contained in the tablet in an amount of from 25 to 100 mg.
In a particularly preferred embodiment, the pharmacologically active compound is oxymorphone, preferably its HCl salt, and the tablet is adapted for administration once daily, twice daily, thrice daily or more frequently. In this embodiment, the pharmacologically active compound is preferably contained in the tablet in an amount of from 5 to 40 mg. In another particularly preferred embodiment, the pharmacologically active compound is oxymorphone, preferably its HCl salt, and the tablet is adapted for administration once daily. In this embodiment, the pharmacologically active compound is preferably contained in the tablet in an amount of from 10 to 80 mg.
In another particularly preferred embodiment, the pharmacologically active compound is oxycodone, preferably its HCl salt, and the tablet is adapted for administration once daily, twice daily, thrice daily or more frequently. In this embodiment, the pharmacologically active compound is preferably contained in the tablet in an amount of from 5 to 80 mg.
In still another particularly preferred embodiment, the pharmacologically active compound is hydromorphone, preferably its HCl, and the tablet is adapted for administration once daily, twice daily, thrice daily or more frequently. In this embodiment, the pharmacologically active compound is preferably contained in the tablet in an amount of from 2 to 52 mg. In another particularly preferred embodiment, the pharmacologically active compound is hydromorphone, preferably its HCl, and the tablet is adapted for administration once daily, twice daily, thrice daily or more frequently. In this embodiment, the pharmacologically active compound is preferably contained in the tablet in an amount of from 4 to 104 mg.
The coated particulates present in the tablets according to the invention preferably comprise 3 to 75 wt.-% of pharmacologically active compound, more preferably 5 to 70 wt.-% of pharmacologically active compound, still more preferably 7.5 to 65 wt.-% of pharmacologically active compound, based on the total weight of a particulate.
Preferably, the content of the pharmacologically active compound is at least 25 wt.-%, more preferably at least 30 wt.-%, still more preferably at least 35 wt.-%, yet more preferably at least 40 wt.-%, most preferably at least 45 wt.-%, based on the total weight of a particulate.
Preferably, the content of the pharmacologically active compound is at most 70 wt.-%, more preferably at most 65 wt.-%, still more preferably at most 60 wt.-%, yet more preferably at most 55 wt.-%, most preferably at most 50 wt.-%, based on the total weight of a particulate.
In a preferred embodiment, the content of the pharmacologically active compound is within the range of 35±30 wt.-%, more preferably 35±25 wt.-%, still more preferably 35±20 wt.-%, yet more preferably 35±15 wt.-%, most preferably 35±10 wt.-%, and in particular 35±5 wt.-%, based on the total weight of a particulate. In another preferred embodiment, the content of the pharmacologically active compound is within the range of 45±30 wt.-%, more preferably 45±25 wt.-%, still more preferably 45±20 wt.-%, yet more preferably 45±15 wt.-%, most preferably 45±10 wt.-%, and in particular 45±5 wt.-%, based on the total weight of a particulate. In still another preferred embodiment, the content of the pharmacologically active compound is within the range of 55±30 wt.-%, more preferably 55±25 wt.-%, still more preferably 55±20 wt.-%, yet more preferably 55±15 wt.-%, most preferably 55±10 wt.-%, and in particular 55±5 wt.-%, based on the total weight of a particulate.
The pharmacologically active compound that is included in the preparation of the tablets according to the invention preferably has an average particle size of less than 500 microns, still more preferably less than 300 microns, yet more preferably less than 200 or 100 microns. There is no lower limit on the average particle size and it may be, for example, 50 microns. The particle size of pharmacologically active compounds may be determined by any technique conventional in the art, e.g. laser light scattering, sieve analysis, light microscopy or image analysis. Generally speaking it is preferable that the largest dimension of the pharmacologically active compound particle be less than the size of the coated particulates (e.g. less than the smallest dimension of the coated particulates).
A skilled person knows how to determine pharmacokinetic parameters such as t1/2, Tmax, Cmax, AUC and bioavailability. For the purposes of the description, the pharmacokinetic parameters, which may be determined from the blood plasma concentrations of 3-(2-dimethylaminomethylcyclohexyl)phenol, are defined as follows:
The above parameters are in each case stated as mean values of the individual values for all investigated patients/test subjects.
A person skilled in the art knows how the pharmacokinetic parameters of the active ingredient may be calculated from the measured concentrations of the active ingredient in the blood plasma. In this connection, reference may be made, for example, to Willi Cawello (ed.) Parameters for Compartment-free Pharmacokinetics, Shaker Verlag Aachen (1999).
In a preferred embodiment, the pharmacologically active compound is tapentadol or a physiologically acceptable salt thereof, e.g. the hydrochloride. Preferably, the tablet according to the invention provides a mean absolute bioavailability of tapentadol at least 22%, more preferably at least 24%, still more preferably at least 26%, yet more preferably at least 28%, most preferably at least 30%, and in particular at least 32%. Tmax of tapentadol is preferably within the range of 1.25±1.20 h, more preferably 1.25±1.00 h, still more preferably 1.25±0.80 h, yet more preferably 1.25±0.60 h, most preferably 1.25±0.40 h, and in particular 1.25±0.20 h. t1/2 of tapentadol is preferably within the range of 4.0±2.8 h, more preferably 4.0±2.4 h, still more preferably 4.0±2.0 h, yet more preferably 4.0±1.6 h, most preferably 4.0±1.2 h, and in particular 4.0±0.8 h. Preferably, when normalized to a dose of 100 mg tapentadol, Cmax of tapentadol is preferably within the range of 90±85 ng/mL, more preferably 90±75 ng/mL, still more preferably 90±65 ng/mL, yet more preferably 90±55 ng/mL, most preferably 90±45 ng/mL, and in particular 90±35 ng/mL; and/or AUC of tapentadol is preferably within the range of 420±400 ng/mL·h, more preferably 420±350 ng/mL·h, still more preferably 420±300 ng/mL·h, yet more preferably 420±250 ng/mL·h, most preferably 420±200 ng/mL·h, and in particular 420±150 ng/mL·h.
In another preferred embodiment, the pharmacologically active compound is oxymorphone or a physiologically acceptable salt thereof, e.g. the hydrochloride. Preferably, the tablet according to the invention provides a mean absolute bioavailability of oxymorphone of at least 1%, more preferably at least 2%, still more preferably at least 4%, yet more preferably at least 6%, most preferably at least 8%, and in particular at least 10%. Tmax of oxymorphone is preferably within the range of 0.5±0.45 h, more preferably 0.5±0.40 h, still more preferably 0.5±0.35 h, yet more preferably 0.5±0.30 h, most preferably 0.5±0.25 h, and in particular 0.5±0.20 h. t1/2 of oxymorphone is preferably within the range of 9.5±8.0 h, more preferably 9.5±7.0 h, still more preferably 9.5±6.0 h, yet more preferably 9.5±5.0 h, most preferably 9.5±4.0 h, and in particular 9.5±3.0 h. Preferably, when normalized to a dose of 20 mg oxymorphone, Cmax of oxymorphone is preferably within the range of 4.4±3.5 ng/mL, more preferably 4.4±3.0 ng/mL, still more preferably 4.4±2.5 ng/mL, yet more preferably 4.4±2.0 ng/mL, most preferably 4.4±1.5 ng/mL, and in particular 4.4±1.0 ng/mL; and/or AUC of oxymorphone is preferably within the range of 20.0±15.0 ng/mL·h, more preferably 20.0±12.5 ng/mL·h, still more preferably 20.0±10.0 ng/mL·h, yet more preferably 20.0±7.5 ng/mL·h, most preferably 20.0±6.0 ng/mL·h, and in particular 20.0±5.0 ng/mL·h.
In another preferred embodiment, the pharmacologically active compound is oxycodone or a physiologically acceptable salt thereof, e.g. the hydrochloride. Preferably, the tablet according to the invention provides a mean absolute bioavailability of oxycodone of at least 40%, more preferably at least 45%, still more preferably at least 50%, yet more preferably at least 55%, most preferably at least 60%, and in particular at least 70%. Tmax of oxycodone is preferably within the range of 2.6±2.5 h, more preferably 2.6±2.0 h, still more preferably 2.6±1.8 h, yet more preferably 2.6±0.1.6 h, most preferably 2.6±1.4 h, and in particular 2.6±1.20 h. t1/2 of oxycodone is preferably within the range of 3.8±3.5 h, more preferably 3.8±3.0 h, still more preferably 3.8±2.5 h, yet more preferably 3.8±2.0 h, most preferably 3.8±1.5 h, and in particular 3.8±1.0 h. Preferably, when normalized to a dose of 30 mg oxycodone, Cmax of oxycodone is preferably within the range of 40±35 ng/mL, more preferably 40±30 ng/mL, still more preferably 40±25 ng/mL, yet more preferably 40±20 ng/mL, most preferably 40±15 ng/mL, and in particular 40±10 ng/mL; and/or AUC of oxycodone is preferably within the range of 270±250 ng/mL·h, more preferably 270±200 ng/mL·h, still more preferably 270±150 ng/mL·h, yet more preferably 270±100 ng/mL·h, most preferably 270±75 ng/mL·h, and in particular 270±50 ng/mL·h.
In still another preferred embodiment, the pharmacologically active compound is morphine or a physiologically acceptable salt thereof, e.g. the sulfate. Preferably, the tablet according to the invention provides a mean absolute bioavailability of morphine of at least 15%, more preferably at least 20%, still more preferably at least 25%, yet more preferably at least 30%, most preferably at least 35%, and in particular at least 40%. Tmax of morphine is preferably within the range of 0.625±0.60 h, more preferably 0.625±0.50 h, still more preferably 0.625±0.40 h, yet more preferably 0.625±0.30 h, most preferably 0.625±0.20 h, and in particular 0.625±0.15 h. Preferably, when normalized to a dose of 30 mg morphine sulfate, Cmax of morphine is preferably within the range of 25±20 ng/mL, more preferably 25±15 ng/mL, still more preferably 25±10 ng/mL, yet more preferably 25±5 ng/mL; and/or AUC of morphine is preferably within the range of 50±45 ng/mL·h, more preferably 50±40 ng/mL·h, still more preferably 50±35 ng/mL·h, yet more preferably 50±30 ng/mL·h, most preferably 50±25 ng/mL·h, and in particular 50±20 ng/mL·h.
The tablets according to the invention may also comprise one or more additional pharmacologically active compounds. The additional pharmacologically active compound may be susceptible to abuse or another pharmaceutical. Additional pharmacologically active compounds may be present within the coated particulates (“intragranular”) or within the matrix (e.g. “extragranular”, or when the matrix material is also provided in form of particulates, also “intragranular”). Where an additional pharmacologically active compound is present intragranularly, it may be present either in combination with one or more pharmacologically active compounds within the same particulates or in a discrete population of particulates alone and separate from any other pharmacologically active compounds present in the tablet.
In a preferred embodiment, the tablet according to the invention, preferably the coated particulates comprise an opioid (agonist) as well as an opioid antagonist.
Any conventional opioid antagonist may be present, e.g. naltrexone or naloxone or their pharmaceutically acceptable salts. Naloxone, including its salts, is particularly preferred. The opioid antagonist may be present within the coated particulates or within the matrix. Alternatively, opioid antagonist may be provided in separate particulates to the pharmacologically active compounds. The preferred composition of such particulates is the same as that described for pharmacologically active compound-containing particulates.
The ratio of opioid agonist to opioid antagonist in the tablets according to the invention is preferably 1:1 to 3:1 by weight, for example, about 2:1 by weight.
In another preferred embodiment, neither the coated particulates nor the tablet comprise any opioid antagonist.
The coated particulates according to the invention contain a physiologically acceptable polymer, preferably a polyalkylene oxide.
Preferably, the physiologically acceptable polymer is selected from the group consisting of polyalkylene oxide, preferably polymethylene oxide, polyethylene oxide, polypropylene oxide; polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyvinyl-pyrrolidone, poly(alk)acrylate, poly(hydroxy fatty acids), such as for example poly(3-hydroxy-butyrate-co-3-hydroxyvalerate) (Biopol®), poly(hydroxyvaleric acid); polycaprolactone, polyvinyl alcohol, polyesteramide, polyethylene succinate, polylactone, polyglycolide, polyurethane, polyamide, polylactide, polyacetal (for example polysaccharides optionally with modified side chains), polylactide/glycolide, polylactone, polyglycolide, polyorthoester, polyanhydride, block polymers of polyethylene glycol and polybutylene terephthalate (Polyactive®), polyanhydride (Polifeprosan), copolymers thereof, block-copolymers thereof (e.g., Poloxamer®), and mixtures of at least two of the stated polymers, or other polymers with the above characteristics. Polyalkylene oxide is particularly preferred.
Preferably, the physiologically acceptable polymer is a polyalkylene oxide, more preferably selected from polymethylene oxide, polyethylene oxide and polypropylene oxide, or copolymers thereof. Polyethylene oxide is preferred.
In a preferred embodiment, the physiologically acceptable polymer, preferably the polyalkylene oxide has a weight average molecular weight (MW) or viscosity average molecular weight (Mη) of at least 200,000 or at least 500,000 g/mol, preferably at least 1,000,000 g/mol or at least 2,500,000 g/mol, more preferably in the range of about 1,000,000 g/mol to about 15,000,000 g/mol, and most preferably in the range of about 5,000,000 g/mol to about 10,000,000 g/mol. Suitable methods to determine MW and Mη are known to a person skilled in the art. Mη is preferably determined by rheological measurements, whereas MW can be determined by gel permeation chromatography (GPC).
The physiologically acceptable polymer, preferably the polyalkylene oxide may comprise a single polymer having a particular average molecular weight, or a mixture (blend) of different polymers, such as two, three, four or five polymers, e.g., polymers of the same chemical nature but different average molecular weight, polymers of different chemical nature but same average molecular weight, or polymers of different chemical nature as well as different molecular weight.
For the purpose of specification, a polyalkylene glycol has a molecular weight of up to 20,000 g/mol whereas a polyalkylene oxide has a molecular weight of more than 20,000 g/mol. In a preferred embodiment, the weight average over all molecular weights of all polyalkylene oxides that are contained in the tablet is at least 200,000 g/mol. Thus, polyalkylene glycols, if any, are preferably not taken into consideration when determining the weight average molecular weight of polyalkylene oxide.
In a preferred embodiment, the physiologically acceptable polymer, preferably the polyalkylene oxide is homogeneously distributed in the coated particulates according to the invention. Preferably, the pharmacologically active compound and the physiologically acceptable polymer, preferably the polyalkylene oxide are intimately homogeneously distributed in the coated particulates so that the coated particulates do not contain any segments where either pharmacologically active compound is present in the absence of physiologically acceptable polymer, preferably polyalkylene oxide or where physiologically acceptable polymer, preferably polyalkylene oxide is present in the absence of pharmacologically active compound.
The particulates are film coated and the physiologically acceptable polymer, preferably the polyalkylene oxide is preferably homogeneously distributed in the core of the coated particulates, i.e. the film coating preferably does not contain physiologically acceptable polymer, preferably polyalkylene oxide. Nonetheless, the film coating as such may of course contain one or more polymers, which however, preferably differ from the physiologically acceptable polymer, preferably the polyalkylene oxide contained in the core.
The physiologically acceptable polymer, preferably the polyalkylene oxide may be combined with one or more different polymers selected from the group consisting of polyalkylene oxide, preferably polymethylene oxide, polyethylene oxide, polypropylene oxide; polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyvinylpyrrolidone, poly(alk)acrylate, poly(hydroxy fatty acids), such as for example poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (Biopol®), poly(hydroxyvaleric acid); polycaprolactone, polyvinyl alcohol, polyesteramide, polyethylene succinate, polylactone, polyglycolide, polyurethane, polyamide, polylactide, polyacetal (for example polysaccharides optionally with modified side chains), polylactide/glycolide, polylactone, polyglycolide, polyorthoester, polyanhydride, block polymers of polyethylene glycol and polybutylene terephthalate (Polyactive®), polyanhydride (Polifeprosan), copolymers thereof, block-copolymers thereof (e.g., Poloxamer®), and mixtures of at least two of the stated polymers, or other polymers with the above characteristics.
Preferably, the molecular weight dispersity Mw/Mn of the physiologically acceptable polymer, preferably the polyalkylene oxide is within the range of 2.5±2.0, more preferably 2.5±1.5, still more preferably 2.5±1.0, yet more preferably 2.5±0.8, most preferably 2.5±0.6, and in particular 2.5±0.4.
The physiologically acceptable polymer, preferably the polyalkylene oxide preferably has a viscosity at 25° C. of 30 to 17,600 cP, more preferably 55 to 17,600 cP, still more preferably 600 to 17,600 cP and most preferably 4,500 to 17,600 cP, measured in a 5 wt.-% aqueous solution using a model RVF Brookfield viscosimeter (spindle no. 2/rotational speed 2 rpm); of 400 to 4,000 cP, more preferably 400 to 800 cP or 2,000 to 4,000 cP, measured on a 2 wt.-% aqueous solution using the stated viscosimeter (spindle no. 1 or 3/rotational speed 10 rpm); or of 1,650 to 10,000 cP, more preferably 1,650 to 5,500 cP, 5,500 to 7,500 cP or 7,500 to 10,000 cP, measured on a 1 wt.-% aqueous solution using the stated viscosimeter (spindle no. 2/rotational speed 2 rpm).
Polyethylene oxide that is suitable for use in the tablets according to the invention is commercially available from Dow. For example, Polyox WSR N-12K, Polyox N-60K, Polyox WSR 301 NF or Polyox WSR 303NF may be used in the tablets according to the invention. For details concerning the properties of these products, it can be referred to e.g. the product specification.
Preferably, the content of the physiologically acceptable polymer, preferably the polyalkylene oxide is within the range of from 1 to 60 wt.-%, more preferably 3 to 55 wt.-%, still more preferably 5 to 50 wt.-%, yet more preferably 7 to 45 wt.-%, most preferably 10 to 40 wt.-% and in particular 15 to 35 wt.-%, based on the total weight of the tablet. In a preferred embodiment, the content of the physiologically acceptable polymer, preferably the polyalkylene oxide is at least 2 wt.-%, more preferably at least 5 wt.-%, still more preferably at least 10 wt.-%, yet more preferably at least 15 wt.-% and in particular at least 20 wt.-%, based on the total weight of the tablet.
In a preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 10±8 wt.-%, more preferably 10±6 wt.-%, most preferably 10±4 wt.-%, and in particular 10±2 wt.-%, based on the total weight of the tablet. In another preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 15±12 wt.-%, more preferably 15±10 wt.-%, most preferably 15±7 wt.-%, and in particular 15±3 wt.-%, based on the total weight of the tablet. In still another preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 20±16 wt.-%, more preferably 20±12 wt.-%, most preferably 20±8 wt.-%, and in particular 20±4 wt.-%, based on the total weight of the tablet. In yet another preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 25±20 wt.-%, more preferably 25±15 wt.-%, most preferably 25±10 wt.-%, and in particular 25±5 wt.-%, based on the total weight of the tablet. In a further preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 30±20 wt.-%, more preferably 30±15 wt.-%, most preferably 30±10 wt.-%, and in particular 30±5 wt.-%, based on the total weight of the tablet. In still a further a preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 35±20 wt.-%, more preferably 35±15 wt.-%, most preferably 35±10 wt.-%, and in particular 35±5 wt.-%. In a still further a preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 40±20 wt.-%, more preferably 40±15 wt.-%, and most preferably 40±10 wt.-%, and in particular 40±5 wt.-%, based on the total weight of the tablet.
Preferably, the content of the physiologically acceptable polymer, preferably the polyalkylene oxide is within the range of from 1 to 99 wt.-%, more preferably 5 to 95 wt.-%, still more preferably 10 to 90 wt.-%, yet more preferably 15 to 85 wt.-%, most preferably 20 to 80 wt.-% and in particular 25 to 75 wt.-%, based on the total weight of the coated particulates. In a preferred embodiment, the content of the physiologically acceptable polymer, preferably the polyalkylene oxide is at least 10 wt.-%, more preferably at least 15 wt.-%, still more preferably at least 20 wt.-%, yet more preferably at least 25 wt.-% and in particular at least 30 wt.-%, based on the total weight of the coated particulates.
In a preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 30±20 wt.-%, more preferably 30±15 wt.-%, most preferably 30±10 wt.-%, and in particular 30±5 wt.-%, based on the total weight of the coated particulates. In another preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 35±20 wt.-%, more preferably 35±15 wt.-%, most preferably 35±10 wt.-%, and in particular 35±5 wt.-%, based on the total weight of the coated particulates. In still another preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 40±20 wt.-%, more preferably 40±15 wt.-%, most preferably 40±10 wt.-%, and in particular 40±5 wt.-%, based on the total weight of the coated particulates. In yet another preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 45±20 wt.-%, more preferably 45±15 wt.-%, most preferably 45±10 wt.-%, and in particular 45±5 wt.-%, based on the total weight of the coated particulates. In a further preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 50±20 wt.-%, more preferably 50±15 wt.-%, most preferably 50±10 wt.-%, and in particular 50±5 wt.-%, based on the total weight of the coated particulates. In still a further a preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 55±20 wt.-%, more preferably 55±15 wt.-%, most preferably 55±10 wt.-%, and in particular 55±5 wt.-%. In a still further a preferred embodiment, the overall content of physiologically acceptable polymer, preferably polyalkylene oxide is within the range of 60±15 wt.-%, more preferably 60±10 wt.-%, most preferably 60±5 wt.-%, and in particular 60±5 wt.-%, based on the total weight of the coated particulates.
Preferably, the relative weight ratio of the physiologically acceptable polymer, preferably the polyalkylene oxide to the pharmacologically active compound is within the range of 1:1.00±0.75, more preferably 1:1.00±0.50, still more preferably 1:1.00±0.40, yet more preferably 1:1.00±0.30, most preferably 1:1.00±0.20, and in particular 1:1.00±0.10.
The coated particulates according to the invention may contain additional pharmaceutical excipients conventionally contained in tablets in conventional amounts, such as antioxidants, preservatives, lubricants, plasticizer, fillers, binders, and the like.
The skilled person will readily be able to determine appropriate further excipients as well as the quantities of each of these excipients. Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate the tablets according to the invention are described in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986).
In a preferred embodiment, the coated particulates do not contain a disintegrant.
Preferably, the coated particulates further comprise an antioxidant. Suitable antioxidants include ascorbic acid, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), salts of ascorbic acid, monothioglycerol, phosphorous acid, vitamin C, vitamin E and the derivatives thereof, coniferyl benzoate, nordihydroguajaretic acid, gallus acid esters, sodium bisulfite, particularly preferably butylhydroxytoluene or butylhydroxyanisole and α-tocopherol. The antioxidant is preferably present in quantities of 0.01 wt.-% to 10 wt.-%, more preferably of 0.03 wt.-% to 5 wt.-%, most preferably of 0.05 wt.-% to 2.5 wt.-%, based on the total weight of the coated particulates.
In a preferred embodiment, the coated particulates further comprise an acid, preferably citric acid. The amount of acid is preferably in the range of 0.01 wt.-% to about 20 wt.-%, more preferably in the range of 0.02 wt.-% to about 10 wt.-%, and still more preferably in the range of 0.05 wt.-% to about 5 wt.-%, and most preferably in the range of 0.1 wt.-% to about 1.0 wt.-%, based on the total weight of the coated particulates.
In a preferred embodiment, the coated particulates further comprise another polymer which is preferably selected from cellulose esters and cellulose ethers, in particular hydroxypropyl methylcellulose (HPMC).
Other preferred polymers are polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymers, such as the one commercially available under the trade name Soluplus®.
The amount of the further polymer, preferably hydroxypropyl methylcellulose, preferably ranges from 0.1 wt.-% to about 30 wt.-%, more preferably in the range of 1.0 wt.-% to about 20 wt.-%, most preferably in the range of 2.0 wt.-% to about 15 wt.-%, and in particular in the range of 3.5 wt.-% to about 10.5 wt.-%, based on the total weight of the coated particulates.
In a preferred embodiment, the relative weight ratio of the physiologically acceptable polymer, preferably the polyalkylene oxide to the further polymer is within the range of 4.5±2:1, more preferably 4.5±1.5:1, still more preferably 4.5±1:1, yet more preferably 4.5±0.5:1, most preferably 4.5±0.2:1, and in particular 4.5±0.1:1. In another preferred embodiment, the relative weight ratio of the physiologically acceptable polymer, preferably the polyalkylene oxide to the further polymer is within the range of 8±7:1, more preferably 8±6:1, still more preferably 8±5:1, yet more preferably 8±4:1, most preferably 8±3:1, and in particular 8±2:1. In still another preferred embodiment, the relative weight ratio of the physiologically acceptable polymer, preferably the polyalkylene oxide to the further polymer is within the range of 11±8:1, more preferably 11±7:1, still more preferably 11±6:1, yet more preferably 11±5:1, most preferably 11±4:1, and in particular 11±3:1.
In another preferred embodiment, the coated particulates according to the invention do not contain any further polymer besides the physiologically acceptable polymer, preferably the polyalkylene oxide and optionally, polyethylene glycol.
In a preferred embodiment, the coated particulates contain at least one lubricant. In another preferred embodiment, the coated particulates contain no lubricant. Especially preferred lubricants are selected from
Preferably, the amount of the lubricant ranges from 0.01 wt.-% to about 10 wt.-%, more preferably in the range of 0.05 wt.-% to about 7.5 wt.-%, most preferably in the range of 0.1 wt.-% to about 5 wt.-%, and in particular in the range of 0.1 wt.-% to about 1 wt.-%, based on the total weight of the coated particulates.
Preferably, the coated particulates further comprise a plasticizer. The plasticizer improves the processability of the physiologically acceptable polymer, preferably the polyalkylene oxide. A preferred plasticizer is polyalkylene glycol, like polyethylene glycol, triacetin, fatty acids, fatty acid esters, waxes and/or microcrystalline waxes. Particularly preferred plasticizers are polyethylene glycols, such as PEG 6000.
Preferably, the content of the plasticizer is within the range of from 0.5 to 30 wt.-%, more preferably 1.0 to 25 wt.-%, still more preferably 2.5 wt.-% to 22.5 wt.-%, yet more preferably 5.0 wt.-% to 20 wt.-%, most preferably 6 to 20 wt.-% and in particular 7 wt.-% to 17.5 wt.-%, based on the total weight of the coated particulates.
In a preferred embodiment, the plasticizer is a polyalkylene glycol having a content within the range of 7±6 wt.-%, more preferably 7±5 wt.-%, still more preferably 7±4 wt.-%, yet more preferably 7±3 wt.-%, most preferably 7±2 wt.-%, and in particular 7±1 wt.-%, based on the total weight of the coated particulates.
In another preferred embodiment, the plasticizer is a polyalkylene glycol having a content within the range of 10±8 wt.-%, more preferably 10±6 wt.-%, still more preferably 10±5 wt.-%, yet more preferably 10±4 wt.-%, most preferably 10±3 wt.-%, and in particular 10±2 wt.-%, based on the total weight of the coated particulates.
In a preferred embodiment, the relative weight ratio of the physiologically acceptable polymer, preferably the polyalkylene oxide to the polyalkylene glycol is within the range of 5.4±2:1, more preferably 5.4±1.5:1, still more preferably 5.4±1:1, yet more preferably 5.4±0.5:1, most preferably 5.4±0.2:1, and in particular 5.4±0.1:1. This ratio satisfies the requirements of relative high polymer content and good extrudability.
Plasticizers can sometimes act as a lubricant, and lubricants can sometimes act as a plasticizer.
The coated particulates and the matrix material of the tablets according to the invention preferably do not contain any polymers selected from the group consisting of
In a preferred embodiment, the tablet according to the invention contains no substances which irritate the nasal passages and/or pharynx, i.e. substances which, when administered via the nasal passages and/or pharynx, bring about a physical reaction which is either so unpleasant for the patient that he/she does not wish to or cannot continue administration, for example burning, or physiologically counteracts taking of the corresponding active compound, for example due to increased nasal secretion or sneezing. Further examples of substances which irritate the nasal passages and/or pharynx are those which cause burning, itching, urge to sneeze, increased formation of secretions or a combination of at least two of these stimuli. Corresponding substances and the quantities thereof which are conventionally to be used are known to the person skilled in the art. Some of the substances which irritate the nasal passages and/or pharynx are accordingly based on one or more constituents or one or more plant parts of a hot substance drug. Corresponding hot substance drugs are known per se to the person skilled in the art and are described, for example, in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd., revised edition, Gustav Fischer Verlag, Stuttgart-New York, 1982, pages 82 et seq. The corresponding description is hereby introduced as a reference and is deemed to be part of the disclosure.
The tablet according to the invention furthermore preferably contains no antagonists for the pharmacologically active compound, preferably no antagonists against psychotropic substances, in particular no antagonists against opioids. Antagonists suitable for a given pharmacologically active compound are known to the person skilled in the art and may be present as such or in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. The tablet according to the invention preferably contains no antagonists selected from among the group comprising naloxone, naltrexone, nalmefene, nalide, nalmexone, nalorphine or naluphine, in each case optionally in the form of a corresponding physiologically acceptable compound, in particular in the form of a base, a salt or solvate; and no neuroleptics, for example a compound selected from among the group comprising haloperidol, promethacine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, chlorpromazine, chlorprothixine, zuclopenthixol, flupentixol, prothipendyl, zotepine, benperidol, pipamperone, melperone and bromperidol.
The tablet according to the invention furthermore preferably contains no emetic. Emetics are known to the person skilled in the art and may be present as such or in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. The tablet according to the invention preferably contains no emetic based on one or more constituents of ipecacuanha (ipecac) root, for example based on the constituent emetine, as are, for example, described in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd, revised edition, Gustav Fischer Verlag, Stuttgart, New York, 1982. The corresponding literature description is hereby introduced as a reference and is deemed to be part of the disclosure. The tablet according to the invention preferably also contains no apomorphine as an emetic.
Finally, the tablet according to the invention preferably also contains no bitter substance. Bitter substances and the quantities effective for use may be found in US-2003/0064099 A1, the corresponding disclosure of which should be deemed to be the disclosure of the present application and is hereby introduced as a reference. Examples of bitter substances are aromatic oils, such as peppermint oil, eucalyptus oil, bitter almond oil, menthol, fruit aroma substances, aroma substances from lemons, oranges, limes, grapefruit or mixtures thereof, and/or denatonium benzoate.
The tablet according to the invention accordingly preferably contains neither substances which irritate the nasal passages and/or pharynx, nor antagonists for the pharmacologically active compound, nor emetics, nor bitter substances.
Particularly preferred contents of pharmacologically active compound, physiologically acceptable polymer, preferably polyalkylene oxide, plasticizer and antioxidant of the coated particulates, relative to the total weight of the coated particulates, are summarized as embodiments B1 to B6 in the table here below:
wherein the pharmacologically active compound is preferably an opioid, particularly preferably tapentadol or a physiologically acceptable salt thereof; the polymer is preferably a polyalkylene oxide, more preferably a polyethylene oxide having a weight average molecular weight of at least 500,000 g/mol; the plasticizer preferably is a polyethylene glycol; and the antioxidant preferably is α-tocopherol.
Besides the coated particulates and the preferably pre-compacted or granulated matrix material, the tablet according to the invention may comprise one or more pharmaceutical excipients such as binders, fillers, lubricants and the like.
In a preferred embodiment, the table additionally comprises a lubricant. Magnesium stearate is preferred. Further preferred lubricants are described above and therefore are not repeated hereinafter.
If the tablet contains an additional lubricant outside the preferably pre-compacted or pre-granulated matrix material, its content is preferably not more than 1 wt.-%, more preferably not more than 0.5 wt.-%, based on the total weight of the tablet.
While the coated particulates that are contained in the tablet according to the invention preferably exhibit increased mechanical strength, the tablet as such preferably has conventional mechanical properties. Typically, the tablet according to the invention can be crushed e.g. by means of a hammer thereby yielding a fractured composition containing the matrix material, the coated particulates and any other ingredients contained in the tablet. However, the coated particulates thereby obtained in more or less isolated form preferably cannot be further crushed and fractured by means of a hammer.
Preferably, the coated particulates are hot melt-extruded and/or have a breaking strength of at least 300 N.
The tablet according to the invention is tamper-resistant. Preferably, tamper-resistance is achieved based on the mechanical properties of the coated particulates so that comminution is avoided or at least substantially impeded. According to the invention, the term comminution means the pulverization of the coated particulates using conventional means usually available to an abuser, for example a pestle and mortar, a hammer, a mallet or other conventional means for pulverizing under the action of force. Thus, tamper-resistance preferably means that pulverization of the coated particulates using conventional means is avoided or at least substantially impeded.
Preferably, the mechanical properties of the coated particulates according to the invention, particularly their breaking strength and deformability, substantially rely on the presence and spatial distribution of physiologically acceptable polymer, preferably polyalkylene oxide, although their mere presence does typically not suffice in order to achieve said properties. The advantageous mechanical properties of the coated particulates according to the invention may not automatically be achieved by simply processing pharmacologically active compound, physiologically acceptable polymer, preferably polyalkylene oxide, and optionally further excipients by means of conventional methods for the preparation of tablets. In fact, usually suitable apparatuses must be selected for the preparation and critical processing parameters must be adjusted, particularly pressure/force, temperature and time. Thus, even if conventional apparatuses are used, the process protocols usually must be adapted in order to meet the required criteria.
In general, the coated particulates exhibiting the desired properties may be obtained only if, during preparation of the particulates,
Thus, regardless of the apparatus used, the process protocols must be adapted in order to meet the required criteria. Therefore, the breaking strength and deformability of the particulates is separable from the composition.
The coated particulates contained in the tablet according to the invention preferably have a breaking strength of at least 300 N, at least 400 N, or at least 500 N, preferably at least 600 N, more preferably at least 700 N, still more preferably at least 800 N, yet more preferably at least 1000 N, most preferably at least 1250 N and in particular at least 1500 N.
In order to verify whether a particulate exhibits a particular breaking strength of e.g. 300 N or 500 N it is typically not necessary to subject said particulate to forces much higher than 300 N and 500 N, respectively. Thus, the breaking strength test can usually be terminated once the force corresponding to the desired breaking strength has been slightly exceeded, e.g. at forces of e.g. 330 N and 550 N, respectively.
The “breaking strength” (resistance to crushing) of a tablet and of a particulate is known to the skilled person. In this regard it can be referred to, e.g., W. A. Ritschel, Die Tablette, 2. Auflage, Editio Cantor Verlag Aulendorf, 2002; H Liebermann et al., Tablets: Tablets, Vol. 2, Informa Healthcare; 2 edition, 1990; and Encyclopedia of Pharmaceutical Technology, Informa Healthcare; 1 edition.
For the purpose of specification, the breaking strength is preferably defined as the amount of force that is necessary in order to fracture the particulate (=breaking force). Therefore, for the purpose of specification a particulate does preferably not exhibit the desired breaking strength when it breaks, i.e., is fractured into at least two independent parts that are separated from one another. In another preferred embodiment, however, the particulate is regarded as being broken if the force decreases by 50% (threshold value) of the highest force measured during the measurement (see below).
For the purpose of specification, the mechanical properties of the coated particulates according to the invention essentially refer to the mechanical properties of the core of said coated particulates, but not to its coating. Thus, if the coated particulates according to the invention are exerted to an external force causing the coating material to separate partially of fully from the core, which in turn, however, is not disrupted, the coated particulates still exhibit the desired properties.
The coated particulates according to the invention are distinguished from conventional particulates that can be contained in tablets in that, due to their breaking strength, they cannot be pulverized by the application of force with conventional means, such as for example a pestle and mortar, a hammer, a mallet or other usual means for pulverization, in particular devices developed for this purpose (tablet crushers). In this regard “pulverization” means crumbling into small particles. Avoidance of pulverization virtually rules out oral or parenteral, in particular intravenous or nasal abuse.
Conventional particulates typically have a breaking strength well below 200 N.
The breaking strength of conventional round tablets/particulates may be estimated according to the following empirical formula: Breaking Strength [in N]=10×Diameter Of The Tablet/Particulate [in mm]. Thus, according to said empirical formula, a round tablet/particulate having a breaking strength of at least 300 N would require a diameter of at least 30 mm). Such a particulate, however, could not be swallowed, let alone a tablet containing a plurality of such particulates. The above empirical formula preferably does not apply to the coated particulates according to the invention, which are not conventional but rather special.
Further, the actual mean chewing force is about 220 N (cf., e.g., P. A. Proeschel et al., J Dent Res, 2002, 81(7), 464-468). This means that conventional particulates having a breaking strength well below 200 N may be crushed upon spontaneous chewing, whereas the coated particulates according to the invention may preferably not.
Still further, when applying a gravitational acceleration of about 9.81 m/s2, 300 N correspond to a gravitational force of more than 30 kg, i.e. the coated particulates according to the invention can preferably withstand a weight of more than 30 kg without being pulverized.
Methods for measuring the breaking strength of a tablet are known to the skilled artisan. Suitable devices are commercially available.
For example, the breaking strength (resistance to crushing) can be measured in accordance with the Eur. Ph. 5.0, 2.9.8 or 6.0, 2.09.08 “Resistance to Crushing of Tablets”. The test is intended to determine, under defined conditions, the resistance to crushing of tablets and particulates, respectively, measured by the force needed to disrupt them by crushing. The apparatus consists of 2 jaws facing each other, one of which moves towards the other. The flat surfaces of the jaws are perpendicular to the direction of movement. The crushing surfaces of the jaws are flat and larger than the zone of contact with the tablet and particulate, respectively. The apparatus is calibrated using a system with a precision of 1 Newton. The tablet and particulate, respectively, is placed between the jaws, taking into account, where applicable, the shape, the break-mark and the inscription; for each measurement the tablet and particulate, respectively, is oriented in the same way with respect to the direction of application of the force (and the direction of extension in which the breaking strength is to be measured). The measurement is carried out on 10 tablets and particulates, respectively, taking care that all fragments have been removed before each determination. The result is expressed as the mean, minimum and maximum values of the forces measured, all expressed in Newton.
A similar description of the breaking strength (breaking force) can be found in the USP. The breaking strength can alternatively be measured in accordance with the method described therein where it is stated that the breaking strength is the force required to cause a tablet and particulate, respectively, to fail (i.e., break) in a specific plane. The tablets and particulates, respectively, are generally placed between two platens, one of which moves to apply sufficient force to the tablet and particulate, respectively, to cause fracture. For conventional, round (circular cross-section) tablets and particulates, respectively, loading occurs across their diameter (sometimes referred to as diametral loading), and fracture occurs in the plane. The breaking force of tablets and particulates, respectively, is commonly called hardness in the pharmaceutical literature; however, the use of this term is misleading. In material science, the term hardness refers to the resistance of a surface to penetration or indentation by a small probe. The term crushing strength is also frequently used to describe the resistance of tablets and particulate, respectively, to the application of a compressive load. Although this term describes the true nature of the test more accurately than does hardness, it implies that tablets and particulate, respectively, are actually crushed during the test, which is often not the case.
Alternatively, the breaking strength (resistance to crushing) can be measured in accordance with WO 2008/107149, which can be regarded as a modification of the method described in the Eur. Ph. The apparatus used for the measurement is preferably a “Zwick Z 2.5” materials tester, Fmax=2.5 kN with a maximum draw of 1150 mm, which should be set up with one column and one spindle, a clearance behind of 100 mm and a test speed adjustable between 0.1 and 800 mm/min together with testControl software. A skilled person knows how to properly adjust the test speed, e.g. to 10 mm/min, 20 mm/min, or 40 mm/min, for example. Measurement is performed using a pressure piston with screw-in inserts and a cylinder (diameter 10 mm), a force transducer, Fmax. 1 kN, diameter=8 mm, class 0.5 from 10 N, class 1 from 2 N to ISO 7500-1, with manufacturers test certificate M according to DIN 55350-18 (Zwick gross force Fmax=1.45 kN) (all apparatus from Zwick GmbH & Co. KG, Ulm, Germany) with Order No BTC-FR 2.5 TH. D09 for the tester, Order No BTC-LC 0050N. P01 for the force transducer, Order No BO 70000 S06 for the centring device.
When using the testControl software (testXpert V10.11), the following exemplified settings and parameters have revealed to be useful: LE-position: clamping length 150 mm. LE-speed: 500 mm/min, clamping length after pre-travel: 195 mm, pre-travel speed: 500 mm/min, no pre-force control—pre-force: pre-force 1N, pre-force speed 10 mm/min—sample data: no sample form, measuring length traverse distance 10 mm, no input required prior to testing—testing/end of test; test speed: position-controlled 10 mm/min, delay speed shift: 1, force shut down threshold 50% Fmax, no force threshold for break-tests, no max length variation, upper force limit: 600N—expansion compensation: no correction of measuring length—actions after testing: LE to be set after test, no unload of sample—TRS: data memory: TRS distance interval until break 1 μm, TRS time interval 0.1 s, TRS force interval 1N—machine; traverse distance controller: upper soft end 358 mm, lower soft end 192 mm—lower test space. Parallel arrangement of the upper plate and the ambos should be ensured—these parts must not touch during or after testing. After testing, a small gap (e.g. 0.1 or 0.2 mm) should still be present between the two brackets in intimated contact with the tested particulate, representing the remaining thickness of the deformed particulate.
In a preferred embodiment, the particulate is regarded as being broken if it is fractured into at least two separate pieces of comparable morphology. Separated matter having a morphology different from that of the deformed particulate, e.g. dust, is not considered as pieces qualifying for the definition of breaking.
The coated particulates according to the invention preferably exhibit mechanical strength over a wide temperature range, in addition to the breaking strength (resistance to crushing) optionally also sufficient hardness, yield strength, fatigue strength, impact resistance, impact elasticity, tensile strength, compressive strength and/or modulus of elasticity, optionally also at low temperatures (e.g. below −24° C., below −40° C. or possibly even in liquid nitrogen), for it to be virtually impossible to pulverize by spontaneous chewing, grinding in a mortar, pounding, etc. Thus, preferably, the comparatively high breaking strength of the particulate according to the invention is maintained even at low or very low temperatures, e.g., when the tablet is initially chilled to increase its brittleness, for example to temperatures below −25° C., below −40° C. or even in liquid nitrogen.
The particulate according to the invention is characterized by a certain degree of breaking strength. This does not mean that the particulate must also exhibit a certain degree of hardness. Hardness and breaking strength are different physical properties. Therefore, the tamper-resistance of the tablet does not necessarily depend on the hardness of the coated particulates. For instance, due to its breaking strength, impact strength, elasticity modulus and tensile strength, respectively, the coated particulates can preferably be deformed, e.g. plastically, when exerting an external force, for example using a hammer, but cannot be pulverized, i.e., crumbled into a high number of fragments. In other words, the coated particulates according to the invention are characterized by a certain degree of breaking strength, but not necessarily also by a certain degree of form stability.
Therefore, in the meaning of the specification, a particulate that is deformed when being exposed to a force in a particular direction of extension but that does not break (plastic deformation or plastic flow) is preferably to be regarded as having the desired breaking strength in said direction of extension.
Preferred particulates present in the tablets according to the invention are those having a suitable tensile strength as determined by a test method currently accepted in the art. Further preferred particulates are those having a Youngs Modulus as determined by a test method of the art. Still further preferred particulates are those having an acceptable elongation at break.
Irrespective of whether the particulates according to the invention have an increased breaking strength or nor, the particulates according to the invention preferably exhibit a certain degree of deformability. The particulates contained in the tablet according to the invention preferably have a deformability such that they show an increase, preferably a steady increase of the force at a corresponding decrease of the displacement in the force-displacement-diagram when being subjected to a breaking strength test as described above. This mechanical property, i.e. the deformability of the individual particulates, is illustrated in
In contrast,
In a preferred embodiment, the particulates contained in the tablet according to the invention have a deformability such that they show an increase, preferably a substantially steady increase of the force at a corresponding decrease of the displacement in the force-displacement-diagram when being subjected to a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant speed), preferably at least until the displacement d of upper jaw (8a) and lower jaw (8b) has been reduced to a value of 90% of the original displacement d0 (i.e. d=0.9·d0), preferably to a displacement d of 80% of the original displacement d0, more preferably to a displacement d of 70% of the original displacement d0, still more preferably to a displacement d of 60% of the original displacement d0, yet more preferably to a displacement d of 50% of the original displacement d0, even more preferably to a displacement d of 40% of the original displacement d0, most preferably to a displacement d of 30% of the original displacement d0, and in particular to a displacement d of 20% of the original displacement d0, or to a displacement d of 15% of the original displacement d0, to a displacement d of 10% of the original displacement d0, or to a displacement d of 5% of the original displacement d0.
In another preferred embodiment, the particulates contained in the tablet according to the invention have a deformability such that they show an increase, preferably a substantially steady increase of the force at a corresponding decrease of the displacement in the force-displacement-diagram when being subjected to a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant speed), preferably at least until the displacement d of upper jaw (8a) and lower jaw (8b) has been reduced to 0.80 mm or 0.75 mm, preferably 0.70 mm or 0.65 mm, more preferably 0.60 mm or 0.55 mm, still more preferably 0.50 mm or 0.45 mm, yet more preferably 0.40 mm or 0.35 mm, even more preferably 0.30 mm or 0.25 mm, most preferably 0.20 mm or 0.15 mm and in particular 0.10 or 0.05 mm.
In still another preferred embodiment, the particulates contained in the tablet according to the invention have a deformability such that they show an increase, preferably a substantially steady increase of the force at a corresponding decrease of the displacement in the force-displacement-diagram when being subjected to a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant speed), at least until the displacement d of upper jaw (8a) and lower jaw (8b) has been reduced to 50% of the original displacement d0 (i.e. d=d0/2), whereas the force measured at said displacement (d=d0/2) is at least 25 N or at least 50 N, preferably at least 75 N or at least 100 N, still more preferably at least 150 N or at least 200 N, yet more preferably at least 250 N or at least 300 N, even more preferably at least 350 N or at least 400 N, most preferably at least 450 N or at least 500 N, and in particular at least 625 N, or at least 750 N, or at least 875 N, or at least 1000 N, or at least 1250 N, or at least 1500 N.
In another preferred embodiment, the particulates contained in the tablet according to the invention have a deformability such that they show an increase, preferably a substantially steady increase of the force at a corresponding decrease of the displacement in the force-displacement-diagram when being subjected to a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant speed), at least until the displacement d of upper jaw (8a) and lower jaw (8b) has been reduced by at least 0.1 mm, more preferably at least 0.2 mm, still more preferably at least 0.3 mm, yet more preferably at least 0.4 mm, even more preferably at least 0.5 mm, most preferably at least 0.6 mm, and in particular at least 0.7 mm, whereas the force measured at said displacement is within the range of from 5.0 N to 250 N, more preferably from 7.5 N to 225 N, still more preferably from 10 N to 200 N, yet more preferably from 15 N to 175 N, even more preferably from 20 N to 150 N, most preferably from 25 N to 125 N, and in particular from 30 N to 100 N.
In yet another embodiment, the particulates contained in the tablet according to the invention have a deformability such that they are deformed without being fractured when subjected to a constant force of e.g. 50 N, 100 N, 200 N, 300 N, 400 N, 500 N or 600 N in a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant force), until the displacement d of upper jaw (8a) and lower jaw (8b) is reduced so that no further deformation takes place at said constant force, whereas at this equilibrated state the displacement d of upper jaw (8a) and lower jaw (8b) is at most 90% of the original displacement d0 (i.e. d≤0.9 d0), preferably at most 80% of the original displacement d0 (i.e. d≤0.8·d0), more preferably at most 70% of the original displacement d0 (i.e. d≤0.7·d0), still more preferably at most 60% of the original displacement d0 (i.e. d≤0.6·d0), yet more preferably at most 50% of the original displacement d0 (i.e. d≤0.5·d0), even more preferably at most 40% of the original displacement d0 (i.e. d≤0.4·d0), most preferably at most 30% of the original displacement d0 (i.e. d≤0.3·d0), and in particular at most 20% of the original displacement d0 (i.e. d≤0.2·d0), or at most 15% of the original displacement d0 (i.e. d≤0.15·d0), at most 10% of the original displacement d0 (i.e. d≤0.1·d0), or at most 5% of the original displacement d0 (i.e. d≤0.05·d0).
Preferably, the particulates contained in the tablet according to the invention have a deformability such that they are deformed without being fractured when subjected to a constant force of e.g. 50 N, 100 N, 200 N, 300 N, 400 N, 500 N or 600 N in a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant force), until the displacement d of upper jaw (8a) and lower jaw (8b) is reduced so that no further deformation takes place at said constant force, whereas at this equilibrated state the displacement d of upper jaw (8a) and lower jaw (8b) is at most 0.80 mm or at most 0.75 mm, preferably at most 0.70 mm or at most 0.65 mm, more preferably at most 0.60 mm or at most 0.55 mm, still more preferably at most 0.50 mm or at most 0.45 mm, yet more preferably at most 0.40 mm or at most 0.35 mm, even more preferably at most 0.30 mm or at most 0.25 mm, most preferably at most 0.20 mm or at most 0.15 mm and in particular at most 0.10 or at most 0.05 mm.
In another embodiment, the particulates contained in the tablet according to the invention have a deformability such that they are deformed without being fractured when subjected to a constant force of e.g. 50 N, 100 N, 200 N, 300 N, 400 N, 500 N or 600 N in a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant force), until the displacement d of upper jaw (8a) and lower jaw (8b) is reduced so that no further deformation takes place at said constant force, whereas at this equilibrated state the displacement d of upper jaw (8a) and lower jaw (8b) is at least 5% of the original displacement d0 (i.e. d≥0.05·d0), preferably at least 10% of the original displacement d0 (i.e. d≥0.1·d0), more preferably at least 15% of the original displacement d0 (i.e. d 0.15≥d0), still more preferably at least 20% of the original displacement d0 (i.e. d≥0.2·d0), yet more preferably at least 30% of the original displacement d0 (i.e. d≥0.3·d0), even more preferably at least 40% of the original displacement d0 (i.e. d≥0.4·d0), most preferably at least 50% of the original displacement d0 (i.e. d≥0.5·d0), and in particular at least 60% of the original displacement d0 (i.e. d≥0.6·d0), or at least 70% of the original displacement d0 (i.e. d≥0.7·d0), at least 80% of the original displacement d0 (i.e. d≥0.8·d0), or at least 90% of the original displacement d0 (i.e. d≥0.9·d0).
Preferably, the particulates contained in the tablet according to the invention have a deformability such that they are deformed without being fractured when subjected to a constant force of e.g. 50 N, 100 N, 200 N, 300 N, 400 N, 500 N or 600 N in a breaking strength test as described above (“Zwick Z 2.5” materials tester, constant force), until the displacement d of upper jaw (8a) and lower jaw (8b) is reduced so that no further deformation takes place at said constant force, whereas at this equilibrated state the displacement d of upper jaw (8a) and lower jaw (8b) is at least 0.05 mm or at least 0.10 mm, preferably at least 0.15 mm or at least 0.20 mm, more preferably at least 0.25 mm or at least 0.30 mm, still more preferably at least 0.35 mm or at least 0.40 mm, yet more preferably at least 0.45 mm or at least 0.50 mm, even more preferably at least 0.55 mm or at least 0.60 mm, most preferably at least 0.65 mm or at least 0.70 mm and in particular at least 0.75 or at least 0.80 mm.
Preferably, the tablet according to the invention provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
The term “immediate release” as applied to tablets is understood by persons skilled in the art which has structural implications for the respective tablets. The term is defined, for example, in the current issue of the US Pharmacopoeia (USP), General Chapter 1092, “THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION”, heading “STUDY DESIGN”, “Time Points”. For immediate-release dosage forms, the duration of the procedure is typically 30 to 60 minutes; in most cases, a single time point specification is adequate for Pharmacopeia purposes. Industrial and regulatory concepts of product comparability and performance may require additional time points, which may also be required for product registration or approval. A sufficient number of time points should be selected to adequately characterize the ascending and plateau phases of the dissolution curve. According to the Biopharmaceutics Classification System referred to in several FDA Guidances, highly soluble, highly permeable drugs formulated with rapidly dissolving products need not be subjected to a profile comparison if they can be shown to release 85% or more of the active drug substance within 15 minutes. For these types of products a one-point test will suffice. However, most products do not fall into this category. Dissolution profiles of immediate-release products typically show a gradual increase reaching 85% to 100% at about 30 to 45 minutes. Thus, dissolution time points in the range of 15, 20, 30, 45, and 60 minutes are usual for most immediate-release products.
Preferably, under physiological conditions the tablet according to the invention has released after 30 minutes at least 70%, more preferably at least 75%, still more preferably at least 80%, yet more preferably at least 82%, most preferably at least 84% and in particular at east 86% of the pharmacologically active compound originally contained in the tablet.
Preferably, under physiological conditions the tablet according to the invention has released after 10 minutes at least 70%, more preferably at least 73%, still more preferably at least 76%, yet more preferably at least 78%, most preferably at least 80% and in particular at east 82% of the pharmacologically active compound originally contained in the tablet.
Further preferred release profiles C1 to C10 are summarized in the table here below [all data in wt.-% of released pharmacologically active compound]:
Preferably, the release profile, the drug and the pharmaceutical excipients of the tablet according to the invention are stable upon storage, preferably upon storage at elevated temperature, e.g. 40° C., for 3 months in sealed containers.
In connection with the release profile “stable” means that when comparing the initial release profile with the release profile after storage, at any given time point the release profiles deviate from one another by not more than 20%, more preferably not more than 15%, still more preferably not more than 10%, yet more preferably not more than 7.5%, most preferably not more than 5.0% and in particular not more than 2.5%.
In connection with the drug and the pharmaceutical excipients “stable” means that the tablets satisfy the requirements of EMEA concerning shelf-life of pharmaceutical products.
Suitable in vitro conditions are known to the skilled artisan. In this regard it can be referred to, e.g., the Eur. Ph. Preferably, the release profile is measured under the following conditions: Paddle apparatus equipped without sinker, 50 rpm, 37±5° C., 900 mL simulated intestinal fluid pH 6.8 (phosphate buffer) or pH 4.5. In a preferred embodiment, the rotational speed of the paddle is increased to 75 rpm.
In a preferred embodiment, the tablet according to the invention is adapted for administration once daily. In another preferred embodiment, the tablet according to the invention is adapted for administration twice daily. In still another preferred embodiment, the tablet according to the invention is adapted for administration thrice daily. In yet another preferred embodiment, the tablet according to the invention is adapted for administration more frequently than thrice daily, for example 4 times daily, 5 times daily, 6 times daily, 7 times daily or 8 times daily.
For the purpose of specification, “twice daily” means equal or nearly equal time intervals, i.e., about every 12 hours, or different time intervals, e.g., 8 and 16 hours or 10 and 14 hours, between the individual administrations.
For the purpose of specification, “thrice daily” means equal or nearly equal time intervals, i.e., about every 8 hours, or different time intervals, e.g., 6, 6 and 12 hours; or 7, 7 and 10 hours, between the individual administrations.
Preferably, the tablet according to the invention has under in vitro conditions a disintegration time measured in accordance with Ph. Eur. of at most 5 minutes, more preferably at most 4 minutes, still more preferably at most 3 minutes, yet more preferably at most 2.5 minutes, most preferably at most 2 minutes and in particular at most 1.5 minutes.
It has been surprisingly found that oral dosage forms can be designed that provide the best compromise between tamper-resistance, disintegration time and drug release, drug load, processability (especially tablettability) and patient compliance.
It has been found that the disintegration time of the tablets according to the invention can be influenced by the relative weight ratio of matrix material: particulates. In general, it was observed that the higher this ratio the faster disintegration. However, this ratio cannot be increased ad ultimo, as further tablet properties need to be taken into account, particularly drug load and total tablet size and weight. As a certain dosage of pharmacologically active compound needs to be administered, the content of particulates should still be sufficiently high and the total tablet weight should not exceed a certain limit, as this would deteriorate patient compliance, e.g. swallowability.
The situation is more complicated by trends in opposite direction. In particular, it has been found that the tablettability of the tablets according to the invention can also be influenced by the relative weight ratio of matrix material: particulates. In general, it was observed that the lower this ratio the better the tablettability. This trend parallels the trend of the drug load.
Thus, disintegration time on the one hand and tablettability/drug load on the other hand can be optimized by finding the best compromise.
Similarly, tamper-resistance and drug release also antagonize each other. While smaller particulates should typically show a faster release of the pharmacologically active compound, tamper-resistance requires some minimal size of the coated particulates in order to effectively prevent abuse, e.g. i.v. administration. The larger the coated particulates are the less they are suitable for being abused nasally. The smaller the coated particulates are the faster gel formation occurs.
Thus, drug release on the one hand and tamper-resistance on the other hand can be optimized by finding the best compromise.
Preferred embodiments D1 to D4 of the tablets according to the invention are summarized in the table here below:
The coated particulates according to the invention are preferably prepared by melt-extrusion, although also other methods of thermoforming may be used in order to manufacture the coated particulates according to the invention such as press-molding at elevated temperature or heating of particulates that were manufactured by conventional compression in a first step and then heated above the softening temperature of the physiologically acceptable polymer, preferably the polyalkylene oxide in the coated particulates in a second step to form hard tablets. In this regards, thermoforming means the forming, or molding of a mass after the application of heat. In a preferred embodiment, the coated particulates are thermoformed by hot-melt extrusion.
In a preferred embodiment, the coated particulates are prepared by hot melt-extrusion, preferably by means of a twin-screw-extruder. Melt extrusion preferably provides a melt-extruded strand that is preferably cut into monoliths, which are then optionally compressed and formed into particulates. Preferably, compression is achieved by means of a die and a punch, preferably from a monolithic mass obtained by melt extrusion. If obtained via melt extrusion, the compressing step is preferably carried out with a monolithic mass exhibiting ambient temperature, that is, a temperature in the range from 20 to 25° C. The strands obtained by way of extrusion can either be subjected to the compression step as such or can be cut prior to the compression step. This cutting can be performed by usual techniques, for example using rotating knives or compressed air, at elevated temperature, e.g. when the extruded stand is still warm due to hot-melt extrusion, or at ambient temperature, i.e. after the extruded strand has been allowed to cool down. When the extruded strand is still warm, singulation of the extruded strand into extruded particulates is preferably performed by cutting the extruded strand immediately after it has exited the extrusion die. However, when the extruded strand is cut in the cooled state, subsequent singulation of the extruded strand into extruded particulates is preferably performed by optionally transporting the still hot extruded strand by means of conveyor belts, allowing it to cool down and to congeal, and subsequently cutting it into extruded particulates. Alternatively, the shaping can take place as described in EP-A 240 906 by the extrudate being passed between two counter-rotating calender rolls and being shaped directly to particulates. It is of course also possible to subject the extruded strands to the compression step or to the cutting step when still warm, that is more or less immediately after the extrusion step. The extrusion is preferably carried out by means of a twin-screw extruder.
The coated particulates according to the invention may be produced by different processes, the particularly preferred of which are explained in greater detail below. Several suitable processes have already been described in the prior art. In this regard it can be referred to, e.g., WO 2005/016313, WO 2005/016314, WO 2005/063214, WO 2005/102286, WO 2006/002883, WO 2006/002884, WO 2006/002886, WO 2006/082097, and WO 2006/082099.
In general, the process for the production of the coated particulates according to the invention preferably comprises the following steps:
Heat may be supplied directly, e.g. by contact or by means of hot gas such as hot air, or with the assistance of ultrasound; or is indirectly supplied by friction and/or shear. Force may be applied and/or the particulates may be shaped for example by direct tabletting or with the assistance of a suitable extruder, particularly by means of a screw extruder equipped with one or two screws (single-screw-extruder and twin-screw-extruder, respectively) or by means of a planetary gear extruder.
The final shape of the particulates may either be provided during the hardening of the mixture by applying heat and force (step (c)) or in a subsequent step (step (e)). In both cases, the mixture of all components is preferably in the plastified state, i.e. preferably, shaping is performed at a temperature at least above the softening point of the physiologically acceptable polymer, preferably the polyalkylene oxide. However, extrusion at lower temperatures, e.g. ambient temperature, is also possible and may be preferred.
Shaping can be performed, e.g., by means of a tabletting press comprising die and punches of appropriate shape.
Suitable methods for providing particulates with a coating, preferably with a film coating, are known to the skilled person such as fluidized bed coating, pan-coating, coazervation, dry powder coating, extrusion coating, and phoqus technology (copy-coating). Preferably, the particulates are coated by spraying (top-spray or bottom-spray) e.g. in a fluidized bed spray dry granulator.
A particularly preferred process for the manufacture of the coated particulates according to the invention involves hot-melt extrusion. In this process, the coated particulates according to the invention are produced by thermoforming with the assistance of an extruder, preferably without there being any observable consequent discoloration of the extrudate.
This process is characterized in that
Mixing of the components according to process step a) may also proceed in the extruder.
The components may also be mixed in a mixer known to the person skilled in the art. The mixer may, for example, be a roll mixer, shaking mixer, shear mixer or compulsory mixer.
The, preferably molten, mixture which has been heated in the extruder at least up to the softening point of physiologically acceptable polymer, preferably polyalkylene oxide is extruded from the extruder through a die with at least one bore.
The process according to the invention requires the use of suitable extruders, preferably screw extruders. Screw extruders which are equipped with two screws (twin-screw-extruders) are particularly preferred.
Preferably, extrusion is performed in the absence of water, i.e., no water is added. However, traces of water (e.g., caused by atmospheric humidity) may be present.
The extruder preferably comprises at least two temperature zones, with heating of the mixture at least up to the softening point of the physiologically acceptable polymer, preferably the polyalkylene oxide proceeding in the first zone, which is downstream from a feed zone and optionally mixing zone. The throughput of the mixture is preferably from 1.0 kg to 15 kg/hour. In a preferred embodiment, the throughput is from 0.5 kg/hour to 3.5 kg/hour. In another preferred embodiment, the throughput is from 4 to 15 kg/hour.
In a preferred embodiment, the die head pressure is within the range of from 25 to 200 bar. The die head pressure can be adjusted inter alia by die geometry, temperature profile, extrusion speed, number of bores in the dies, screw configuration, first feeding steps in the extruder, and the like.
The die geometry or the geometry of the bores is freely selectable. The die or the bores may accordingly exhibit a round, oblong or oval cross-section, wherein the round cross-section preferably has a diameter of 0.1 mm to 2 mm. Preferably, the die or the bores have a round cross-section. The casing of the extruder used according to the invention may be heated or cooled. The corresponding temperature control, i.e. heating or cooling, is so arranged that the mixture to be extruded exhibits at least an average temperature (product temperature) corresponding to the softening temperature of the physiologically acceptable polymer, preferably the polyalkylene oxide and does not rise above a temperature at which the pharmacologically active compound to be processed may be damaged. Preferably, the temperature of the mixture to be extruded is adjusted to below 180° C., preferably below 150° C., but at least to the softening temperature of the physiologically acceptable polymer, preferably the polyalkylene oxide. Typical extrusion temperatures are 120° C. and 150° C.
In a preferred embodiment, the extruder torque is within the range of from 30 to 95%. Extruder torque can be adjusted inter alia by die geometry, temperature profile, extrusion speed, number of bores in the dies, screw configuration, first feeding steps in the extruder, and the like.
After extrusion of the molten mixture and optional cooling of the extruded strand or extruded strands, the extrudates are preferably singulated. This singulation may preferably be performed by cutting up the extrudates by means of revolving or rotating knives, wires, blades or with the assistance of laser cutters.
Preferably, intermediate or final storage of the optionally singulated extrudate or the final shape of the particulates according to the invention is performed under oxygen-free atmosphere which may be achieved, e.g., by means of oxygen-scavengers.
The singulated extrudate may be press-formed into particulates in order to impart the final shape to the particulates.
The application of force in the extruder onto the at least plasticized mixture is adjusted by controlling the rotational speed of the conveying device in the extruder and the geometry thereof and by dimensioning the outlet orifice in such a manner that the pressure necessary for extruding the plasticized mixture is built up in the extruder, preferably immediately prior to extrusion. The extrusion parameters which, for each particular composition, are necessary to give rise to a tablet with desired mechanical properties, may be established by simple preliminary testing.
For example but not limiting, extrusion may be performed by means of a twin-screw-extruder type ZSE 18 or ZSE27 (Leistritz, Nurnberg, Germany), screw diameters of 18 or 27 mm. Screws having eccentric or blunt ends may be used. A heatable die with a round bore or with a multitude of bores each having a diameter of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 mm may be used. The extrusion parameters may be adjusted e.g. to the following values: rotational speed of the screws: 120 Upm; delivery rate 2 kg/h for a ZSE 18 or 3 kg/h, 8 kg/h, or even 10 kg/h and more for a ZSE27; product temperature: in front of die 125° C. and behind die 135° C.; and jacket temperature: 110° C. The throughput can generally be increased by increasing the number of dies at the extruder outlet.
Preferably, extrusion is performed by means of twin-screw-extruders or planetary-gear-extruders, twin-screw extruders (co-rotating or contra-rotating) being particularly preferred.
The particulates according to the invention are preferably produced by thermoforming with the assistance of an extruder without any observable consequent discoloration of the extrudates.
The process for the preparation of the coated particulates according to the invention is preferably performed continuously. Preferably, the process involves the extrusion of a homogeneous mixture of all components. It is particularly advantageous if the thus obtained intermediate, e.g. the strand obtained by extrusion, exhibits uniform properties. Particularly desirable are uniform density, uniform distribution of the active compound, uniform mechanical properties, uniform porosity, uniform appearance of the surface, etc. Only under these circumstances the uniformity of the pharmacological properties, such as the stability of the release profile, may be ensured and the amount of rejects can be kept low.
Preferably, the coated particulates according to the invention can be regarded as “extruded pellets”. The term “extruded pellets” has structural implications which are understood by persons skilled in the art. A person skilled in the art knows that pelletized dosage forms can be prepared by a number of techniques, including:
Accordingly, “extruded pellets” can be obtained either by hot-melt extrusion or by extrusion-spheronization.
“Extruded pellets” can be distinguished from other types of pellets, as extruded pellets typically have a different shape. The shape of the extruded pellets is typically more cut-rod-like than perfectly globated round.
“Extruded pellets” can be distinguished from other types of pellets because they are structurally different. For example, drug layering on nonpareils yields multilayered pellets having a core, whereas extrusion typically yields a monolithic mass comprising a homogeneous mixture of all ingredients. Similarly, spray drying and spray congealing typically yield spheres, whereas extrusion typically yields cylindrical extrudates which can be subsequently spheronized.
The structural differences between “extruded pellets” and “agglomerated pellets” are significant because they may affect the release of active substances from the pellets and consequently result in different pharmacological profiles. Therefore, a person skilled in the pharmaceutical formulation art would not consider “extruded pellets” to be equivalent to “agglomerated pellets”.
The tablets according to the invention may be prepared by any conventional method. Preferably, however, the tablets are prepared by compression. Thus, coated particulates as hereinbefore defined are preferably mixed, e.g. blended and/or granulated (e.g. wet granulated), with matrix material and the resulting mix (e.g. blend or granulate) is then compressed, preferably in moulds, to form tablets. It is also envisaged that the coated particulates herein described may be incorporated into a matrix using other processes, such as by melt granulation (e.g. using fatty alcohols and/or water-soluble waxes and/or water-insoluble waxes) or high shear granulation, followed by compression.
When the tablets according to the invention are manufactured by means of an eccentric press, the compression force is preferably within the range of from 5 to 15 kN. When the tablets according to the invention are manufactured by means of a rotating press, the compression force is preferably within the range of from 5 to 40 kN, in certain embodiments >25 kN, in other embodiments about 13 kN.
The tablets according to the invention may optionally comprise a coating, e.g. a cosmetic coating. The coating is preferably applied after formation of the tablet. The coating may be applied prior to or after the curing process. Preferred coatings are Opadry® coatings available from Colorcon. Other preferred coating are Opaglos® coatings, also commercially available from Colorcon.
The tablet according to the invention is characterized by excellent storage stability. Preferably, after storage for 4 weeks at 40° C. and 75% rel. humidity, the content of pharmacologically active compound amounts to at least 98.0%, more preferably at least 98.5%, still more preferably at least 99.0%, yet more preferably at least 99.2%, most preferably at least 99.4% and in particular at least 99.6%, of its original content before storage. Suitable methods for measuring the content of the pharmacologically active compound in the tablet are known to the skilled artisan. In this regard it is referred to the Eur. Ph. or the USP, especially to reversed phase HPLC analysis. Preferably, the tablet is stored in closed, preferably sealed containers.
Further aspects according to the invention—basis for additional claim categories
The coated particulates and tablets according to the invention may be used in medicine, e.g. as an analgesic. The coated particulates and tablets are therefore particularly suitable for the treatment or management of pain. In such tablets, the pharmacologically active compound is preferably an analgesic.
A further aspect according to the invention relates to the tablet as described above for use in the treatment of pain.
A further aspect according to the invention relates to the use of a tablet as described above for avoiding or hindering the abuse of the pharmacologically active compound contained therein.
A further aspect according to the invention relates to the use of a tablet as described above for avoiding or hindering the unintentional overdose of the pharmacologically active compound contained therein.
In this regard, the invention also relates to the use of a pharmacologically active compound as described above and/or a physiologically acceptable polymer, preferably a polyalkylene oxide as described above for the manufacture of the tablet according to the invention for the prophylaxis and/or the treatment of a disorder, thereby preventing an overdose of the pharmacologically active compound, particularly due to comminution of the tablet by mechanical action.
The following examples further illustrate the invention but are not to be construed as limiting its scope.
The relevance of the particulate size on tamper resistance was investigated.
It was found that comparatively small particulates, e.g. particulates having a diameter and length of 0.5 mm×0.5 mm already provide a certain degree of tamper resistance: when administered nasally they cause an unpleasant feeling and furthermore, due to the lack of water on the mucous membrane, do not release the pharmacologically active compound as quick as when being administered orally. Therefore, a kick or rush can unlikely be achieved by nasal administration of such particulates. Thus, even when being administered nasally, such comparatively small particulates already provide tamper resistance, i.e. avoid drug abuse or at least make drug abuse substantially more difficult. Furthermore, such comparatively small particulates have excellent swelling properties thereby effectively preventing conversion into a liquid formulation for intravenous administration.
It was found that tamper-resistance can even further be improved by increasing the particulate size, e.g. to a diameter and length of 1.0 mm×1.0 mm. Such particulates even provide a more unpleasant feeling when being administered nasally and in the absence of sufficient water, rather slowly release the pharmacologically active compound. Further, they cannot be easily converted into a liquid formulation for intravenous administration either.
As such a more pronounced retardant effect, however, is detrimental for the desired immediate release upon prescribed oral administration of the tablets, a compromise must be found between tamper resistance on the one hand and immediate drug release upon prescribed oral administration on the other hand, particularly with respect to disintegration time and drug release kinetics. Furthermore, drug load, processability (especially tablettability) and patient compliance are also important requirements to be satisfied with.
A predetermined particulate size of 800 μm×800 μm was considered most appropriate, i.e. it was considered most appropriate to adjust the diameter of the extrusion die as well as cutting length of the extruded stand to 800 μm taking into consideration that die swelling may occur during the extrusion process, particularly when the strand exits the die, so that the diameter of the extruded strand in fact is expanded, depending upon the composition and the extrusion parameters to a diameter of about 1000 μm. Thus, when proceedings this way, it was considered most appropriate to manufacture extruded particulates having a diameter of about 1000 μm (after die swelling, diameter of extrusion die 800 μm) and a length of about 800 μm.
Different particulate compositions were investigated and particulates of different sizes were manufactured thereform.
The particulate compositions are summarized in the table here below:
All materials were weighed, sieved (manual sieve, 1 mm), blended (Bohle LM40 with MC5 or MC10, depending on size of bath) for 15 minutes at 14 rpm, and hot-melt extruded (Leistritz extruder Type ZSE18 with different configuration of screws).
The compositions 1 to 9 were extruded under the following extrusion conditions:
For larger scales, screw configuration can be adopted and temperatures can be raised (e.g., HZ8 and 10: 130° C., HZ11: 145° C.; or HZ11: 150° C. and extreme shear configuration, throughput 25 g/min).
The in vitro release characteristics were monitored in 900 mL 0.1N HCl at 37° C., using a paddle apparatus 50 rpm. The results are depicted in
The influence of the content of particulates in the tablet was investigated.
The following compositions were tested:
The most promising compromise between tablettability and size revealed to be 250 mg particulates in tablets having a total weight of 500 mg. Tablets having a total weight of 600 mg were considered too large with respect to patient compliance, although the relative weight ratio of particulates to matrix material of about 1:1 appeared advantageous with respect to disintegration time and dissolution time.
The influence of the matrix material was investigated—wet granulation.
Granules having the following composition were prepared for manufacturing of pellet-tablets. Granules for outer the phase, i.e. the matrix material, were manufactured by wet granulation. Granules and pellets were blended. Segregation (optically) and disintegration of tablets after compression were evaluated. Tablets were manufactured “manually” (components were separately weighed for each tablet and mixed directly prior to tabletting) using a single station press (Korsch EK0):
It was not possible to manufacture rapidly disintegrating tablets from the above compositions, probably because the disintegrants lose the disintegrating capacity in the course of the wet granulation process.
The influence of the matrix material was investigated—dry granulation—roller compaction.
The following compositions were processed by slugging involving the steps of:
The experimental results are summarized in the following table:
The release characteristics of tablets containing the thus compacted matrix material were investigated. The results are depicted in
Since the slugging method is not state of the art for dry granulation, corresponding tests concerning dry granulation were conducted by means of a roller compactor. This has the advantage that all relevant parameters (roller displacement, compression force, granulator size) can be adjusted such that a granulate having the desired properties is obtained (particle size, hardness, compressibility, density).
The thus prepared compacts (dry granulates) were blended with particulates and compressed to tablets. Upon blending, lubricant (magnesium stearate and sodium stearylfumarate, respectively) was added as an external excipient neither contained in the compacts nor in the particulates.
The experiments revealed that tablets made from compacts and made from slugging-granulates show a similarly fast release.
Confirming Experiments:
12%
10%
Tablets (500 mg) were prepared from the particulates according to Example 2-5 (250 mg) and the matrix material according to Example 4-3 #12 (250 mg).
The in vitro release was determined according to Ph. Eur.:
The in vitro release of the tablets was compared to a non-tamper resistant commercial product containing Tapentadol HCl (film coated tablets). After 30 minutes (according to Ph. Eur. 2.9.3), both formulations released the entire amount of the pharmacologically active ingredient (100%).
The mechanical properties of conventional, commercial neutral pellets were investigated under the following conditions:
The reduction of the displacement between plate and ambos x in mm (=“compression [c]”) and the corresponding force f in N were measured. The maximum force fmax measured during the measurement and the corresponding reduction of displacement xmax are summarized in the table here below:
It becomes clear from the above data that the comparative particulates of example 5-1 break at very low forces of only about 5 N and can be deformed by less than 0.1 mm. In contrast, the inventive particulates of examples 5-2 and 5-3 do not break at all, and can be deformed (flattened) by more than 0.8 mm.
The corresponding force-displacement-diagrams are shown in
| Number | Date | Country | Kind |
|---|---|---|---|
| 11006254 | Jul 2011 | EP | regional |
This application claims priority of U.S. Provisional Patent Application No. 61/512,943 filed on Jul. 29, 2011, and European Patent Application No. 11 006 254.4 filed on Jul. 29, 2011, the contents of both of which patent applications are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2524855 | Schnider et al. | Oct 1950 | A |
| 2806033 | Lewenstein et al. | Sep 1957 | A |
| 2987445 | Levesque | Jun 1961 | A |
| 3332950 | Blumberg et al. | Jul 1967 | A |
| 3370035 | Ogura et al. | Feb 1968 | A |
| 3652589 | Flick et al. | Mar 1972 | A |
| 3806603 | Gaunt et al. | Apr 1974 | A |
| 3865108 | Hartop | Feb 1975 | A |
| 3941865 | Miller et al. | Mar 1976 | A |
| 3966747 | Monkovic et al. | Jun 1976 | A |
| 3980766 | Shaw et al. | Sep 1976 | A |
| 4002173 | Manning et al. | Jan 1977 | A |
| 4014965 | Stube et al. | Mar 1977 | A |
| 4070494 | Hoffmeister et al. | Jan 1978 | A |
| 4070497 | Wismer et al. | Jan 1978 | A |
| 4175119 | Porter | Nov 1979 | A |
| 4200704 | Anderson et al. | Apr 1980 | A |
| 4207893 | Michaels | Jun 1980 | A |
| 4262017 | Kuipers | Apr 1981 | A |
| 4343789 | Kawata et al. | Aug 1982 | A |
| 4353887 | Hess et al. | Oct 1982 | A |
| 4404183 | Kawata et al. | Sep 1983 | A |
| 4427681 | Munshi et al. | Jan 1984 | A |
| 4427778 | Zabriskie | Jan 1984 | A |
| 4457933 | Gordon et al. | Jul 1984 | A |
| 4462941 | Lee et al. | Jul 1984 | A |
| 4473640 | Combie et al. | Sep 1984 | A |
| 4483847 | Augart | Nov 1984 | A |
| 4485211 | Okamoto | Nov 1984 | A |
| 4529583 | Porter | Jul 1985 | A |
| 4599342 | La Hann | Jul 1986 | A |
| 4603143 | Schmidt | Jul 1986 | A |
| 4612008 | Wong et al. | Sep 1986 | A |
| 4629621 | Snipes | Dec 1986 | A |
| 4667013 | Reichle | May 1987 | A |
| 4690822 | Uemura | Sep 1987 | A |
| 4711894 | Wenzel et al. | Dec 1987 | A |
| 4713243 | Schiraldi et al. | Dec 1987 | A |
| 4744976 | Snipes et al. | May 1988 | A |
| 4764378 | Keitn et al. | Aug 1988 | A |
| 4765989 | Wong et al. | Aug 1988 | A |
| 4774074 | Snipes | Sep 1988 | A |
| 4774092 | Hamilton | Sep 1988 | A |
| 4783337 | Wong et al. | Nov 1988 | A |
| 4806337 | Snipes et al. | Feb 1989 | A |
| RE33093 | Schiraldi et al. | Oct 1989 | E |
| 4880585 | Klimesch et al. | Nov 1989 | A |
| 4892778 | Theeuwes et al. | Jan 1990 | A |
| 4892889 | Kirk | Jan 1990 | A |
| 4940556 | MacFarlane et al. | Jul 1990 | A |
| 4954346 | Sparta et al. | Sep 1990 | A |
| 4957668 | Placard | Sep 1990 | A |
| 4957681 | Klimesch et al. | Sep 1990 | A |
| 4960814 | Wu et al. | Oct 1990 | A |
| 4992278 | Khanna | Feb 1991 | A |
| 4992279 | Palmer et al. | Feb 1991 | A |
| 5004601 | Snipes | Apr 1991 | A |
| 5051261 | McGinty | Sep 1991 | A |
| 5073379 | Klimesch et al. | Dec 1991 | A |
| 5082668 | Wong et al. | Jan 1992 | A |
| 5126151 | Bodor et al. | Jun 1992 | A |
| 5139790 | Snipes | Aug 1992 | A |
| 5145944 | Steinmann | Sep 1992 | A |
| 5149538 | Granger et al. | Sep 1992 | A |
| 5169645 | Shukla et al. | Dec 1992 | A |
| 5190760 | Baker | Mar 1993 | A |
| 5198226 | MacFarlane et al. | Mar 1993 | A |
| 5200194 | Edgren et al. | Apr 1993 | A |
| 5200197 | Wright et al. | Apr 1993 | A |
| 5211892 | Gueret | May 1993 | A |
| 5225417 | Dappen | Jul 1993 | A |
| 5227157 | Mc Ginity et al. | Jul 1993 | A |
| 5229164 | Pins et al. | Jul 1993 | A |
| 5273758 | Royce | Dec 1993 | A |
| 5326852 | Fujikake | Jul 1994 | A |
| 5350741 | Takada | Sep 1994 | A |
| 5378462 | Boedecker et al. | Jan 1995 | A |
| 5387420 | Mitchell | Feb 1995 | A |
| 5427798 | Ludgwig et al. | Jun 1995 | A |
| RE34990 | Khanna et al. | Jul 1995 | E |
| 5458887 | Chen et al. | Oct 1995 | A |
| 5460826 | Merrill et al. | Oct 1995 | A |
| 5472943 | Crain et al. | Dec 1995 | A |
| 5508042 | Oshlack et al. | Apr 1996 | A |
| 5552159 | Mueller et al. | Sep 1996 | A |
| 5556640 | Ito et al. | Sep 1996 | A |
| 5562920 | Demmer et al. | Oct 1996 | A |
| 5591452 | Miller et al. | Jan 1997 | A |
| 5593694 | Hayashida et al. | Jan 1997 | A |
| 5601842 | Bartholomaeus | Feb 1997 | A |
| 5620697 | Tormala et al. | Apr 1997 | A |
| 5679685 | Cincotta et al. | Oct 1997 | A |
| 5681517 | Metzger | Oct 1997 | A |
| 5707636 | Rodriguez et al. | Jan 1998 | A |
| 5741519 | Rosenberg et al. | Apr 1998 | A |
| 5792474 | Rauchfuss | Aug 1998 | A |
| 5801201 | Gradums et al. | Sep 1998 | A |
| 5811126 | Krishanamurthy | Sep 1998 | A |
| 5849240 | Miller et al. | Dec 1998 | A |
| 5866164 | Kuczynski et al. | Feb 1999 | A |
| 5900425 | Kanikanti et al. | May 1999 | A |
| 5908850 | Zeitlin et al. | Jun 1999 | A |
| 5914132 | Kelm et al. | Jun 1999 | A |
| 5916584 | O'Donoghue et al. | Jun 1999 | A |
| 5928739 | Pophusen et al. | Jul 1999 | A |
| 5939099 | Grabowski et al. | Aug 1999 | A |
| 5945125 | Kim | Aug 1999 | A |
| 5948787 | Merill et al. | Sep 1999 | A |
| 5962488 | Lang | Oct 1999 | A |
| 5965161 | Oshlack et al. | Oct 1999 | A |
| 5968925 | Knidlberger | Oct 1999 | A |
| 6001391 | Zeidler et al. | Dec 1999 | A |
| 6009390 | Gupta et al. | Dec 1999 | A |
| 6009690 | Rosenberg et al. | Jan 2000 | A |
| 6051253 | Zettler et al. | Apr 2000 | A |
| 6071970 | Mueller et al. | Jun 2000 | A |
| 6077538 | Merrill et al. | Jun 2000 | A |
| 6090411 | Pillay et al. | Jul 2000 | A |
| 6093420 | Baichwal | Jul 2000 | A |
| 6096339 | Ayer et al. | Aug 2000 | A |
| 6117453 | Seth et al. | Sep 2000 | A |
| 6120802 | Breitenbach et al. | Sep 2000 | A |
| 6133241 | Bok et al. | Oct 2000 | A |
| 6183781 | Burke | Feb 2001 | B1 |
| 6235825 | Yoshida et al. | Feb 2001 | B1 |
| 6228863 | Palermo et al. | May 2001 | B1 |
| 6238697 | Kumar et al. | May 2001 | B1 |
| 6245357 | Edgren et al. | Jun 2001 | B1 |
| 6248737 | Buschmann et al. | Jun 2001 | B1 |
| 6251430 | Zhang et al. | Jun 2001 | B1 |
| 6254887 | Miller et al. | Jul 2001 | B1 |
| 6261599 | Oshlack | Jul 2001 | B1 |
| 6290990 | Grabowski et al. | Sep 2001 | B1 |
| 6306438 | Oshlack et al. | Oct 2001 | B1 |
| 6309668 | Bastin et al. | Oct 2001 | B1 |
| 6318650 | Breitenbach et al. | Nov 2001 | B1 |
| 6322811 | Verma et al. | Nov 2001 | B1 |
| 6322819 | Burnside et al. | Nov 2001 | B1 |
| 6326027 | Miller et al. | Dec 2001 | B1 |
| 6335035 | Drizen et al. | Jan 2002 | B1 |
| 6337319 | Wang | Jan 2002 | B1 |
| 6340475 | Shell et al. | Jan 2002 | B2 |
| 6344215 | Bettman et al. | Feb 2002 | B1 |
| 6344535 | Timmermann et al. | Feb 2002 | B1 |
| 6348469 | Seth | Feb 2002 | B1 |
| 6355656 | Zeitlin et al. | Mar 2002 | B1 |
| 6375957 | Kaiko et al. | Apr 2002 | B1 |
| 6375963 | Repka et al. | Apr 2002 | B1 |
| 6387995 | Sojka | May 2002 | B1 |
| 6399100 | Clancy et al. | Jun 2002 | B1 |
| 6419954 | Chu et al. | Jul 2002 | B1 |
| 6436441 | Sako et al. | Aug 2002 | B1 |
| 6455052 | Marcussen et al. | Sep 2002 | B1 |
| 6461644 | Jackson et al. | Oct 2002 | B1 |
| 6488939 | Zeidler et al. | Dec 2002 | B1 |
| 6488962 | Berner et al. | Dec 2002 | B1 |
| 6488963 | McGinity et al. | Dec 2002 | B1 |
| 6534089 | Ayer et al. | Mar 2003 | B1 |
| 6547977 | Yan et al. | Apr 2003 | B1 |
| 6547997 | Breitenbach et al. | Apr 2003 | B1 |
| 6562375 | Sako et al. | May 2003 | B1 |
| 6569506 | Jerdee et al. | May 2003 | B1 |
| 6572889 | Guo | Jun 2003 | B1 |
| 6592901 | Durig et al. | Jul 2003 | B2 |
| 6623754 | Guo et al. | Sep 2003 | B2 |
| 6635280 | Shell et al. | Oct 2003 | B2 |
| 6696088 | Oshlack et al. | Feb 2004 | B2 |
| 6699503 | Sako et al. | Mar 2004 | B1 |
| 6723340 | Gusler et al. | Apr 2004 | B2 |
| 6723343 | Kugelmann | Apr 2004 | B2 |
| 6733783 | Oshlack et al. | May 2004 | B2 |
| 6753009 | Luber et al. | Jun 2004 | B2 |
| 6821588 | Hammer et al. | Nov 2004 | B1 |
| 6979722 | Hamamoto et al. | Dec 2005 | B2 |
| 7074430 | Miller et al. | Jul 2006 | B2 |
| 7129248 | Chapman et al. | Oct 2006 | B2 |
| 7141250 | Oshlack et al. | Nov 2006 | B2 |
| 7157103 | Sackler | Jan 2007 | B2 |
| 7176251 | Bastioli et al. | Feb 2007 | B1 |
| RE39593 | Buschmann et al. | Apr 2007 | E |
| 7201920 | Kumar et al. | Apr 2007 | B2 |
| 7214385 | Gruber | May 2007 | B2 |
| 7230005 | Shafer et al. | Jun 2007 | B2 |
| 7300668 | Pryce et al. | Nov 2007 | B2 |
| 7332182 | Sackler | Feb 2008 | B2 |
| 7388068 | Falk et al. | Jun 2008 | B2 |
| 7399488 | Hirsh et al. | Jul 2008 | B2 |
| 7510726 | Kumar et al. | Mar 2009 | B2 |
| 7674799 | Chapman et al. | Mar 2010 | B2 |
| 7674800 | Chapman et al. | Mar 2010 | B2 |
| 7683072 | Chapman et al. | Mar 2010 | B2 |
| 7776314 | Bartholomaus et al. | Aug 2010 | B2 |
| 7842307 | Oshlack et al. | Nov 2010 | B2 |
| 7851482 | Dung et al. | Dec 2010 | B2 |
| 7932258 | Petereit et al. | Apr 2011 | B2 |
| 7939543 | Kupper | May 2011 | B2 |
| 7968119 | Farrell | Jun 2011 | B2 |
| 7994364 | Fischer et al. | Aug 2011 | B2 |
| 8075872 | Arkenau-Maric et al. | Dec 2011 | B2 |
| 8101630 | Kumar et al. | Jan 2012 | B2 |
| 8114383 | Bartholomaus et al. | Feb 2012 | B2 |
| 8114384 | Arkenau et al. | Feb 2012 | B2 |
| 8114838 | Marchionni | Feb 2012 | B2 |
| 8192722 | Arkenau-Maric et al. | Jun 2012 | B2 |
| 8202542 | Mehta et al. | Jun 2012 | B1 |
| 8309060 | Bartholomaus et al. | Nov 2012 | B2 |
| 8309122 | Kao et al. | Nov 2012 | B2 |
| 8323889 | Arkenau-Maric et al. | Dec 2012 | B2 |
| 8329216 | Kao et al. | Dec 2012 | B2 |
| 8337888 | Wright et al. | Dec 2012 | B2 |
| 8383152 | Jans et al. | Feb 2013 | B2 |
| 8420056 | Arkenau-Maric et al. | Apr 2013 | B2 |
| 8445023 | Guimberteau et al. | May 2013 | B2 |
| 8722086 | Arkenau-Mari et al. | May 2014 | B2 |
| 8858963 | Devarakonda et al. | Oct 2014 | B1 |
| 8901113 | Leech et al. | Dec 2014 | B2 |
| 9044758 | Niwa et al. | Jun 2015 | B2 |
| 9192578 | McGinity et al. | Nov 2015 | B2 |
| 9629807 | Arkenau-Maric et al. | Apr 2017 | B2 |
| 9675610 | Bartholomaeus et al. | Jun 2017 | B2 |
| 9737490 | Barnscheid et al. | Aug 2017 | B2 |
| 9925146 | Barnscheid et al. | Mar 2018 | B2 |
| 20010038852 | Kolter et al. | Nov 2001 | A1 |
| 20020012701 | Kolter et al. | Jan 2002 | A1 |
| 20020015730 | Hoffmann et al. | Feb 2002 | A1 |
| 20020187192 | Arilla et al. | Feb 2002 | A1 |
| 20020051820 | Shell et al. | May 2002 | A1 |
| 20020114838 | Ayer et al. | Aug 2002 | A1 |
| 20020132359 | Waterman | Sep 2002 | A1 |
| 20020132395 | Iyer et al. | Sep 2002 | A1 |
| 20020176888 | Bartholomaeus et al. | Nov 2002 | A1 |
| 20020192277 | Oshlack et al. | Dec 2002 | A1 |
| 20030008409 | Spearman et al. | Jan 2003 | A1 |
| 20030015814 | Krull et al. | Jan 2003 | A1 |
| 20030017532 | Biswas et al. | Jan 2003 | A1 |
| 20030021546 | Sato | Jan 2003 | A1 |
| 20030031546 | Araki et al. | Feb 2003 | A1 |
| 20030044458 | Wright et al. | Mar 2003 | A1 |
| 20030044464 | Zeigler et al. | Mar 2003 | A1 |
| 20030064099 | Oshlack et al. | Apr 2003 | A1 |
| 20030068276 | Hughes et al. | Apr 2003 | A1 |
| 20030068370 | Sackler et al. | Apr 2003 | A1 |
| 20030068371 | Oshlack et al. | Apr 2003 | A1 |
| 20030068375 | Wright et al. | Apr 2003 | A1 |
| 20030068392 | Sackler | Apr 2003 | A1 |
| 20030069263 | Breder et al. | Apr 2003 | A1 |
| 20030077297 | Chen et al. | Apr 2003 | A1 |
| 20030077327 | Durig et al. | Apr 2003 | A1 |
| 20030091630 | Louie-Helm et al. | May 2003 | A1 |
| 20030092724 | Huaihung et al. | May 2003 | A1 |
| 20030104052 | Berner et al. | Jun 2003 | A1 |
| 20030104053 | Gusler et al. | Jun 2003 | A1 |
| 20030118641 | Maloney | Jun 2003 | A1 |
| 20030124185 | Oshlack et al. | Jul 2003 | A1 |
| 20030125347 | Anderson et al. | Jul 2003 | A1 |
| 20030129230 | Baichwal et al. | Jul 2003 | A1 |
| 20030133985 | Louie-Helm et al. | Jul 2003 | A1 |
| 20030143269 | Oshlack et al. | Jul 2003 | A1 |
| 20030152622 | Louie-Helm et al. | Aug 2003 | A1 |
| 20030158242 | Kugelmann | Aug 2003 | A1 |
| 20030158265 | Radhakrishnan et al. | Aug 2003 | A1 |
| 20030175326 | Thombre | Sep 2003 | A1 |
| 20030198677 | Pryce Lewis et al. | Oct 2003 | A1 |
| 20030215508 | Davis et al. | Nov 2003 | A1 |
| 20030224051 | Fink et al. | Dec 2003 | A1 |
| 20030232895 | Omidian et al. | Dec 2003 | A1 |
| 20040010000 | Ayer et al. | Jan 2004 | A1 |
| 20040011806 | Luciano et al. | Jan 2004 | A1 |
| 20040170680 | Oshlack et al. | Jan 2004 | A1 |
| 20040049079 | Murray et al. | Mar 2004 | A1 |
| 20040052731 | Hirsh et al. | Mar 2004 | A1 |
| 20040052844 | Hsiao et al. | Mar 2004 | A1 |
| 20040081694 | Oshlack | Apr 2004 | A1 |
| 20040091528 | Rogers et al. | May 2004 | A1 |
| 20040126428 | Hughes et al. | Jul 2004 | A1 |
| 20040131671 | Zhang et al. | Jul 2004 | A1 |
| 20040156899 | Louie-Helm et al. | Aug 2004 | A1 |
| 20040170567 | Sackler | Sep 2004 | A1 |
| 20040185105 | Berner et al. | Sep 2004 | A1 |
| 20040213845 | Sugihara | Oct 2004 | A1 |
| 20040213848 | Li et al. | Oct 2004 | A1 |
| 20040253310 | Fischer et al. | Dec 2004 | A1 |
| 20050015730 | Gunturi et al. | Jan 2005 | A1 |
| 20050031546 | Bartholomaus et al. | Feb 2005 | A1 |
| 20050058706 | Bartholomaeus et al. | Mar 2005 | A1 |
| 20050063214 | Takashima | Mar 2005 | A1 |
| 20050089475 | Gruber | Apr 2005 | A1 |
| 20050089569 | Bar-Shalom | Apr 2005 | A1 |
| 20050095291 | Oshlack et al. | May 2005 | A1 |
| 20050106249 | Hwang et al. | May 2005 | A1 |
| 20050112067 | Kumar et al. | May 2005 | A1 |
| 20050127555 | Gusik et al. | Jun 2005 | A1 |
| 20050152843 | Bartholomaus et al. | Jul 2005 | A1 |
| 20050181046 | Oshlack et al. | Aug 2005 | A1 |
| 20050186139 | Bartholomaus et al. | Aug 2005 | A1 |
| 20050191244 | Bartholomaeus et al. | Sep 2005 | A1 |
| 20050191352 | Hayes | Sep 2005 | A1 |
| 20050192333 | Hinze et al. | Sep 2005 | A1 |
| 20050214223 | Bartholomaeus et al. | Sep 2005 | A1 |
| 20050220877 | Patel | Oct 2005 | A1 |
| 20050222188 | Chapman et al. | Oct 2005 | A1 |
| 20050236741 | Arkenau et al. | Oct 2005 | A1 |
| 20050245556 | Brogmann et al. | Nov 2005 | A1 |
| 20050266084 | Li et al. | Dec 2005 | A1 |
| 20060002859 | Arkenau et al. | Jan 2006 | A1 |
| 20060002860 | Bartholomaus et al. | Jan 2006 | A1 |
| 20060004034 | Hinze et al. | Jan 2006 | A1 |
| 20060009478 | Friedman et al. | Jan 2006 | A1 |
| 20060012701 | Sung-Bin | Jan 2006 | A1 |
| 20060017916 | Clarke et al. | Jan 2006 | A1 |
| 20060039864 | Bartholomaus et al. | Feb 2006 | A1 |
| 20060073102 | Huaihung et al. | Apr 2006 | A1 |
| 20060099250 | Tian et al. | May 2006 | A1 |
| 20060104909 | Vaghefi et al. | May 2006 | A1 |
| 20060182801 | Breder et al. | Aug 2006 | A1 |
| 20060188447 | Arkenau-Maric et al. | Aug 2006 | A1 |
| 20060193782 | Bartholomeus et al. | Aug 2006 | A1 |
| 20060193914 | Ashworth et al. | Aug 2006 | A1 |
| 20060194759 | Eidelson | Aug 2006 | A1 |
| 20060194826 | Oshlack et al. | Aug 2006 | A1 |
| 20060240105 | Devane et al. | Oct 2006 | A1 |
| 20060240110 | Kiick et al. | Oct 2006 | A1 |
| 20060269603 | Brown Miller et al. | Nov 2006 | A1 |
| 20070003616 | Arkenau-Maric et al. | Jan 2007 | A1 |
| 20070003617 | Fischer et al. | Jan 2007 | A1 |
| 20070020188 | Sackler | Jan 2007 | A1 |
| 20070020335 | Chen et al. | Jan 2007 | A1 |
| 20070042044 | Fischer et al. | Feb 2007 | A1 |
| 20070048228 | Arkenau-Maric et al. | Mar 2007 | A1 |
| 20070065365 | Kugelmann et al. | Mar 2007 | A1 |
| 20070092573 | Joshi et al. | Apr 2007 | A1 |
| 20070183979 | Arkenau-Maric et al. | Aug 2007 | A1 |
| 20070183980 | Arkenau-Maric et al. | Aug 2007 | A1 |
| 20070184117 | Gregory et al. | Aug 2007 | A1 |
| 20070190142 | Breitenbach et al. | Aug 2007 | A1 |
| 20070196396 | Pilgaonkar et al. | Aug 2007 | A1 |
| 20070196481 | Amidon et al. | Aug 2007 | A1 |
| 20070224129 | Guimberteau et al. | Sep 2007 | A1 |
| 20070231268 | Emigh et al. | Oct 2007 | A1 |
| 20070259045 | Mannion et al. | Nov 2007 | A1 |
| 20070264327 | Kumar et al. | Nov 2007 | A1 |
| 20070269505 | Flath et al. | Nov 2007 | A1 |
| 20070292508 | Szamosi et al. | Dec 2007 | A1 |
| 20080020032 | Crowley et al. | Jan 2008 | A1 |
| 20080023452 | Grek et al. | Jan 2008 | A1 |
| 20080063725 | Guimberteau et al. | Mar 2008 | A1 |
| 20080069871 | Vaughn et al. | Mar 2008 | A1 |
| 20080075669 | Soscia et al. | Mar 2008 | A1 |
| 20080075768 | Vaughn et al. | Mar 2008 | A1 |
| 20080081290 | Wada et al. | Apr 2008 | A1 |
| 20080085304 | Baichwal et al. | Apr 2008 | A1 |
| 20080131503 | Holm et al. | Jun 2008 | A1 |
| 20080145429 | Leyenecker et al. | Jun 2008 | A1 |
| 20080152595 | Emigh et al. | Jun 2008 | A1 |
| 20080181932 | Bortz et al. | Jul 2008 | A1 |
| 20080220079 | Chen | Sep 2008 | A1 |
| 20080233178 | Reidenberg et al. | Sep 2008 | A1 |
| 20080234352 | Fischer et al. | Sep 2008 | A1 |
| 20080247959 | Bartholomaus et al. | Oct 2008 | A1 |
| 20080248113 | Bartholomaus et al. | Oct 2008 | A1 |
| 20080260836 | Boyd | Oct 2008 | A1 |
| 20080280975 | Badul | Nov 2008 | A1 |
| 20080311049 | Arkenau-Maric et al. | Dec 2008 | A1 |
| 20080311187 | Ashworth et al. | Dec 2008 | A1 |
| 20080311197 | Arkenau-Maric et al. | Dec 2008 | A1 |
| 20080311205 | Habib et al. | Dec 2008 | A1 |
| 20080312264 | Arkenau-Maric et al. | Dec 2008 | A1 |
| 20080317695 | Everaert et al. | Dec 2008 | A1 |
| 20080317854 | Arkenau et al. | Dec 2008 | A1 |
| 20090004267 | Arkenau-Maric et al. | Jan 2009 | A1 |
| 20090005408 | Arkenau-Maric et al. | Jan 2009 | A1 |
| 20090011016 | Cailly-Dufestel et al. | Jan 2009 | A1 |
| 20090017121 | Berner et al. | Jan 2009 | A1 |
| 20090022798 | Rosenberg et al. | Jan 2009 | A1 |
| 20090081287 | Wright et al. | Mar 2009 | A1 |
| 20090081290 | KcKenna et al. | Mar 2009 | A1 |
| 20090117191 | Brown Miller | May 2009 | A1 |
| 20090202634 | Jans et al. | Aug 2009 | A1 |
| 20090215808 | Yum et al. | Aug 2009 | A1 |
| 20090232887 | Odidi et al. | Sep 2009 | A1 |
| 20090253730 | Kumar et al. | Oct 2009 | A1 |
| 20090317355 | Roth et al. | Dec 2009 | A1 |
| 20090318395 | Schramm et al. | Dec 2009 | A1 |
| 20100015223 | Cailly-Deufestel et al. | Jan 2010 | A1 |
| 20100035886 | Cincotta et al. | Feb 2010 | A1 |
| 20100047345 | Growley et al. | Feb 2010 | A1 |
| 20100092553 | Guimberteau | Apr 2010 | A1 |
| 20100098758 | Bartholomaus et al. | Apr 2010 | A1 |
| 20100099696 | Soscia et al. | Apr 2010 | A1 |
| 20100104638 | Dai et al. | Apr 2010 | A1 |
| 20100151028 | Ashworth et al. | Jun 2010 | A1 |
| 20100168148 | Wright et al. | Jul 2010 | A1 |
| 20100172989 | Roth et al. | Jul 2010 | A1 |
| 20100203129 | Anderson et al. | Aug 2010 | A1 |
| 20100221322 | Bartholomaus et al. | Sep 2010 | A1 |
| 20100249045 | Babul | Sep 2010 | A1 |
| 20100260833 | Bartholomaus et al. | Oct 2010 | A1 |
| 20100280047 | Kolter et al. | Nov 2010 | A1 |
| 20100291205 | Downie et al. | Nov 2010 | A1 |
| 20100297229 | Sesha | Nov 2010 | A1 |
| 20110020451 | Bartholomaus et al. | Jan 2011 | A1 |
| 20110020454 | Lamarca Casado | Jan 2011 | A1 |
| 20110038930 | Barnscheid et al. | Feb 2011 | A1 |
| 20110082214 | Fauer et al. | Apr 2011 | A1 |
| 20110092515 | Qiu et al. | Apr 2011 | A1 |
| 20110097404 | Oshlack et al. | Apr 2011 | A1 |
| 20110129535 | Mantelle | Jun 2011 | A1 |
| 20110159100 | Anderson et al. | Jun 2011 | A1 |
| 20110187017 | Haupts | Aug 2011 | A1 |
| 20110223244 | Liversidge et al. | Sep 2011 | A1 |
| 20110245783 | Stinchcomb | Oct 2011 | A1 |
| 20110262496 | Desai | Oct 2011 | A1 |
| 20120034171 | Arkenau-Maric et al. | Feb 2012 | A1 |
| 20120059065 | Barnscheid et al. | Mar 2012 | A1 |
| 20120065220 | Barnscheid et al. | Mar 2012 | A1 |
| 20120077879 | Vasanthavada et al. | Mar 2012 | A1 |
| 20120107250 | Bartholomaus et al. | May 2012 | A1 |
| 20120108622 | Wright et al. | May 2012 | A1 |
| 20120135071 | Bartholomaus et al. | May 2012 | A1 |
| 20120136021 | Barnscheid et al. | May 2012 | A1 |
| 20120141583 | Mannion et al. | Jun 2012 | A1 |
| 20120202838 | Ghosh et al. | Aug 2012 | A1 |
| 20120225901 | Leyendecker et al. | Sep 2012 | A1 |
| 20120231083 | Carley et al. | Sep 2012 | A1 |
| 20120251637 | Bartholomaus et al. | Oct 2012 | A1 |
| 20120321716 | Vachon et al. | Dec 2012 | A1 |
| 20130028970 | Schwier et al. | Jan 2013 | A1 |
| 20130028972 | Schwier et al. | Jan 2013 | A1 |
| 20130090349 | Gei Ler et al. | Apr 2013 | A1 |
| 20130129825 | Billoet et al. | May 2013 | A1 |
| 20130129826 | Gei Ler et al. | May 2013 | A1 |
| 20130171075 | Arkenau-Maric et al. | Jul 2013 | A1 |
| 20130209557 | Barnscheid | Aug 2013 | A1 |
| 20130225625 | Barnscheid et al. | Aug 2013 | A1 |
| 20130251643 | Bartholomäus et al. | Sep 2013 | A1 |
| 20130289062 | Kumar et al. | Oct 2013 | A1 |
| 20130303623 | Barnscheid et al. | Nov 2013 | A1 |
| 20130330409 | Mohammad | Dec 2013 | A1 |
| 20140010874 | Sackler | Jan 2014 | A1 |
| 20140356428 | Barnscheid et al. | Feb 2014 | A1 |
| 20140079780 | Arkenau Maric et al. | Mar 2014 | A1 |
| 20140080858 | Bartholomäus et al. | Mar 2014 | A1 |
| 20140080915 | Bartholomäus et al. | Mar 2014 | A1 |
| 20140094481 | Fleischer et al. | Apr 2014 | A1 |
| 20140112984 | Arkenau Maric et al. | Apr 2014 | A1 |
| 20140112989 | Bartholomäus et al. | Apr 2014 | A1 |
| 20140170079 | Arkenau Maric et al. | Jun 2014 | A1 |
| 20140186440 | Han et al. | Jul 2014 | A1 |
| 20140275143 | Devarakonda et al. | Sep 2014 | A1 |
| 20140356426 | Barnscheid et al. | Dec 2014 | A1 |
| 20140378498 | Devarakonda et al. | Dec 2014 | A1 |
| 20150017250 | Wening et al. | Jan 2015 | A1 |
| 20150030677 | Adjei et al. | Jan 2015 | A1 |
| 20150064250 | Ghebre-Sellassie et al. | Mar 2015 | A1 |
| 20150079150 | Fischer et al. | Mar 2015 | A1 |
| 20150118300 | Haswani et al. | Apr 2015 | A1 |
| 20150118302 | Haswani et al. | Apr 2015 | A1 |
| 20150118303 | Haswani et al. | Apr 2015 | A1 |
| 20150374630 | Arkenau Maric et al. | Dec 2015 | A1 |
| 20160089439 | Rajagopalan | Mar 2016 | A1 |
| 20160175256 | Bartholomaeus et al. | Jun 2016 | A1 |
| 20160184297 | Arkenau-Maric et al. | Jun 2016 | A1 |
| 20160256456 | Caruso et al. | Sep 2016 | A1 |
| 20160263037 | Arkenau Maric et al. | Sep 2016 | A1 |
| 20160361308 | Bartholomaeus et al. | Dec 2016 | A1 |
| 20160367549 | Bartholomaeus et al. | Dec 2016 | A1 |
| 20170027886 | Bartholomaeus et al. | Feb 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 46994 | Dec 2004 | AR |
| 045353 | Oct 2005 | AR |
| 049562 | Aug 2006 | AR |
| 049839 | Sep 2006 | AR |
| 053304 | May 2007 | AR |
| 054222 | Jun 2007 | AR |
| 054328 | Jun 2007 | AR |
| 769807 | Mar 2001 | AU |
| 2003237944 | Dec 2003 | AU |
| 2003274071 | May 2004 | AU |
| 2003278133 | May 2004 | AU |
| 2003279317 | May 2004 | AU |
| 2004264666 | Feb 2005 | AU |
| 2004264667 | Feb 2005 | AU |
| 2004308653 | Apr 2005 | AU |
| 2005259476 | Jan 2006 | AU |
| 2005259478 | Jan 2006 | AU |
| 2006210145 | Aug 2006 | AU |
| 2006210145 | Aug 2006 | AU |
| 2009207796 | Jul 2009 | AU |
| 2009243681 | Nov 2009 | AU |
| 2006311116 | Jan 2013 | AU |
| P10413318 | Oct 2006 | BR |
| P10413361 | Oct 2006 | BR |
| P10513300 | May 2008 | BR |
| P10606145 | Feb 2009 | BR |
| 722109 | Nov 1965 | CA |
| 2082573 | May 1993 | CA |
| 2577233 | Oct 1997 | CA |
| 2650637 | Oct 1997 | CA |
| 2229621 | Mar 1998 | CA |
| 2317747 | Jul 1999 | CA |
| 2343234 | Mar 2000 | CA |
| 2352874 | Jun 2000 | CA |
| 2414349 | Jan 2002 | CA |
| 2456322 | Feb 2003 | CA |
| 2502965 | May 2004 | CA |
| 2503155 | May 2004 | CA |
| 2534925 | Feb 2005 | CA |
| 2534932 | Feb 2005 | CA |
| 2489855 | Apr 2005 | CA |
| 2551231 | Jul 2005 | CA |
| 2572352 | Jan 2006 | CA |
| 2572491 | Jan 2006 | CA |
| 2595954 | Jul 2006 | CA |
| 2229650 | Aug 2006 | CA |
| 2594713 | Aug 2006 | CA |
| 2595979 | Aug 2006 | CA |
| 2625055 | Apr 2007 | CA |
| 2713128 | Jul 2009 | CA |
| 2723438 | Nov 2009 | CA |
| 2595954 | Jan 2011 | CA |
| 689109 | Oct 1998 | CH |
| 20162004 | May 2005 | CL |
| 20172004 | May 2005 | CL |
| 200403308 | Sep 2005 | CL |
| 200500952 | Nov 2005 | CL |
| 200501624 | Dec 2005 | CL |
| 200501625 | Jun 2006 | CL |
| 424-2013 | Mar 2012 | CL |
| 43762013 | Mar 2012 | CL |
| 87102755 | Oct 1987 | CN |
| 1135175 | Nov 1996 | CN |
| 1473562 | Feb 2004 | CN |
| 1980643 | Apr 2005 | CN |
| 101010071 | Jun 2005 | CN |
| 1671475 | Sep 2005 | CN |
| 101022787 | Jan 2006 | CN |
| 001863513 | Nov 2006 | CN |
| 001863514 | Nov 2006 | CN |
| 01917862 | Feb 2007 | CN |
| 1942174 | Apr 2007 | CN |
| 101011395 | Aug 2007 | CN |
| 101027044 | Aug 2007 | CN |
| 101057849 | Oct 2007 | CN |
| 101484135 | Nov 2007 | CN |
| 101091721 | Dec 2007 | CN |
| 101111232 | Jan 2008 | CN |
| 101175482 | Feb 2008 | CN |
| 101370485 | Feb 2009 | CN |
| 101394839 | Mar 2009 | CN |
| 101652128 | Feb 2010 | CN |
| 2530563 | Jan 1977 | DE |
| 4229085 | Mar 1994 | DE |
| 4309528 | Sep 1994 | DE |
| 4446470 | Jun 1996 | DE |
| 69400215 | Oct 1996 | DE |
| 19522899 | Dec 1996 | DE |
| 2808505 | Jan 1997 | DE |
| 19753534 | Jun 1999 | DE |
| 19800689 | Jul 1999 | DE |
| 19800698 | Jul 1999 | DE |
| 19822979 | Dec 1999 | DE |
| 69229881 | Dec 1999 | DE |
| 19855440 | Jun 2000 | DE |
| 19856147 | Jun 2000 | DE |
| 19940740 | Mar 2001 | DE |
| 19960494 | Jun 2001 | DE |
| 10036400 | Jun 2002 | DE |
| 69429710 | Aug 2002 | DE |
| 10250083 | Dec 2003 | DE |
| 10250084 | May 2004 | DE |
| 10250087 | May 2004 | DE |
| 10250088 | May 2004 | DE |
| 10336400 | Mar 2005 | DE |
| 10361596 | Sep 2005 | DE |
| 102004019916 | Nov 2005 | DE |
| 102004020220 | Nov 2005 | DE |
| 10 2004 032049 | Jan 2006 | DE |
| 10 2004 032051 | Jan 2006 | DE |
| 10 2004 032103 | Jan 2006 | DE |
| 10 2005 005446 | Aug 2006 | DE |
| 10 2005 005449 | Aug 2006 | DE |
| 102007011485 | Sep 2008 | DE |
| 1658055 | Jul 2007 | DK |
| 1658054 | Oct 2007 | DK |
| 1515702 | Jan 2009 | DK |
| SP066345 | Aug 2006 | EC |
| 0008131 | Feb 1980 | EP |
| 0216453 | Feb 1980 | EP |
| 0043254 | Jan 1982 | EP |
| 0008131 | Dec 1982 | EP |
| 0177893 | Apr 1986 | EP |
| 0216453 | Apr 1987 | EP |
| 0226061 | Jun 1987 | EP |
| 0228417 | Jul 1987 | EP |
| 0229652 | Jul 1987 | EP |
| 0232877 | Aug 1987 | EP |
| 0239973 | Oct 1987 | EP |
| 0240906 | Oct 1987 | EP |
| 0261616 | Mar 1988 | EP |
| 0270954 | Jun 1988 | EP |
| 0277289 | Aug 1988 | EP |
| 0293066 | Nov 1988 | EP |
| 0261616 | Feb 1989 | EP |
| 0328775 | Aug 1989 | EP |
| 0358105 | Mar 1990 | EP |
| 0228417 | Aug 1990 | EP |
| 0229652 | Oct 1991 | EP |
| 0477135 | Mar 1992 | EP |
| 0277289 BI | Apr 1992 | EP |
| 0293066 | Apr 1993 | EP |
| 0270954 | May 1993 | EP |
| 0544144 | Jun 1993 | EP |
| 0583726 | Feb 1994 | EP |
| 0598606 | May 1994 | EP |
| 0636370 | Feb 1995 | EP |
| 0641195 | Mar 1995 | EP |
| 0647448 | Apr 1995 | EP |
| 0654263 | May 1995 | EP |
| 0654263 | May 1995 | EP |
| 0661045 | Jul 1995 | EP |
| 0675710 | Oct 1995 | EP |
| 0682945 | Nov 1995 | EP |
| 0693475 | Jan 1996 | EP |
| 0820693 | Jan 1996 | EP |
| 0696598 | Feb 1996 | EP |
| 0583726 | Nov 1996 | EP |
| 0756480 | Feb 1997 | EP |
| 0760654 | Mar 1997 | EP |
| 0780369 | Jun 1997 | EP |
| 0785775 | Jul 1997 | EP |
| 0761211 | Dec 1997 | EP |
| 0809488 | Dec 1997 | EP |
| 0820698 | Jan 1998 | EP |
| 0820753 | Jan 1998 | EP |
| 0857062 | Aug 1998 | EP |
| 0864324 | Sep 1998 | EP |
| 0864326 | Sep 1998 | EP |
| 0598606 | Jun 1999 | EP |
| 0675710 | Aug 1999 | EP |
| 0980894 | Feb 2000 | EP |
| 0988106 | Mar 2000 | EP |
| 1014941 | Jul 2000 | EP |
| 1070504 | Jan 2001 | EP |
| 1127871 | Aug 2001 | EP |
| 1138321 | Oct 2001 | EP |
| 1152026 | Nov 2001 | EP |
| 1138321 | Jan 2002 | EP |
| 1166776 | Jan 2002 | EP |
| 1201233 | May 2002 | EP |
| 0661045 | Jul 2002 | EP |
| 1250045 | Oct 2002 | EP |
| 1250045 | Oct 2002 | EP |
| 1251120 | Oct 2002 | EP |
| 1293127 | Mar 2003 | EP |
| 1293195 | Mar 2003 | EP |
| 1293196 | Mar 2003 | EP |
| 1127871 | Sep 2003 | EP |
| 1201233 | Dec 2004 | EP |
| 1251120 | Dec 2004 | EP |
| 1492506 | Jan 2005 | EP |
| 1166776 | Feb 2005 | EP |
| 1502592 | Feb 2005 | EP |
| 1658054 | Feb 2005 | EP |
| 1658055 | Feb 2005 | EP |
| 1515702 | Mar 2005 | EP |
| 1527775 | Apr 2005 | EP |
| 1558221 | Aug 2005 | EP |
| 1558257 | Aug 2005 | EP |
| 1560585 | Aug 2005 | EP |
| 1611880 | Jan 2006 | EP |
| 1658054 | May 2006 | EP |
| 1138321 | Jan 2007 | EP |
| 1740161 | Jan 2007 | EP |
| 1658055 | Mar 2007 | EP |
| 1765303 | Mar 2007 | EP |
| 1786403 | May 2007 | EP |
| 1558221 | Jun 2007 | EP |
| 1658054 | Jun 2007 | EP |
| 1842533 | Oct 2007 | EP |
| 1845955 | Oct 2007 | EP |
| 1845956 | Oct 2007 | EP |
| 1859789 | Nov 2007 | EP |
| 1980245 | Oct 2008 | EP |
| 1897545 | Dec 2008 | EP |
| 2131830 | Dec 2009 | EP |
| 2246063 | Nov 2010 | EP |
| 2249811 | Nov 2010 | EP |
| 2273983 | Jan 2011 | EP |
| 2402004 | Jan 2012 | EP |
| 2336571 | Dec 2004 | ES |
| 2260042 | Nov 2006 | ES |
| 2285497 | Nov 2007 | ES |
| 2288621 | Jan 2008 | ES |
| 2289542 | Feb 2008 | ES |
| 2315505 | Apr 2009 | ES |
| 1147210 | Apr 1969 | GB |
| 1567727 | May 1980 | GB |
| 2047095 | Nov 1980 | GB |
| 2057878 | Apr 1981 | GB |
| 2238478 | Jun 1991 | GB |
| P20070272 | Jun 2007 | HR |
| 20070456 | Nov 2007 | HR |
| S36-022895 | Nov 1961 | JP |
| S55162714 | Dec 1980 | JP |
| S5659708 | May 1981 | JP |
| S56169622 | Dec 1981 | JP |
| S62240061 | Oct 1987 | JP |
| H0249719 | Feb 1990 | JP |
| 3 0501737 | Apr 1991 | JP |
| H0517566 | Jan 1993 | JP |
| H06507645 | Sep 1994 | JP |
| 08053331 | Feb 1996 | JP |
| 8 505076 | Jun 1996 | JP |
| H09508410 | Aug 1997 | JP |
| H1057450 | Mar 1998 | JP |
| H10251149 | Sep 1998 | JP |
| 2002524150 | Aug 2002 | JP |
| 2002 275175 | Sep 2002 | JP |
| 2003125706 | May 2003 | JP |
| 2003526598 | Sep 2003 | JP |
| 2004143071 | May 2004 | JP |
| 2005506965 | Mar 2005 | JP |
| 2005515152 | May 2005 | JP |
| 2005-314407 | Nov 2005 | JP |
| 2005534664 | Nov 2005 | JP |
| 2007501201 | Jan 2007 | JP |
| 2007501202 | Jan 2007 | JP |
| 2007513147 | May 2007 | JP |
| 2007533692 | Nov 2007 | JP |
| 2008024603 | Feb 2008 | JP |
| 2008504327 | Feb 2008 | JP |
| 2008528654 | Jul 2008 | JP |
| 2009523833 | Jun 2009 | JP |
| 2009531453 | Sep 2009 | JP |
| 2009536927 | Oct 2009 | JP |
| 2009537456 | Oct 2009 | JP |
| 2010534204 | Nov 2010 | JP |
| 2011504455 | Feb 2011 | JP |
| 2011506493 | Mar 2011 | JP |
| 2011510034 | Mar 2011 | JP |
| WO 2011059074 | May 2011 | JP |
| 2012515735 | Jul 2012 | JP |
| 2012528845 | Nov 2012 | JP |
| 2013155124 | Aug 2013 | JP |
| 2013536810 | Sep 2013 | JP |
| 2014505736 | Mar 2014 | JP |
| 2014528437 | Oct 2014 | JP |
| 6085307 | Feb 2017 | JP |
| 2013523780 | Jun 2017 | JP |
| 1020060069832 | Jun 2006 | KR |
| 20070039041 | Apr 2007 | KR |
| 20070111510 | Nov 2007 | KR |
| 20090085312 | Aug 2009 | KR |
| 20100111303 | Oct 2010 | KR |
| 20110016921 | Feb 2011 | KR |
| 2007000008 | Mar 2007 | MX |
| 2007000009 | Mar 2007 | MX |
| 2007009393 | Aug 2007 | MX |
| 2010008138 | Aug 2010 | MX |
| 2010012039 | Nov 2010 | MX |
| 20061054 | Mar 2006 | NO |
| 20070578 | Jan 2007 | NO |
| 20074412 | Nov 2007 | NO |
| 528302 | Feb 2007 | NZ |
| 1699440 | Dec 2004 | PT |
| 1658054 | May 2006 | PT |
| 1658055 | Jul 2007 | PT |
| 1515702 | Dec 2008 | PT |
| 2131244 | Jun 1999 | RU |
| 2198197 | Feb 2003 | RU |
| 2220715 | Jan 2004 | RU |
| 2328275 | May 2004 | RU |
| 2396944 | Jul 2004 | RU |
| 2326654 | Sep 2005 | RU |
| 2339365 | Dec 2007 | RU |
| 2354357 | Dec 2007 | RU |
| 2007103712 | Sep 2008 | RU |
| 2007103707 | Nov 2008 | RU |
| 2007132975 | Apr 2009 | RU |
| 2567723 | Nov 2015 | RU |
| 1515702 | Apr 2009 | SI |
| 1699440 | Nov 2009 | SI |
| 10612003 | Jan 2004 | SK |
| 1759445 | Sep 1992 | SU |
| I254634 | May 2006 | TW |
| 8000841 | May 1980 | WO |
| 8905624 | Jun 1989 | WO |
| 9003776 | Apr 1990 | WO |
| WO 199003776 | Apr 1990 | WO |
| 9306723 | Apr 1993 | WO |
| 9310758 | Jun 1993 | WO |
| 9311749 | Jun 1993 | WO |
| WO 9310765 | Jun 1993 | WO |
| 9323017 | Nov 1993 | WO |
| 9406414 | Mar 1994 | WO |
| 9408567 | Apr 1994 | WO |
| 9517174 | Jun 1995 | WO |
| 9520947 | Aug 1995 | WO |
| 9522319 | Aug 1995 | WO |
| WO 199520947 | Aug 1995 | WO |
| 9530422 | Nov 1995 | WO |
| 9600066 | Jan 1996 | WO |
| 9603979 | Feb 1996 | WO |
| 9614058 | May 1996 | WO |
| 9733566 | Sep 1997 | WO |
| WO 1997000673 | Sep 1997 | WO |
| 9749384 | Dec 1997 | WO |
| 9835655 | Feb 1998 | WO |
| 9820073 | May 1998 | WO |
| 98028698 | Jul 1998 | WO |
| 9835655 | Aug 1998 | WO |
| WO 1998051758 | Nov 1998 | WO |
| 99012864 | Mar 1999 | WO |
| 9932120 | Jul 1999 | WO |
| 9944591 | Sep 1999 | WO |
| 9948481 | Sep 1999 | WO |
| WO1999045887 | Sep 1999 | WO |
| WO 20000013647 | Mar 2000 | WO |
| 2000033835 | Jun 2000 | WO |
| 0040205 | Jul 2000 | WO |
| 0108661 | Feb 2001 | WO |
| 01012230 | Feb 2001 | WO |
| 0115667 | Mar 2001 | WO |
| 0152651 | Jul 2001 | WO |
| WO 2001058451 | Aug 2001 | WO |
| WO 2001058451 | Aug 2001 | WO |
| 0197783 | Dec 2001 | WO |
| 0226061 | Apr 2002 | WO |
| 0226262 | Apr 2002 | WO |
| 0226928 | Apr 2002 | WO |
| 0235991 | May 2002 | WO |
| 02071860 | Sep 2002 | WO |
| 02088217 | Nov 2002 | WO |
| WO 2002094254 | Nov 2002 | WO |
| 03006723 | Jan 2003 | WO |
| WO03007802 | Jan 2003 | WO |
| 03013476 | Feb 2003 | WO |
| 03013479 | Feb 2003 | WO |
| 03015531 | Feb 2003 | WO |
| WO 2003013433 | Feb 2003 | WO |
| WO 2003013538 | Feb 2003 | WO |
| WO 2003013538 | Feb 2003 | WO |
| 03024430 | Mar 2003 | WO |
| 2003024426 | Mar 2003 | WO |
| WO 2003018015 | Mar 2003 | WO |
| 03026624 | Apr 2003 | WO |
| 03028698 | Apr 2003 | WO |
| 03028990 | Apr 2003 | WO |
| 03031546 | Apr 2003 | WO |
| 2003026743 | Apr 2003 | WO |
| 03035029 | May 2003 | WO |
| 03035053 | May 2003 | WO |
| 03035054 | May 2003 | WO |
| 03035177 | May 2003 | WO |
| WO 2003039561 | May 2003 | WO |
| WO 2003049689 | Jun 2003 | WO |
| 03053417 | Jul 2003 | WO |
| 03068392 | Aug 2003 | WO |
| WO 2003070191 | Aug 2003 | WO |
| 03092648 | Nov 2003 | WO |
| 03094812 | Nov 2003 | WO |
| 03105808 | Dec 2003 | WO |
| 04004693 | Jan 2004 | WO |
| 2004043967 | Feb 2004 | WO |
| 2004026262 | Apr 2004 | WO |
| 2004026263 | Apr 2004 | WO |
| WO 2004026280 | Apr 2004 | WO |
| 2004037230 | May 2004 | WO |
| 2004037259 | May 2004 | WO |
| 2004037260 | May 2004 | WO |
| WO 2004037222 | May 2004 | WO |
| WO 2004043449 | May 2004 | WO |
| 04066910 | Aug 2004 | WO |
| WO 2004078212 | Sep 2004 | WO |
| 04084869 | Oct 2004 | WO |
| 04093801 | Nov 2004 | WO |
| 04100894 | Nov 2004 | WO |
| 2004093819 | Nov 2004 | WO |
| 2004 098567 | Nov 2004 | WO |
| 2005016313 | Feb 2005 | WO |
| 2005016314 | Feb 2005 | WO |
| 05032524 | Apr 2005 | WO |
| 2005041968 | May 2005 | WO |
| 05055981 | Jun 2005 | WO |
| 2005053656 | Jun 2005 | WO |
| 2005053587 | Jun 2005 | WO |
| 05065646 | Jul 2005 | WO |
| 2005063214 | Jul 2005 | WO |
| 2005066183 | Jul 2005 | WO |
| WO 2005060942 | Jul 2005 | WO |
| 2005079760 | Sep 2005 | WO |
| 2005102286 | Nov 2005 | WO |
| 2005105036 | Nov 2005 | WO |
| WO 2005102286 | Nov 2005 | WO |
| WO 2005102294 | Nov 2005 | WO |
| 2006002883 | Jan 2006 | WO |
| 2006002884 | Jan 2006 | WO |
| 2006002886 | Jan 2006 | WO |
| WO 2006002884 | Mar 2006 | WO |
| WO 2006039692 | Apr 2006 | WO |
| 2005102294 | May 2006 | WO |
| 2006058249 | Jun 2006 | WO |
| 2006082097 | Aug 2006 | WO |
| 2006082099 | Aug 2006 | WO |
| WO 2006105615 | Oct 2006 | WO |
| WO 20060128471 | Dec 2006 | WO |
| 2007005716 | Jan 2007 | WO |
| 2007008752 | Jan 2007 | WO |
| WO 2007014061 | Feb 2007 | WO |
| 2007045462 | Apr 2007 | WO |
| 2007048233 | May 2007 | WO |
| 2007053698 | May 2007 | WO |
| 2007045462 | Jun 2007 | WO |
| 2007085024 | Jul 2007 | WO |
| 2007085024 | Jul 2007 | WO |
| 2007103105 | Sep 2007 | WO |
| 2007103286 | Sep 2007 | WO |
| 2007112285 | Oct 2007 | WO |
| WO 2007112286 | Oct 2007 | WO |
| WO 2007131357 | Nov 2007 | WO |
| 2008 023261 | Feb 2008 | WO |
| WO 2008109462 | Feb 2008 | WO |
| 2008033523 | Mar 2008 | WO |
| WO 2008069941 | Jun 2008 | WO |
| 2008086804 | Jul 2008 | WO |
| 2008107149 | Sep 2008 | WO |
| 2008107149 | Sep 2008 | WO |
| WO 2008107149 | Sep 2008 | WO |
| WO2008132707 | Nov 2008 | WO |
| WO 2008142627 | Nov 2008 | WO |
| 2008148798 | Dec 2008 | WO |
| 2009003776 | Jan 2009 | WO |
| WO 2009005803 | Jan 2009 | WO |
| WO 2009014534 | Jan 2009 | WO |
| WO 2009034541 | Mar 2009 | WO |
| WO 2009034541 | Mar 2009 | WO |
| WO 2009034541 | Mar 2009 | WO |
| WO 2009035474 | Mar 2009 | WO |
| WO 2009051819 | Apr 2009 | WO |
| WO 2009076764 | Jun 2009 | WO |
| 2009092601 | Jul 2009 | WO |
| 2009092601 | Jul 2009 | WO |
| 2009112273 | Sep 2009 | WO |
| WO 2009110005 | Sep 2009 | WO |
| 2009135680 | Nov 2009 | WO |
| WO 2010022193 | Feb 2010 | WO |
| WO 2010044842 | Apr 2010 | WO |
| 2010057036 | May 2010 | WO |
| WO 2010066034 | Jun 2010 | WO |
| WO 2010069050 | Jun 2010 | WO |
| WO 20100083843 | Jul 2010 | WO |
| WO 2010083894 | Jul 2010 | WO |
| WO 20100088911 | Aug 2010 | WO |
| WO 2010105672 | Sep 2010 | WO |
| 2010140007 | Dec 2010 | WO |
| 20100140007 | Dec 2010 | WO |
| WO 20100149169 | Dec 2010 | WO |
| 2011009602 | Jan 2011 | WO |
| 2011009603 | Jan 2011 | WO |
| 2011009604 | Jan 2011 | WO |
| WO 2011008298 | Jan 2011 | WO |
| 2011095314 | Aug 2011 | WO |
| WO 2011095314 | Aug 2011 | WO |
| 2011109441 | Sep 2011 | WO |
| WO 2011128630 | Oct 2011 | WO |
| WO 2011154414 | Dec 2011 | WO |
| 2012028317 | Mar 2012 | WO |
| 2012028318 | Mar 2012 | WO |
| WO 2012028319 | Mar 2012 | WO |
| WO 2012061779 | May 2012 | WO |
| WO 2012076907 | Jun 2012 | WO |
| WO 2012085657 | Jun 2012 | WO |
| WO 2012119727 | Sep 2012 | WO |
| WO 2012166474 | Dec 2012 | WO |
| WO 2013003845 | Jan 2013 | WO |
| WO 2013017234 | Feb 2013 | WO |
| WO 2013017242 | Feb 2013 | WO |
| WO 2013025449 | Mar 2013 | WO |
| WO 2013030177 | Mar 2013 | WO |
| WO 2013050539 | Apr 2013 | WO |
| WO 2013072395 | May 2013 | WO |
| WO 2013084059 | Jun 2013 | WO |
| WO 2013127830 | Sep 2013 | WO |
| WO 2013127831 | Sep 2013 | WO |
| WO 2013128276 | Sep 2013 | WO |
| WO 2013156453 | Oct 2013 | WO |
| WO 2013167735 | Nov 2013 | WO |
| WO 2014059512 | Apr 2014 | WO |
| WO 2014190440 | Dec 2014 | WO |
| WO 2014191396 | Dec 2014 | WO |
| WO 2014191397 | Dec 2014 | WO |
| WO 2015004245 | Jan 2015 | WO |
| WO 2015103379 | Jul 2015 | WO |
| Entry |
|---|
| Zeeshan, F. and N. Bukhari, “Development and Evaluation of a Novel Modified-Release Pellet-Based Tablet System for the Delivery of Loratadine and Psuedoephedrine Hydrochloride as Model Drugs,” AAPS PharmaSciTech 11(2): 910-916 (available on-line May 22, 2010). |
| Kalant et al., Death in Amphetamine Users: Causes and Rates, CMA Journal, vol. 112, Feb. 8, 1975 pp. 299-304. |
| Deighan, C.J. et al., Rhabdomyolysis and acute rend failure resulting from alcohol and drug abuse, Q.J. Med, vol. 93, 2000, pp. 29-33. |
| Woodburn, K.R., Vascular complications of injecting drug misuse, Br. J. of Surgery, vol. 83, 1996, pp. 1329-1334. |
| Dow Chemical Company, Dow Excipients for Controlled Release of Drugs in Hydrophilic Matrix Systems, 2006, pp. 1-36. |
| Sax et al., Hawley's Condensed Chemical Dictionary, 11th ed., 1987, p. 1233, definition of “wax”. |
| Riippi et al., The effect of compression force on surface structure, crushing strength, friability and disintegration time of erythromycin acistrate tablets, Eur J Pharm Biopharm, vol. 46, 1998, pp. 339-345. |
| Goodman and Gilman, “The Pharmacological Basis of Therapeutics, Seventh Edition”, MacMillan Publishing Company, Chapter 22, pp. 491-530. 1985. |
| Goodman and Gilman, “The Pharmacological Basis of Therapeutics, Seventh Edition”, MacMillan Publishing Company, Chapter 23, pp. 533-579. 1985. |
| Rowe et al., Handbook of Pharmaceutical Excipients, Seventh Edition, 2012, Table of Contents. |
| Costa et al., Eur. J. Pharm. Sci. 2001, 13(2), 123-133. |
| Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1st Edition, 1996, Table of Contents. |
| Note for Guidance on Stability Testing, EMEA, Aug. 2003, pp. 1-20. |
| International Search Report and Written Opinion for Application No. PCT/EP2010/004459 dated Dec. 1, 2010. |
| International Search Report and Written Opinion for Application No. PCT/EP2013/053894 dated Mar. 22, 2013. |
| Tranquilan-Aranilla et al., “Kappa-carrageenan-polyethylene oxide hydrogel blends prepared by gamma irradiation,” Radiation Physics and Chemistry vol. 55, pp. 127-131, 1999. |
| Application of a modelling system in the formulation of extended release hydrophilic matrices, Reprinted from Pharmaceutical Technology Europe, Jul. 2006. |
| Application of Opadry II, complete film coating system, on metformin HCI extended release matrices containing Polyox water soluble resin, Colorcon Apr. 2009. |
| Evaluation of Verapamil HCI (240 mg) Extended Release Matrix Formulation Using USP Apparatus III in Biorelevant Dissolution Media, Jul. 2009. |
| Formulation of Poiyox ER Matrices for a Highly Soluble Active. Colorcon Jul. 2009. |
| Investigation of a Directly Compressible Metformin HCI 500mg Extended Release Formulation Based on Hypromellose, Colorcon Jul. 2009. |
| Metformin Hydrochloride 750 mg Extended Release Tablets, Lubrizol Advanced Materials, Inc., Sep. 2010. |
| Metformin Hydrochloride1000 mg Extended Release Tablets, Lubrizol Advanced Materials, Inc., Nov. 20, 2009, Previous Edition Dec. 19, 2008. |
| Pentoxifylline 400 mg Extended Release Tablets, Lubrizol Advanced Materials, Inc., Mar. 3, 2011, Previous Edition Nov. 19, 2009. |
| Physico-mechanical Characterization of Polyox for Table Manufacture, Colorcon Jul. 2009. |
| Tramadol Hydrochloride 100 mg Extended Release Tablets, Lubrizol Advanced Materials, Inc., Sep. 2010. |
| Perez-Marcos. B., Usefulness of certain varieties of Carbomer in the formulation of hydrophilic furosemide matrices, International Journal of Pharmaceutics, 67 (1991) 113-121. |
| Tikhonov, A. et al., Bionhannacy, The Manual for Students of Pharmaceutical Universities and Departments. 2003, pp. 40-41, Kharkov, Ukraine. (Full English translation attached.). |
| Handbuch der Kunststoff-Extrusionstechnik 1, “Grundlagen” in Chapter 1.2 “Klassifizierung von Extrudern”, pp. 3-6. 1989. |
| 2.9 Methoden der pharmazeutischen Technologie 143-144, 1997. |
| Apicella A., Biomaterials, vol. 14, No. 2, pp. 83-90, 1993. |
| Arnold, “Teen Abuse of Painkiller OxyContin on the Rise,” www.npr.org, Dec. 19, 2005. |
| Bailey F.E., et al., “Some properties of poly(ethylene oxide)' in aqueous solution,” Journal of Applied Polymer Science, vol. 1, Issue No. 1, pp. 56-62, 1959. |
| Bauer, Coated Pharmaceutical Dosage Forms, CRC Press, 1998, 1-10. |
| Baum et al., Public Health Reports, 102(4): 426-429 (1987). |
| Braun, et al. Angel Orthodontist, vol. 65 (5) pp. 373-377, 1995. |
| Caraballo, Journal of Controlled Release, vol. 69, pp. 345-355, 2000. |
| Coppens et al., “Hypromellose, Ethylcellulose, and Polyethylene Oxide Use in Hot Melt Extrusion”; Pharmaceutical Technology, 62-70, Jan. 2005. |
| Crowley M.M. et al., Biomaterials 23, 2002, pp. 4241-4248. |
| Dachille, F. et al., “High-Pressure Phase Transformation in Laboratory Mechanical Mixers and Mortars”, 1960., Nature, 186, pp. 1-2 (abstract). |
| Davies, et al; European Journal of Pharmaceutics and Biopharmaceutics, 67, 2007, pp. 268-276. |
| Dejong (Pharmaceutisch Weekblad Scientific Edition 1987, p. 24-28. |
| Dow Excipients Chem. of Poly. Water Soluble-Resin 2004. |
| Dow Technical Data, POLYOX, Feb. 2003. |
| Efentakis M.,Pharmaceutical Development and Technology, 5 (3), pp. 339-346, 2000. |
| El-Sherbiny, European Polymer Journal, vol. 41, pp. 2584-2591, 2005. |
| Adel El-Egakey et al, Pharmacerutica Acta Helvetiae, vol. 46, pp. 31-53,Mar. 19, 1970. |
| Committee for Proprietary Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2001. pp. 1-18. |
| Fell, et al, Journal of Pharmaceutical Sciences, vol. 59, No. 5, May 1970, pp. 688-691. |
| Follonier N., Drug Development and Industrial Pharmacy, 20(8), pp. 1323-1339, 1994. |
| Follonier N. et al., Journal of Controlled Release 36, pp. 243-250, 1995. |
| Freed et al., “pH Control of Nucleophilic/electrophilic oxidation”, International Journal of Pharmaceutics, vol. 357, pp. 180-188 (2008). |
| Graham N.B., Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, Chapter 17, 1992. |
| Griffith, Drug Administration, vol. 19, No. 1, pp. 41-42, 2003. |
| Hanning C.D., British Journal of Anaesthesia, 61, pp. 221-227, 1988. |
| Inert gas—Wikipedia, Dec. 2009. |
| Janicki S., Acta Pharm. Technol. 33 (3) 154-155, 1987. |
| Katz et al., Clin. J. Pain, 23(8): 648-660 (2007). |
| Kim C.-J. J Pharm. Sciences 1995, 84(3): pp. 303-306. |
| Kim, Chem. Pharm Bull. 1992, 40(10), 2800-2804. |
| J.W. McGinity—Letter of Jan. 26, 2009. |
| Dr. Rick Matos, Ph.D—Letter Jan. 6, 2011. |
| Levina et al., Drug Development and Industrial Pharmacy, vol. 28, No. 5, pp. 495-514, 2002. |
| Levina, Journal of Pharmaceutical Sciences, vol. 89, No. 6, pp. 705-723, Jun. 2000. |
| Lockhart et al, “Packaging of Pharnaceuticals and Health Care Products”; Blackie Academic & Professional; First Edition 1996. |
| Madorsky S.L., Journal of Polymer Science, vol. 36, No. 3, Mar. 1959. |
| Maggi. Therapeutic Potential of Capsaicin-like Molecules. Life Sciences, vol. 51, pp. 1777-1781, 1992. |
| Maggi et al., Biomaterials, 2002, 23, 1113-1119. |
| Maggi L.et al, “High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage form”, 2000, International Journal of Pharmaceutics, 195 pp. 229-238. |
| Mank R., Pharmazie 44, H. 11, pp. 773-776, 1989. |
| Mank R., Pharmazie 45, H. 8, pp. 592-593 1990. |
| Mesiha M.S., Drug Development and Industrial Pharmacy, 19(8), pp. 943-959, 1993. |
| Miller, Nursing, pp. 50-52, Feb. 2000. |
| Mitchell, Special Resource, vol. 35, No. 5, pp. 553-567, 2000. |
| Moroni A., Drug Development and Industrial Pharmacy, 21(12) pp. 1411-1428, 1995. |
| Ohnishi N. et al., Chem. Pharm. Bull, 35(8), pp. 3511-3515, 1987. |
| Ozeki T. et al., Journal of Controlled Release 58, pp. 87-95, 1999. |
| Purdue News, “Purdue Pharma Provides Update on Development of New Abuse-Resistant Pain Medications; FDA Cites Patient Needs as First Priority; New Drug Application Delayed,” www.headaches.about.com, Jun. 18, 2002. |
| Verna et al., Manthena et al, Am. J. Drug Deliv. 2004: 2 (1): 43-57. |
| Pharmazeutische Biologie—Drogen and ihre Inhaltsstoffe—Scharfstoffdrogen, 1982, pp. 82-92 (Wagner). |
| Pharm. Research, Official Journal of the American Association of Pharmaceutical Scientists, Sep. 1989, 6(9), S-98. |
| Pharm. Research, Official Journal of the American Association of Pharmaceutical Scientists, Oct. 1991, 8(10), S-192. |
| Prapaitrakul W., J. Pharm. Pharmacol. 43, pp. 377-381, 1991. |
| Proeschel, J. Dent. Res., vol. 81, No. 7, pp. 464-468, 2002. |
| Radko S., Applied ad Theoretical Electrophoresis 5, pp. 79-88, 1995. |
| Remington's Pharmaceutical Sciences, pp. 1553-1593, Ch. 89, 1980, 16th Edition. |
| Remington's Pharmaceutical Sciences 17th ed., 1418 (1985). |
| Rippie E.G., Journal of Pharmaceutical Sciences, Vo. 58, No. 4, pp. 428-431, Apr. 1969. |
| Search result conducted on http://www.unitconversion.org/force/newtons-to-kiloponds-conversion.html, on Jul. 5, 2011 (Conversion of 18.8 kiloponds to newtons). |
| Scheirs J., “Characterizing the Solid-State Thermal Oxidation of Poly (ethylene oxide) Powder”, Polymer, vol. 32, No. 11, 1991. |
| Schroeder J.,Granulierung hydrophober Wirkstoffe im Planetwalzenextruder 2003, vol. 65, No. 4, 367-372. |
| Shivanand P.Pharmaceutical Research, Oct. 1991, vol. 8, No. 10, p. S-192. |
| Sprockel O.L., J. Pharma. Pharmacol. 42, pp. 152-157, 1990. |
| Stafford J., überzogene feste Formen, 1991, 347-68. |
| Strang, British Med. J., 302: 969 (1991). |
| Stringer J.L., Journal of Controlled Release 42, pp. 195-202, 1996. |
| Summers et al; Journal of Pharmaceutical Sciences, vol. 66, No. 8, Aug. 1977, pp. 1172-1175. |
| Tablet, www.docstoc.com (2011). |
| Third Party Observations, Feb. 2, 2009. |
| Thoma V.K. et al. “Bestimmung der In-vitro-Freigabe von schwach basischen Wirkstoffen aus Ratardarzneiformen”, Pharm. Ind. 51, Nr. 3, 1989. |
| Tipler, et al, Physics for Scientists and Engineers, 6th Edition, pp. 234-235, 2003. |
| Tompkins et al., Psychopharma., 210: 471-480 (2010). |
| US Pharmacopoeia, Chapter 1217, Aug. 1, 2008. |
| Waltimo, et al, “A novel bite force recorder and maximal isometric bite force values for healthy young adults”, Scandinavian Journal of Dental Research 1993; 101: 171-175. |
| Waltimo, et al, “Maximal bite force and its association with signs and symptoms of craniomandibular disorders in young Finnish non-patients”, Acta Odontol Scand 53 (1995) : 254-258. |
| Waterman et al., “Stabilization of Pharmaceuticals to Oxidative Degredation”, Pharmaceutical Development and Technology, vol. 71(1), pp. 1-32, (2002). |
| Waters et al., Am. J. Psychiatry, 164(1): pp. 173-174 (2007). |
| Wu N, Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights, J Control Release. Feb. 16, 2005;102(3):569-81. |
| Yang, et al; “Characterization of Compressibility and Compactibility of Poly(ethylene oxide) Polymers for Modified Release Application by Compaction Simulator”: Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996. |
| Yarbrough et al, Letters to Nature 322, 347-349 (Jul. 24, 1986) “Extraordinary effects of mortar-and-pestle grinding on microstructure of sintered alumina gel”. |
| Zhang et al., Pharmaceutical Development and Technology, 1999, 4, 241-250. |
| Rowe et al. Handbook of Pharmaceutical Excipients. Sixth Edition. 2009, pp. v-ix, Table of Contents. |
| Herbert A. Lieberman, Pharmaceutical Dosage Forms, Tablets, Second Edition, Revised and Expanded, 1990. |
| Brown, “The Dissolution Procedure: Development and Validation” vol. 31(5). Chapter 1092, 2006, pp. 1-15. |
| Ritschel et al. Die Tablette: Handbuch der Entwicklung, Herstellung and Qualitatssicherung. 2002, Ch 6, pp. 515-519. |
| Bauer et al. Lehrbuch der Pharmazeutischen Technologie. 1999. pp. IX-XV, Table of contents. |
| European Pharmacopoeia, Third Edition, Council of Europe, Strasbourg, 1997, pp. 127-152. |
| European Pharmacopoeia, Third Edition Supplement 2000, Council of Europe, Strasbourg, 2000, pp. 85-107. |
| Hong et al. Dissolution kinetics and physical characterization of three-layered tablet with poly(ethylene oxide) core matrix capped by Carbopol. Int .J. Pharmacol. 2008, vol. 356, pp. 121-129. |
| Hoepfner et al. Fiedler Encyclopedia of Excipients. 2007, Table of Contents only. |
| Cawello, “Parameters for Compartment-free Pharmacokinetics—Standardization of Study Design, Data Analysis and Reporting” 1999, pp. XI-XIII (table of contents). |
| Ravin, Louis. Preformulation. Chapter 76. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Disanto, Anthony. Bioavailability and Bioequivalency Testing. Chapter 77. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Knevel, Adelbert. Separation. Chapter 78. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Phillips, G. Briggs. Sterilization. Chapter 79. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Siegel, Frederick. Tonicity, Osmoticity, Osmolality, and Osmolarity. Chapter 80. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Giles et al. Plastic Packaging Materials. Chapter 81. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Lintner, Carl. Stability of Pharmaceutical Products. Chapter 82. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Erskine, Jr., Clyde. Quality Assurance and Control. Chapter 83. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Nairn, J.G., Solutions, Emulsion, Suspensions and Extractives. Chapter 84. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Avis, Kenneth. Parenteral Preparations. Chapter 85. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Turco et al. Intravenous Admixtures. Chapter 86. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Mullins, John. Ophthalmic Preparations. Chapter 87. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Block, Lawrence. Medicated Applications. Chapter 88. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Rippie, Edward. Powders. Chapter 89. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| King et al. Oral Solid Dosage Forms. Chapter 90. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Porter, Stuart. Coating of Pharmaceutical Dosage Forms. Chapter 91. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Longer et al. Sustained-Release Drug Delivery Systems. Chapter 92. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Sciarra et al. Aerosols. Chapter 93. In Remington's Pharmaceutical Sciences, 17th Ed, 1985. |
| Repka MA,Drug Dev Ind Pharm. Oct. 2007;33(10):1043-57. (Abstract). |
| O.G. Piringer, A.L. Baner, Plastic Packaging: Interactions with Food and Pharmaceuticals, Wiley VCH, 2nd Completely Revised Edition, Feb. 13, 2008. |
| Guidance for Industry—Bioavailability and Bioequivalence—Studies for Orally Administered Drug Products—General Considerations, FDA, BP, Announced in the Federal Register: vol. 68, No. 53/Mar. 19, 2003. |
| Crowley MM,Drug Dev Ind Pharm. Sep. 2007;33(9):909-26. |
| D.A. Dean, E.R. Evans, I.H. Hall, Pharmaceutical Packaging Technology, Taylor & Francis, 1st Edition, Nov. 30, 2000. |
| Dexheimer, Terahertz Spectroscopy: Principles and Applications (Optical Science and Engineering Series), CRC; 1 edition 2007. |
| Encyclopedia of Pharmaceutical Technology, Third Edition, vol. 1, edited by James Swarbrick. Informa Healthcare, 3rd Edition, Oct. 25, 2006. |
| Encyclopedia of Pharmaceutical Technology, Third Edition, vol. 2, edited by James Swarbrick. Informa Healthcare, 3rd Edition, Oct. 25, 2006. |
| Encyclopedia of Pharmaceutical Technology, Third Edition, vol. 3, edited by James Swarbrick. Informa Healthcare, 3rd Edition, Oct. 25, 2006. |
| Encyclopedia of Pharmaceutical Technology, Third Edition, vol. 4, edited by James Swarbrick. Informa Healthcare, 3rd Edition, Oct. 25, 2006. |
| Encyclopedia of Pharmaceutical Technology, Third Edition, vol. 5, edited by James Swarbrick. Informa Healthcare, 3rd Edition, Oct. 25, 2006. |
| Encyclopedia of Pharmaceutical Technology, Third Edition, vol. 6, edited by James Swarbrick. Informa Healthcare, 3rd Edition, Oct. 25, 2006. |
| Y.-S. Lee et al., Principles of Terahertz Science and Technology (Lecture Notes in Physics), Springer; 1 edition 2008. |
| R.E. Miles et al., Terahertz Frequency Detection and Identification of Materials and Objects (NATO Science for Peace and Security Series B: Physics and Biophysics), Springer; 1 edition 2007. |
| Guidance for Industry—Statistical Approaches to Establishing Bioequivalence, FDA, BP, Jan. 2001. |
| Note for Guidance on the Investigation of Bioavailability and Bioequivalence, EMEA, London, Jul. 26, 2001 (CPMP/EWP/QWP/1401/98. |
| Andre et al., “O-Demethylation of Opiod Derivatives With Methane Sulfonic Acid/Methoinine: Application to the Synthesis of Naloxone and Analogues” Synthetic Comm. 22(16), pp. 2313-2327, 1992. |
| Augustine, R.L., Catalytic Hydrogenation of a, B-Unsaturated Ketones. III The Effect of Quantity and Type of Catalysts, J.Org Chem. 28(1), pp. 152-155, Abstract 1963. |
| Goodman and Gilman, “The Pharmacological Basis of Therapeutics, Seventh Edition”, MacMillan Publishing Company, Table of Contents. 1985. |
| McGinity et al., Hot-Melt Extrusion as a Pharmaceutical Process, American Pharmaceutical Review, vol. 4 (2), pp. 25-36, 2001. |
| Weiss, U., “Derivatives of Morphine. I 14-Dihydroxydihydromorphinone,” J. Am. Chem. Soc. 77, pp. 5891-5892, Nov. 20, 1955. |
| European Search Report, Application No./Patent No. 11006253.6-2112, dated Dec. 16, 2011. |
| European Search Report, Application No./Patent No. 11006254.4-2112, dated Dec. 16, 2011. |
| European Search Report, Application No./Patent No. 11008131.2-1219, dated Feb. 24, 2012. |
| European Search Report, Application No./Patent No. 12001296.8-1219, dated Jun. 26, 2012. |
| European Search Report, Application No./Patent No. 11009129.5-2112, dated Apr. 10, 2012. |
| European Search Report, Application No./Patent No. 12001301.6-1219, dated Jun. 26, 2012. |
| A. James, “The legal and clinical implications of crushing tablet medication”, Nurse Times 100(50), 28-33, 2004. |
| C. W. McGary, Jr. “Degradation of Poly(ethylene Oxide)”, Journal of Polymer Science vol. XLVI,1960, pp. 51-57. |
| P. Cornish “Avoid the Crush”: hazards of medication administration in patients with dysphagia or a feeding tube, CMA Media Inc., CMAJ. 172(7), pp. 871-872, 2005. |
| European Pharmacopoeia 2.9.40 “Uniformity of Dosage Units”, 2006, pp. 3370-3373. |
| European Pharmacopoeia 5.0, 2.9.8 “Resistance to Crushing of Tablets”, 2005, p. 235. |
| Griffin, “Classification of Surface-Active Agents by HLB” Journal of the Society of Cosmetic Chemists, Atlas Powder Company, 1949, pp. 311-326. |
| Griffith et al. “Tablet Crushing and the Law: The Implications for Nursing” Professional Nurse 19(1), pp. 41-42, 2003. |
| Mitchell, “Oral Dosage Forms That Should Not Be Crushed: 2000 Update” Hospital Pharmacy 35(5), 553-557, 2000. |
| Munjal et al.“Polymeric Systems for Amorphous Delta^9—Tetrahydrocannabinol Produced by a Hot-Melt Method. Part II: Effect of Oxidation Mechanisms and Chemical Interactions on Stability” Journal of Pharmaceutical Sciences vol. 95 No. 11, Wiley InterScience, 2006, pp. 2473-2485. |
| Ozeki et al. “Control of Medicine Release From Solid Dispersion Through Poly(eihyleneoxide)-Cartoxyvinylpolymer Interaction”, International Journal of Pharmaceutics, 165, 1998, pp. 239-244. |
| Ozeki et al. “Controlled Release From Solid Dispersion Composed of Poly(ethylene oxide)-Carbopol Interpolymer Complex With Various Cross-Linking Degrees of Carbopol”, Journal of Controlled Release. 63, 2000. pp. 287-295. |
| Munsell Color Company, “The Munsell Book of Color: Glossy Collection”, X-Rite, Originally published in 1966, pp. 1-7. |
| Schier et al. “Fatality from Administration of Labetalol and Crushed Extended-Release Nifedipine” The Annals of Pharmacotherapy vol. 37, 1420-1423, Oct. 2003. |
| “The Dissolution Procedure: Development and Validation”, heading “Study Design”, “Time Points” US Pharmacopoeia (USP), General Chapter 1092, pp. 1-15, 2006. |
| Wade and Weller, “Handbook of Pharmaceutical Excipients: 2nd Edition”, The American Pharmaceutical Association and the Pharmaceutical Press, Table of Contents pp. v-vi, 1994. |
| Yeh et al., Stability of Morphine in Aqueous Solution III: Kinetics of Morphine Degradation in Aqueous Solution, Wiley Subscription Services, Inc., Journal of Pharmaceutical Sciences, 50(1): 35-42 (1961). |
| João F. Pinto et al.,“Evaluation of the Potential Use of Poly(ethylene oxide) as Tablet- and Extrudate-Forming Material,” AAPS PharmSci, 2004; 6 (2), Article 15, pp. 1-10, (http://www.aapspharmsci.org). |
| European Search Report for related EP 12 00 2708.1-1219, dated Sep. 24, 2012. |
| European Search Report, Application No./Patent No. 12003743.7-1219, dated Sep. 24, 2012. |
| Henrist et al. In vitro and in vivo evaluation of starch-based hot stage extruded double matrix systems. Journal of Controlled Release. 2001, vol. 75, pp. 391-400. |
| McNeill et al. Properties controlling the diffusion and release of water-soluble solutes from poly(ethylene oxide) hydrogels. 4. Extended constant rate release from partly-coated spheres. Journal Biomat. Sci. Polynn. Ed. 1996, vol. 7, pp. 953-963. |
| Pillay et al. A novel approach for constant rate delivery of highly soluble bioactives from a simple monolithic system. Journal of Controlled Release. 2000, vol. 67, pp. 67-78. |
| Evonik Industries, Eudragit Application Guidelines, 10th Edition, 2008, Table of Contents. |
| Yang et al., “Zero-Order Release Kinetics from a Self-Correcting Floatable Asymmetric Configuration Drug Delivery System”, Journal of Pharmaceutical Sciences, vol. 85, No. 2, Feb. 1996, pp. 170-173. |
| Bennet et al., “A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man”, Pain, 33 (1988), pp. 87-107. |
| Carey et al., Advanced Organic Chemistry, Part A: Structure and Mechanism, Fifth Edition, 2007, Table of Contents, pp. i-xxi. |
| Carey et al., Advanced Organic Chemistry, Part B: Reactions and Synthese, Fifth Edition, 2007, Table of Contents, pp. i-xxx. |
| Cheng et al., “Relationship Between the Inhibition Constant (KI) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction”, Biochemical Pharmacology, vol. 22, 1973, pp. 3099-3108. |
| Dachille et al., “High-pressure Phase Transofromations in Laboratory Mechanical Mixers and Mortars”, Nature, vol. 186, Apr. 2, 1960, pp. 34 and 71. |
| D'Amour et al., “A Method for Determining Loss of Pain Sensation”, Loss of Pain Sensation, 1941, pp. 74-79. |
| Dubuisson et al., “The Formalin Test: A Quantitative Study of the Analgesic Effects of Morphine, Meperidine, and Brain Stem Stimulation in Rats and Cats”, Pain, 4 (1977), pp. 161-174. |
| Kim et al., “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat”, Pain, 50 (1992), pp. 355-363. |
| Liu et al., “Properties of Lipophilic Matrix Tables Containing Phenylpropanolamine Hydrochloride Prepared by Hot-Melt Extrusion”, European Journal of Pharmaceutics and Biopharmaceutics, 52 (2001), pp. 181-190. |
| Repka et al., Bioadhesive Properties of Hydroxypropylcellulose Topical Films Produced by Hot-Melt Extrusion, Journal of Controlled Release, 70 (2001), pp. 341-351. |
| Smith et al., March's Advanced Organic Chemistry, Sixth Edition, 2007, Table of Contents, pp. xiii-xiv. |
| Smith, Compendium of Organic Synthetic Methods, vol. 12, Wiley, 2009, Table of Contents, pp. i-xviii. |
| Mises à jour cumulatives, Vidal, Jan./Oct. 2002. |
| European Search Report and Written Opinion for EP Application No. 13197503.9-1460, dated Feb. 18, 2014. |
| PCT Second Written Opinion for PCT Application No. PCT/EP2013/053893 dated Feb. 21, 2014. |
| Carbopol 71G, retrieved Mar. 10, 2014 from http://www.lubrizol.com/LifeScience/Products/Carbopol71G-NF.html. |
| Polyox WSR-303, retrieved Mar. 10, 2014 from URL http://www.dow.com/dowwolff/en/industrial_solutions/polymers/polyethylene. |
| Albertini, B. “New spray congealing atomizer for the microencapsulation of highly concentrated solid and liquid substances,” European Journal of Pharmaceutics and Biopharmaceutics 69 (2008) 348-357. |
| Jannetto, P. et al, “Oxycodone: Recognition and Pharmacogenomics,” Toxicology News, Mar. 2003, 1-7. |
| Kolter, K., “Compression Behaviour of Kollidon SR,” APV/ APGI 2002, Florence, Apr. 11, 2002. |
| Mises à jour cumulat ves, Vidal, Jan./Oct. 2002. |
| Oxycodon (Oxygesic): Missbrauch, Abhaengigkeit and toedliche Foigen durch Injection zerstossener Retardtabletten, Deutsches Ärzteblatt, vol. 36, A2326-A2326, Sep. 5, 2003. |
| Oxycontin: Balancing Risks and Benefits, United States Senate, Hearing, Feb. 12, 2002. |
| Pontier, C. et al, “Use of cycles of compression to characterize the behavior of apatitic phosphate powders,” Journal of the European Ceramic Society 22 (2002), 1205-1216. |
| Silver, J. “Painkiller OxyContin ‘most commonly abused prescription drug on the streets of Western Pennsylvania’” Pittsburg Post-Gazette, Apr. 8, 2001. |
| Wikipedia—Dextromethorphan Aug. 12, 2013 (and attached related English-language entry dated Dec. 11, 2013). |
| European Search Report and Opinion Application No. 14176277.3-1460, dated Dec. 15, 2014. |
| Hartauer, Kerry J. “Influence of Peroxide Impurities in Povidone and Crospovidone on the Stability of Raloxife” Pharma. Dev. & Tech, 5 (3) 303-310 (2000). |
| Morissette et al. Adv. Drug. Del. Rev. 26 (2004), 275-300. |
| Vippagunta et al. Adv. Del. Rev. (2001), 3-26. |
| European Search Report and Written Opinion for EP Application No. 14169801.9-1455 dated Oct. 20, 2014. |
| Dierickx et al., “Co-extrusion as manufacturing technique for fixed-dose combination mini-matrices,” European Journal of Pharmaceutics and Biopharmaceutics 81 (2012), 683-689. |
| Oliveira et al., “Production and characterization of laminar coextrudates at room temperature in the absence of solvents,” AAPS Annual Meeting and Exposition, Oct. 14-18, 2012, Chicago, USA. |
| Quintavalle et al., “Preparation of sustained release co-extrudates by hot-melt extrusion an mathematical modelling of in vitro/in vivo drug release profiles,” European Journal of Pharmaceutical Sciences 33 (2008), 282-293. |
| Rosiaux et al. “Ethanol-resistant ethylcellulose/guar gum coatings—Importance for formulation parameters” European Journal of Pharmaceutics and Bioharmaceutics, vol. 85, N0. 3, (Jul. 25, 2013). pp. 1250-12586. |
| Salomies et al., “Determination of Oxycodone Hydrochloride in Oral Solutions by High-Performance Thin-Layer Chromatography/Densitometry,” Journal of AOAC International, 83:1497-1501 (2000). |
| Almeida, A. et al., Ethylene vinyl acetate as matrix for oral sustained release dosage forms produced via hot-melt extrusion, European Journal of Pharmaceutics and Biopharmaceutics 77 (2011) 297-305. |
| Almeida, A. et al., Sustained release from hot-melt extruded matrices based on ethylene vinyl acetate and polyethylene oxide, European Journal of Pharmaceutics and Biopharmaceutics 82 (2012) 526-533. |
| Bauer et al. Lehrbuch der Pharmazeutischen Technologie. Eight Edition 2006. Stuttgart, pp. 343-352. |
| Encyclopedia of Pharmacological Technology, Informa Healthcare, 1st Ed., 1996, vol. 14 (Table of Content only). |
| European Search Report and Written Opinion for EP Application No. 13176309.9-1460, dated Oct. 9, 2013. |
| European Search Report and Written Opinion for EP Application No. 13169658.5, dated Aug. 6, 2013. |
| European Search Report and Written Opinion for EP Application No. 13169659.3, dated Aug. 6, 2013. |
| Foye, W., Principles of Medicinal Chemistry; Analgesics pp. 241-242, at 241 (1989). |
| Foye, W., Principles of Medicinal Chemistry; Structural Features and Pharmacologic Activity, pp. 63-66 at 65 (1989). |
| Handbook of Pharmaceutical Excipients, 1986, American Pharmaceutical Association, Washington, DC and London (Table of Content Only). |
| Marques, Tablet breaking force, 2008. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2009/003290 dated Jul. 9, 2009. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2013/059728 dated Aug. 6, 2013. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2013/053894 dated Mar. 22. 2013. |
| Polyox water soluble resins 2003. http://www.dow.com/webapps/lit/litorder.asp?filepath=polyox/pdfs/noreg/326-00002.pdf. |
| Polyox water-soluble resins (DOW Mar. 2002); see http://msdssearch.dow.com/PublishedLiteratureDOWCOM/dh_0031/0901b80380031a4a.pdf?filepath=/326-00001.pdf&fromPage=GetDoc). |
| Remington, The Science and Practice of Pharmacy, 19th ed., vol. II, p. 1457 (1995) (providing a table of DFA-approved commercially marketed salts). |
| Ritschel et al. Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitatssicherung. 2nd Edition, 2002, Ch 6, pp. 69-82 and 115-136. |
| Ritschel et al. Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitatssicherung, 2nd Edition, 2002, Table of content. |
| Spassov et al., Stereochemistry of Diastereomeric 3-Dialkylaminopropanols and O-Derivatives, J.f. prakt. Chemie, 323:5, 793-800 (1981). |
| Sreenivasa, B. et al, Design and Evaluation of Ethylene Vinyl Acetate Sintered Matrix Tablets, Indian Journal of Pharmaceutical Sciences, Sep.-Oct. 2003, 65(5): 496-502. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 1, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 10, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 11, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 12, table of contents. |
| Swarbrick Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 13, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 14, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 15, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 16, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 18, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 19, table of content. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 2, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, edition, vol. 20, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 3, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 4, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 5, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 6, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 7, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 8, table of contents. |
| Swarbrick, Encyclopedia of Pharmaceutical Technology, Informa Healthcare, 1988, 1st edition, vol. 9, table of contents. |
| Wagner, Pharmazeutische Biologie—Drogen and ihre Inhaltsstoffe—Scharfstoffdrogen, 2nd., revised edition, Gustav Fischer Verlag, Stuttgart-N.Y., 1982, Table of Content. |
| Moorman-Li, R. et al, “A Review of Abuse-Deterrent Opioids for Chronic Nonmalignant Pain.” Pharmacy and Therapeutics, vol. 37 No. 7, Jul. 2012, pp. 412-421. |
| Eudragit NE40D web page from Evonik website; downloaded Feb. 24, 2015. |
| Eudragit RS PO web page from Evonik website; downloaded Feb. 24, 2015. |
| Glyceryl behenate monograph; European Pharmacopeia 5.0; dated Jan. 2005; downloaded Feb. 24, 2015. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2014/075618 dated Feb. 11, 2015. |
| PCT international Search Report and Written Opinion for PCT Application No. PCT/EP2014/0777748 dated Feb. 12, 2015. |
| Bingwen et al, 2008, p. 367. |
| Bruce et al, Properties of hot-melt extuded tablet formulations for the colonic delivery of 5-aminosalicylic acid, European Journal of Pharmaceutics and Biopharmaceutics, 59 (2005) 85-97. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2015/060377 dated Jul. 23, 2015. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2015/061343 dated Jul. 21, 2015. |
| West, Anthony R., Solid state chemistry and its applications, Wiley, New York, 1988, pp. 358 and 365. |
| Extended European Search Report and Opinion for Application No. EP 15153679.4-1455, dated Jun. 30, 2015. |
| Cuesov, 1999, pp. 351-352,. |
| Eggleston, “The seat of the emetic action of various drugs,” J. Pharmacol. Exp. Ther, 7, 225-253 (1915). |
| European Search Report and Written Opinion for EP Application No. 13425151.1-1460, dated Mar. 11, 2014. |
| Evonik Rohm GmbH product brochure: EUDRAGIT acrylic polymers for solid oral dosage forms (2009). |
| Extended European Search Report and Opinion for Application No. EP 15165064.5-1455, dated Oct. 16, 2015. |
| Extended European Search Report and Opinion for Application No. EP 15165065.2-1455, dated Nov. 2, 2015. |
| Extended European Search Report and Opinion for Application No. EP 15165067.8-1455, dated Nov. 2, 2015. |
| Extended European Search Report and Opinion for Application No. EP 15165069.4-1455, dated Nov. 2, 2015. |
| Extended European Search Report and Opinion for Application No. EP 15165070.2-1455, dated Nov. 2, 2015. |
| Gryczke et al, “Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion”, Colloids and surfaces., B, Biointerfaces, Elsevier, Amsteram, NL, vol. 86, No. 2, Apr. 5, 2011, pp. 275-284. |
| Kondrat, T. , “Technology dosage forms” Moscow 1991, p. 96. |
| Lenindzer, A., “The molecular basis of the structure and functions of cells” Moscow 1974, p. 68. |
| Li et al, “Characterization of Poly(Ethylene Oxide) as a Drug Carrier in Hot-Melt Extrusion”, Drug Development and Industrial Pharmacy, vol. 32, No. 8, Jan. 1, 2006, pp. 991-1002. |
| Morissette et al. Advanced Drug Delivery Review 26 (2004), 275-300. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2013/057851 dated Jun. 12, 2013. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2014/064830 dated Aug. 6, 2014. |
| PCT Second Written Opinion for PCT Application No. PCT/EP2013/057851 dated Apr. 15, 2014. |
| Polyox, Colorcon, Application Data (Apr. 2009) downloaded from http://www.colorcon.com/literature/marketing/mr/Extended%20Release/POLYOX/English/ads_PEO_Antioxidant.pdf. |
| Sidhu et al., “Watching for nonpsychotropics causing psychiatric side effects,” Current Psychiatry, vol. 7, No. 4, 2008, 61-74. |
| Verhoeven et al., “Influence of polyethylene glycol/polyethylene oxide on the release characteristics of sustained-release ethylcellulose mini-matrices produced by hot-melt extrusion. In vitro and in vivo evaluations,” European Journal of Pharmaceutics and Biopharmaceutics 72 (2009) 463-470. |
| Vippagunta et al. Crystalline Solids, Advanced Drug Delivery Review 48 (2001), 3-26. |
| Vynckier et al.,“Hot-melt co-extrusion for the production of fixed-dose combination products with a controlled release ethylcellulose matrix core,” International Journal of Pharmaceutics 464 (2014), 65-74. |
| Chibuzor et al. “Formulation Development and Evaluation of Drug Release Kinetics from Colon-Targeted Ibuprofen Tablets Based on Eudragit RL 100-Chitosan Interpolyelectrolyte Complexes,” Hindawi Publ. Corporation ISRN Pharmaceutics, vol. 2013, Article ID 838403. |
| Satish et al. “Formulation and Characterization of Matrix and Triple Layer Matrix Tablets for Controlled Delivery of Tramadol Hydrochloride,” International Journal of Pharmaceutical Sciences; 5(4) (2013) 458-464. |
| Verhoeven, et al. “Xanthan gum to tailor drug release of sustained-release ethylcellulose mini-matrices prepared via hotmelt extrusion: in vitro and in vivo evaluation,” European Journal of Pharmaceutics and Biopharmaceutics, 63 (2006) 320-330. |
| Monolithic: retrieved from internet: http:/merriam-webster.com/dictionary/monolithic. Retrieved on Sep. 2, 2015. |
| Borquist et al., “Simulation of the release from a multiparticulate system validated by single pellet and dose release experiements,” J. Controlled Release, 97: 453-465 (2004). |
| Alekseeva et al, Chemical-Pharmaceutical Journal, vol. 41 No. 9, 2007, 49-52. (English abstract included.). |
| Extended European Search Report and Opinion for Application No. EP 15184634.2-1455, dated Mar. 3, 2016. |
| Saleem et al. “Formulation and Evaluation of Tramadol hydrochloride Rectal Suppositories,” Indian J. Pharm Sci. Sep.-Oct. 2008; 70(5), 640-644. |
| The Merck Index, 14th Ed. (2006) No. 0006360 Nalefene. |
| The Merck Index, 14th Ed. (2006) No. 0006362 Naloxone. |
| The Merck Index, 14th Ed. (2006) No, 0006363 Naltrexone. |
| The Merck Index, 14th Ed. (2006) No. 0006959 Oxycodone. |
| Alekseeva et al, Chemical-Pharmaceutical Journal, vol. 41, No. 9, 2007, 49-52. (Full translation attached.). |
| Tikhonov, A. et al., Biopharmacy. The Manual for Students of Pharmaceutical Universities and Departments. 2003, pp. 40-41, Kharkov, Ukraine, (Full English translation attached.). |
| Efentakis et al, Effects of Excipients on Swelling and Drug Release from Compressed Matrices, in Drug Development and Industrial Pharmacy 23(1):107-112, Jan. 1997, Abstract. |
| Cuesov, Drug Production Technology, Khar'kov, 1999, pp. 351-352. |
| Tennant, “Simultaneous Use of Stimlants and Opioids,” 2011 [online] retrieved on Jul. 7, 2016 from: http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/simultaneous-use-stimulants-opioids; 7 pages. |
| Fathima, N. et al. “Drug-excipient interaction and its importance in dosage form development,” Journal of Applied Pharmaceutical Science 01 (06); 2011, pp. 66-71. |
| Starch 1500, Partially Pregelatinized Maize Starch, technical data from Colorcon, Feb. 2016, 6 pages. |
| Remington, Chapter 45, pp. 996-1035. |
| Linz et al. “Cebranopadol: A Novel Potent Analgesic Nociception/Orphanin FQ Peptide and Opioid Receptor Agonist,” J Pharmacol. Exp. Ther. 2014; 349: 535-548; available online Apr. 8, 2014. |
| Extended European Search Report for Application No. EP 16183922.0-1460, dated Oct. 31, 2016. |
| Meyer et al., “Awareness Topic: Mitigating the Risks of Ethanol Induced Dose Dumping from Oral Sustained/Controlled Release Dosage Forms,” FDA ACPS Meeting, Oct. 2005, p. 1-4. |
| Schilling, et al., “Novel application of hot-melt extrusion for the preparation of monolithic matrices containing enteric-coated particles.” International Journal of Pharmaceutics 400 (2010) 34-31. |
| U.S. Court of Appeals, Federal Circuit, Purdue Pharma L.P. v. Epic Pharma, LLC, 117 USPQ2d 1733 (Fed. Cir. 2016). |
| Decision of the United States District Court for the Southern District of New York, in In re Endo Pharmaceuticals Inc. and Grüunenthal GmbH v. Amneal Pharmaceuticals, LLC et al., Findings of Fact and Conclusions of Law, District Judge Thomas P. Griesa, New York, New York, Jan. 14, 2015. |
| Decision of the United States District Court for the Southern District of New York, in In re Oxycontin Antitrust Litigation, Purdue Pharma LP v. Teva Pharmaceuticals, Findings of Fact and Conclusions of Law, District Judge Sidney H. Stein, New York, New York, Jan. 14, 2014. |
| Al-Angari, A. et al. “The compaction properties of polyethylene glycols,” J Pharm. Pharmacol. (1985) 37:151-153. |
| Al-Nasassrah et al. , “The effect of an increase in chain length on the mechanical properties of polyethylene glycols,” European Journal of Pharmaceutics and Biopharmaceutics 46 (1998) 31-38. |
| Anderson, S.L. et al., “A Model for Antiplasticization in Polystyrene,” Macromolecules 28:2944-54 (1995). |
| Back, D.M.et al., “Ethylene Oxide Polymers”, in Kirk-Othmer Encyclopedia of Chemical Technology, 2000, John Wiley & Sons, Inc., vol. 10, 673-696. |
| Bailey, F.E., et al., “High Molecular Weight Polymers of Ethylene Oxide” Solution Properties Industrial and Engineering Chemist, 1958. 50(1): 8-11. |
| Balogh, Tastes in and Tastes of Paprika, in Taste: Proceedings of the Oxford Symposium on Food and Cookery 28 (Tom Jaine Ed. 1988). |
| Baumann, T., “Pain Management,” Pharmacotherapy: A Pathophysiologic Approach (J.T. DiPiro et al. eds., McGraw-Hill 4th ed. 1999), Ch. 56, 1014-1026. |
| Baumrucker, S.J., “OxyContin, the Media, and Law Enforcement”, American Journal of Hospice & Palliative Care, 18: 154-156 (May/Jun. 2001). |
| Choi, S. et al, “Hydrophilic Matrix Formulations of Dihydrocodeine Bitartrate with Polyethylene Oxide by Direct Compression,” Proceedings of the 29th Annual Meeting of the Controlled Release Society, in collaboration with the Korea Society for Biomaterials, Minneapolis, 1st Edition, 2002, 984-985. |
| Choi, S.U., et al., “Development of a Directly Compressible Poly(Ethylene Oxide) Matrix for the Sustained-Release of Dihydrocodeine Bitartrate”, Drug Development and Industrial Pharmacy, vol. 29, No. 10, pp. 1045-1052, 2003. |
| Ciccone, P. E., “Attempted Abuse of Concerta,” Letters to the Editor, J. Am. Acad. Child Adolesc. Psychiatry, 41:7 (Jul. 2002). |
| Controversies in ADHD: A Breakfast Symposium—Concerta. |
| Crowley M. et al. Pharmaceutical Applications of Hot-Melt Extrusion: Part I. Dru Dev. & Indus. Pharmacy (2007) 33:909-926. |
| Crowley M., “Physicochemical and Mechanical Characterization of Hot-Melt Extruded Dosage Forms.” Dissertation presented to the Faculty of the Graduate School of The University of Texas at Austin. (May 2003). |
| Crowley, M. et al., “Properties of Hot-Melt Extruded CPM Tablets Using Hydrophilic Polymers,” poster presentation, (2000). |
| Crowley, M., et al., “Evaluation of a Hot Melt Extrusion Technique using a Hydrophilic Thermal Polymer and Retardant for the Preparation of Extended Release Chlorpheniramine Maleate Tablets,” in American Association of Pharmaceutical Scientists: Indianapolis, IN (2000). |
| CROWLEY0000001-CROWLEY0000127. |
| Davies, N. “Sustained Release and Enteric Coated NSAIDs: Are They Really GI Safe?”J. Pharm. & Pharmaceut. Sci., 2(1):5-14, 1999. |
| Declaration of Dr. James W. McGinity, dated Oct. 28, 2009; online, retrieved from: http://www.accessdata.fda.gov/dmgsatfda_docs/labeV2013/021121s032lbl.pdf. |
| Dimitrov, M, et al., “Study of Verapamil hydrochloride release from compressed hydrophilic Polyox-Wsr tablets.” Int'l J Pharmaceutics (1999) 189:105-111. |
| Dittmer, D.K., et al., “Glue-Sniffing Neuropathies,” Canadian Family Physician 39:1965-1971 (1993). |
| Donnelly, C.L., “ADHD Medications: Past and Future,” Behavioral Health Management, May/Jun. 2002, 28 & 30. |
| Dow, “Material Safety Data Sheet: Polyox(TM) WSR 30” (effective date: Sep. 18, 2001). |
| Dow, “Polyox Water-Soluble Resins: Degradation of Water-Soluble Resins,” Technical Data (Oct. 2002). |
| Drug Bank “Oxymorphone,” 2015; online, available at: www.dmgbank.ca/chugs/db01192 printed Jul. 1, 2015. |
| Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (S.D.N.Y 2015)—Redacted Version. |
| FDA News Release, “FDA approves abuse-deterrent labeling for reformulated OxyContin,” Apr. 16, 2013, available at http://www.fda.gov/NewsEvents/Newsroom/Press.Announcments/ucm348252.htm. |
| FDA, “Notice of Determination that OxyContin Drug Products Covered by NDA 20-553 Were Withdrawn From Sale for Reasons of Safety or Effectiveness.” Federal Register, vol. 78, No. 75, Apr. 18, 2013, 23273-23274. |
| Final Draft Labeling for Concerta Extended-Release Tablets Attachment to Approval Letter (2000); available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21121lbl.pdf. |
| Greenhill, L.L., et al., “Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults,” J. Am. Acad. Child Adolesc. Psychiatry, 41:2 Supplement, 26S-49S (Feb. 2002). |
| Griffith, D., “Potential new ADHD drug creating lots of big hopes,” Sacramento Bee (California), Oct. 30, 2002. |
| Huang, H. et al., “Preparation of Controlled Release Oral Dosage Forms by Low Temperature Melt Extrusion,” AAPS PharmSci. 2000 2(S1). |
| Jaffe, S.L., “Failed Attempts at Intranasal Abuse of Concerta,” Letters to the Editor, J. Am. Acad. Child Adolesc. Psychiatry, 41:1 (Jan. 2002). |
| Jannsen Pharmaceuticals, Inc. Concerta Labeling Revisioins, Dec. 12, 2013; online, retrieved from: http://www.accessdata.fda.gov/dmgsatfda_docs/labeV2013/021121s032lbl.pdf. |
| Joint Claim Construction and Prehearing Statement, dated Jul. 11, 2014. Janssen Pharmaceuticals, Inc. and Grünenthal GMBH v. Actavis Elizabeth LLC and Alkem Laboratories Limited, Civil Action No. 2:13-cv-04507 CCC-MF (D.N.J.), Janssen Pharmaceuticals, Inc. and Grünenthal GMBH v. Roxane Laboratories, Inc., Civil Action No. 2:13-cv-06929 CCC-MF (D.N.J.), and Janssen Pharmaceuticals, Inc. and Grünenthal GMBH v. Alkem Laboratories Limited, Civil Action No. 2:13-cv-07803 CCC-MF (D.N.J.). |
| Kibbe, Coloring Agents, in Handbook of Pharmaceutical Excipients (3d ed. 2000). |
| Kidokoro, M. et al. ,“Properties of Tablets Containing Granulations of Ibuprofen and Acrylic Copolymers Prepared by Thermal Processes,” Pharm Dev. and Tech., 6:263- 275 (2001). |
| Kinjo, N. et al, “Antiplasticization in the Slightly Plasticized Poly(vinyl chloride),” Polymer Journal 4(2):143-153 (1973). |
| Larhib, H. et al., “Compressing polyethyelene glycols: the effect of compression pressure and speed,” Int 'l J Pharmaceutics (1997) 147: 199-205. |
| Lieberman, H., et al., Pharmaceutical Dosage Forms: Tablets, vol. 2, Ch. 5: Granulation Technology and Tablet Characterization (1990), Table of contents and 245-348. |
| Lyons et al., “Twitch Interpolation in the Assessment of the Maximum Force-Generating Capacity of the Jaw-Closing Muscles in Man,” Arch. Oral. Biol. 41:12, 1161-1168 (1996). |
| Makki, A, et. Al., Eds., A Dictionary of American Idioms, 4th Ed. Barron's, New York (2004), 342-343. |
| Markovitz, H., et al. “Calculations of Entanglement Coupling Spacings in Linear Polymers.” Journal of Physical Chemistry, 1962. 66(8): 1567-1568. |
| McCrum, N., et al., Principles of Polymer Engineering. 2nd ed., New York: Oxford University Press. 447(1997), Chapter 7, 296-351. |
| McGinity, J.W. et al., “Melt-Extruded Controlled-Release Dosage Forms” in Pharmaceutical Extrusion Technology, Ghebre-Sellassie, I. and Martin, C., Eds., Marcel Dekker, Inc., New York, 2003, Chapter 10, 183-208. |
| McQuay, H. et a. “Methods of Therapeutic Trials,” Textbook of Pain 1125-1138 (P.D. Wall & R. Melzack eds., Elsevier 4th ed. 1999), Table of Contents and 1125-1138. |
| Miura et al., “Comparison of Maximum Bite Force and Dentate Status Between Healthy and Frail Elderly Persons,” J. Oral Rehabilitation, vol. 28 (2001), pp. 592-595. |
| Miyagawa, Y. et al., “Controlled-release of diclofenac sodium from wax matrix ranulate,” Int 'l J. Pharmaceutics (1996) 138:215-224. |
| National Drug Intelligence Center Information Bulletin “OxyContin Diversion and Abuse” Jan. 2001. |
| Payne, H. et al., Denatonium Benzoate as a Bitter Aversive Additive in Ethylene Glycol and Methanol-Based Automotive Products, SAE Technical Paper 930589, Abstract (1993). |
| Pilpel, N., et al. “The effect of temperature on the tensile strength and isintegration of paracetamol and oxytetracylcine tablets,” J Pharm Pharmac., 29:389-392 (1977). |
| Polyox Water-Soluble Resins NF in Pharmaceutical Applications, Dow Chemical Company, Aug. 2002. |
| Purdue Pharma LP Material Safety Data Sheet, OxyContin Tablets, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, Version Sep 16, 2010; available at www.purduephruma.com/msdss/oxycontin_msds.pdf. |
| Rauwendaal, Chris, PHD, Responsive Expert Report of Chris Rauwendaal, Ph.D. Regarding Expert Report of Michael M. Crowley, Ph.D., dated Jul. 17, 2015. |
| Repka, M. et al. Pharmaceutical Applications of Hot-Melt Extrusion: Part II. Drug Dev. & Indus. Pharmacy (2007) 33:1043-1057. |
| Saravanan, M. et al., “The Effect of Tablet Formulation and Hardness on in Vitro Release of Cephalexin from Eudragit L100 Based Extended Release Tablets,” Biol. Pharm. Bull. (2002) 25(4):541-545. |
| Seitz, J.A.; et al., “Evaluation of the Physical Properties of Compressed Tablets 1: Tablet Hardness and Friability,” J. of Pharm. Sci. , 54:1353-1357 (1965). |
| Shah, et al., “Some Effects of Humidity and Heat on the Tableting Properties of Microcrystalline Cellulose Formulations 1,” J. of Pharm. Sci., 57:181-182 (1967). |
| Singhal, et al., Handbook of Indices of Food Quality and Authenticity (1997), “Capsicum” p. 398-299. |
| Smith, K.L. et al. “High Molecular Weight Polymers of Ethylene Oxide—Plastic Properties.” Industrial and Engineering Chemistry, 1958. 50(1): 12-16. |
| Tapentadol Pre-Review Report, Expert Committee on Drug Dependency Thirty-Fifth Meeting Hammamet, Tunisia, Jun. 4-8, 2012, available at http ://www.who.int/medicines/areas/quality_safety/5.2Tapentadolpre-review.pdf. |
| Tiwari, D., et al., “Evaluation of polyoxyethylene homopolymers for buccal bioadhesive drug delivery device formulations.” AAPS Pharmsci, 1999. 1(3): Article 13. |
| Wilkins, J.N., “Pharmacotherapy of Schizophrenia Patients with Comorbid Substance Abuse,” Schizophrenia Bulletin, 23:215-228 (1997). |
| World Health Org., Cancer Pain Relief With a Guide to Opioid Availability (2d ed. 1996). |
| Yin, T.P., et al., “Viscoelastic Properties of Polyethylene Oxide in Rubber-Like State.” Journal of Physical Chemistry, 1961. 65(3): 534-538. |
| Zacny, J. et al. Drug & Alcohol Dependence (2003) 69:215-232. |
| Zhang, F., “Hot-Melt Extrusion as a Novel Technology to Prepare Sustained-Release Dosage Forms,” Dissertation University of Texas at Austin, Dec. 1999. |
| Koziolek, M. et al., “Development of a bio-relevant dissolution test device simulating mechanical aspects present in the fed stomach,” European Journal of Pharmaceutical Sciences 57 (2014) 250-256. |
| Extended European Search Report for Application No. EP 16182124.4-1455, dated Jan. 17, 2017. |
| M. Xu et al., “Evaluation of the coat quality of sustained release pellets by individual pellet dissolution methodolo2y,” Int. J. Pharm. 478 (2015) 318-327. |
| COMPAP 90 technical data sheet Mar. 2014; 1 page. |
| Furu et al. “use of ADHD drugs in the Nordic countries: a population-based comparison study,” Acta Psychiatrica Scandinavia, May 2010. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2017/070396 dated Sep. 8, 2017. |
| Patel, Et. Al., “Poloxamers: A pharmaceutical excipient with therapeutic behaviors,” PharmTech, vol. 1, No. 2, pp. 299-300 (Apr. 2009). |
| Turkington, R., “Amphetamines,” in Chemicais used for Illegal Purposes. A Guide for first Responders to Identify Explosives, Recreationai Drugs, and Poisons, 2010, p. 247. |
| Vezin, W. et al, “Adjustment of precompression force to reduce mixing-time dependence of tablet tensile strength,” J. Pharm. Pharmacol. 1983, 35: 555-558 (Mar. 28, 1983). |
| Sprockel, et. al, “A melt-extrusion process for manufacturing matrix drug delivery systems,” Int. Journal of Pharmaceuticals 155 (1997) 191-199. |
| Definition Granule, Merriam-Webster, accessed online Jun. 28, 2018 (2018). |
| Houston, T.E., et al., “Bite Force and Bite Pressure: Comparison of Humans and Dogs,” http://www.glapbta.com/BFBP.pdf, 2003. pp. 1-7. |
| Sigma-Aldrich entry for CAS No. 9010-88-2; www.sigmaaldrich.com/catalog/products/aldrich/182249?lang=en®ion=US (downloaded Jun. 2018). |
| Sumitomo Seika Chemicals, Co., Ltd, “Certificate of Analysis,” Product: Polyethylene Oxide; Grade: PEO-18NF; Feb. 2, 2016. |
| Sumitemo Seika Chemicais, Co., Ltd, “Certificate of Analysis,” Product: Polyethylene Oxide; Grade: PEO-20NF; Feb. 3, 2016. |
| Sumitemo Seika Chemicais, Co., Ltd, “Certificate of Analysis,” Product: Polyethylene Oxide; Grade: PEO-20NF; Jan. 23, 2012. |
| Sumitemo Seika Chemicais, Co., Ltd, “Certificate of Analysis,” Product: Polyethylene Oxide; Grade: PEO-20NF; May 15, 2013. |
| U.S. Appl. No. 60/287,509, filed Dec. 2, 2002, Joshi et al. |
| U.S. Appl. No. 60/288,211, filed Sep. 2, 2004, Oshlack et al. |
| U.S. Appl. No. 60/310,514, filed Apr. 3, 2003, Oshlack et al. |
| U.S. Appl. No. 60/310,534, filed Apr. 10, 2013, Wright et al. |
| U.S. Appl. No. 60/376,470, filed Jan. 15, 2004, Ayer et al. |
| U.S. Appl. No. 60/384,442, filed Dec. 4, 2003, Fink et al. |
| USP Expert Council, US Pharmacopoeia, Chapter 1092, 2007, 1-15. |
| Dabbagh, et al. “Release of Propanolol Hydrochloride from Matrix Tablets Containing Sodium Carboxymethylcellulose and Hydroxypropylmethylcellulose”; 1999; Pharmaceutical Development and Technology, 4(3), 313-324. |
| Remington, Chapter 45, pp. 996-1035. (Full Translation Attached). |
| King, Remington's Pharmaceutical Sciences 17th ed., Chapter 78, p. 1418-1419 (1985). |
| Pharma Tips ([online] 'retrieved on Mar. 22, 2018 from http://ww.pharmatips.in/Articles/Pharmaceutics/Tablet/Co-Processed-Directly-Compressed-Adjutants.aspx May 2011: 10 pages). |
| European Pharmacopoeia 3.0, 2.9.8 “Resistance to Crushing of Tablets”, 1997, p. 135. |
| Goodman and Gilman, 1985, 7th edition, chapter 29, 674-715. |
| Quadros, E. et al., “Evaluation of a novel colonic delivery device in vivo,” STP Pharma Sci. 5, 77-82 (1995). |
| Theeuwes, Felix et al., Osmotic Systems for Colon-Targeted Drug Delivery in Colonic Drug Absorption and Metabolism (Peter R. Bieck ed., 1993). |
| Wooten, Marvin R. et al., Intracerebral Hemorrhage and Vasculitis Related to Ephedrine Abuse, 13 Annals of Neurology 337 (1983). |
| De Brabander C., et al., “Development and evaluation of sustained release mini-matrices repared via hot melt extrusion” Journal of Controlled Release 89 (2003), 235-247. |
| Nickerson, B., Sample Preparation of Pharmaceutical Dosage Forms, Springer, New York (2011); Chapter 1, pp. 3-48. |
| Polyox Water-Soluble Resins in Pharmaceutical Applications. Dow Chemicals. Published 2004. |
| Bannwarth, Bernard, “Will Abuse-Deterrent Formulations of Opioid Analgesics be Successful in Achieving Their Purpose?”, Drugs, 2012, vol. 72, pp. 1713-1723. |
| PCT International Search Report and Written Opinion for PCT Application No. PCT/EP2016/052046 dated Apr. 12, 2016. |
| Baxter, J.L. et al., “Hydrodynamics-induced variability in the USP apparatus II dissolution test,” International Journal of Pharmaceutics 292 (2005) 17-28. |
| Bellmann et al., “Development of an advanced in vitro model of the stomach and its evaluation versus human gastric psychology.” Food Research International 88 (2016) 191-198. |
| Koziolek, M. et al., “Development of a bio-relevant dissolution test device simulating mechanical aspects present in the fed stomach,” European Journal of Pharmaceuticals Sciences 57 (2014) 250-256. |
| Number | Date | Country | |
|---|---|---|---|
| 20130028970 A1 | Jan 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61512943 | Jul 2011 | US |
